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Abstract 
 
EqHV is the most closely related virus to HCV, and is proposed to have diverged from HCV within 
the last 1000 years. Studying viruses which share a close evolutionary relationship, yet differ 
greatly in their ability to cause disease, provides a unique opportunity to facilitate comparative 
analysis of both replication strategies and pathogenic mechanisms. It has previously been 
demonstrated that, like HCV, the EqHV 5’UTR functioned as an IRES. Here we set out to 
undertake a more detailed structural and functional analysis of the 5’UTR. 
 
A mutational analysis of the structural features of the EqHV 5′UTR was undertaken to investigate 
their roles in its function as an IRES. A complementary study utilising 2’ hydroxyl acylation and 
analysis by primer extension (SHAPE), to experimentally confirm the predicted structure of the 
EqHV 5’UTR in order to reveal how this related to function, was also conducted. This combined 
approach revealed that miR122 mediated enhancement of translation was dependent on a seed 
site located directly upstream of stem-loop (SL) II and that SLI was not required for EqHV IRES 
mediated translation.  SLIII was absolutely essential, as was SLIIId and the conserved GGG motif. 
An essential role for SLIIIb was demonstrated for translation from an EqHV sub-genomic 
replicon. SHAPE experiments revealed that the conserved GGG motif was essential for EqHV 
5′UTR:40S ribosomal subunit interactions, and that a GTC sequence in the apical loop of SLIIIb 
mediated an interaction with eIF3. 
 
This study also set out to establish an EqHV sub-genomic replicon capable of replicating in 
vitro in mammalian cells; however, this could not be achieved. When taken with published data 
it is possible to conclude that current EqHV isolates are not able to replicate in currently available 
cell culture systems and it is likely that new isolates, or cell lines, will be required to achieve in 
vitro replication. 
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1.1 Overview 
 
The recent discovery of a number of animal hepaciviruses has provided an interesting and 
alternative means to investigate the molecular biology of the human pathogen hepatitis C virus 
(HCV). Of these newly discovered hepaciviruses, equine hepacivirus (EqHV) is phylogenetically 
the most closely related to HCV. An animal model of HCV has long been sought in the field; as 
such, investigating the molecular biology of the newly discovered hepaciviruses, and 
establishing replicative clones, is essential to further our understanding of HCV. This thesis 
describes an investigation into the 5′ untranslated region (UTR) of EqHV; its RNA secondary 
structure, its function as an internal ribosome entry site (IRES), and its interactions with host cell 
machinery, as well as the rational construction and assay of an EqHV sub-genomic replicon 
(SGR).  
To this end, the canonical pathway of eukaryotic translation initiation will be introduced and 
viral IRES will be described; specifically focussing on the type IV, HCV-like, IRES and the current 
state of knowledge of the EqHV IRES. Following this, the importance of viral RNA structure, and 
how RNA secondary structure is experimentally determined, will be introduced.  
EqHV is closely related to HCV, and is predicted to have an identical genomic organisation. The 
EqHV proteins are also predicted to carry out identical functions to their HCV counterparts. As 
such the molecular biology of HCV, and the importance of the SGR, will be described. This will 
be followed by the initial discovery and characterisation of EqHV, its prevalence, transmission, 
and pathology, and the current state of knowledge regarding its molecular biology. This 
introduction will conclude with an overview of the other newly discovered hepaciviruses and 
their potential usefulness as a model system with which to investigate HCV.  
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1.2 Translation initiation 
 
1.2.1 Cap-dependent initiation 
 
Eukaryotic cap-dependent translation initiation minimally requires the 40S and 60S ribosomal 
subunits and eukaryotic initiation factors (eIFs) 1, 1A, 2, 2b, 3, 4A, 4B, 4E, 4F, 4G, 4H, 5, and 5B 
(Jackson et al., 2010). It is a two-step process comprising the formation of a 48S initiation 
complex, with Met-tRNA bound to the start codon in the 40S P-site, and the joining of a 60S 
ribosomal subunit; resulting in the formation of an elongation competent 80S ribosome.  
Eukaryotic translation requires the recycling of post-termination complexes (post-TCs) to make 
ribosomal subunits available for a new round of translation initiation. Post-TCs consist of an 80S 
ribosome bound to mRNA, a deacylated tRNA in the P-site, and eukaryotic release factors (eRFs) 
1 and 3. Dissociation of the post-TC is mediated by eukaryotic initiation factors (eIFs) 1, 1A, 3, 
and 3j and absolutely requires eIF3. eIF3j and mRNA bind to 40S subunits with negative 
cooperativity (Unbehaun et al., 2004; Fraser et al., 2007), therefore binding of eIF3j to the 40S 
subunit promotes dissociation from the mRNA. However, P-site codon-anticodon interaction 
protects the 40S-mRNA complex from eIF3j mediated dissociation, therefore eIF1 mediated 
release of the deacylated tRNA is required before 40S subunit dissociation can be achieved 
(Pisarev et al., 2007).  
The 40S ribosomal subunit, in complex with eIF1, 1A, 3, and 3j, and the ternary complex (TC) 
eIF2–GTP–Met-tRNA, constitutes the 43S complex. eIF3, and eIF3j, are known to be positioned 
on the solvent facing side and mRNA binding channel (Siridechadilok, 2005; Fraser et al., 2007), 
respectively. Binding of eIF1 and eIF1A induces a conformational shift in the 40S subunit 
resulting in the opening of the mRNA entry channel. Both factors accelerate TC binding to 40S, 
with eIF1A stabilising this interaction (Passmore et al., 2007). The structured 5′ untranslated 
regions (UTRs) of cellular mRNAs require unwinding in order to facilitate loading of the 43S 
complex. This is carried out by eIF4F, and eIF4B or eIF4H (homologous to a fragment of eIF4B). 
eIF4F consists of eIF4A, eIF4E, and eIF4G, and functions to recruit eIF4E, polyA binding protein 
(PABP), and eIF3. eIF4E binds the cap and eIF4G induces structural changes in eIF4E which 
increase its affinity for the cap (von der Haar et al., 2004). The activity of the DEAD-box helicase 
eIF1A is enhanced by eIF4G and eIF4B/H with eIF4G promoting the “closed”, active, confirmation 
of the two eIF1A domains (Andersen, 2006; Rogers et al., 2001). It has been suggested eIF4B/H 
mediated stimulation of eIF4A helicase activity may be achieved through eIF4B/H binding single 
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stranded mRNA upstream of eIF1A to prevent it from re-annealing; promoting processive 
unidirectional translocation of eIF4A (Marintchev et al., 2009). Loading of the 43S complex onto 
the unwound mRNA therefore proceeds through eIF4G (in complex with eIF4E bound to the cap) 
interacting with eIF3 in the 43S complex (Lefebvre et al., 2006).  
Loading of the 43S complex onto the mRNA is followed by ribosomal scanning of the 
downstream sequence to identify the start codon. eIF1 and eIF1A are both required for efficient 
scanning, indicating that the “open” 40S conformation induced by attachment of these factors 
is crucial in maintaining the scanning competent confirmation of 40S (Pestova and Kolupaeva, 
2002; Passmore et al., 2007).  Scanning of structured 5′UTRs requires ATP, eIF1A, eIF4G, and 
eIF4B. However, 43S complexes are able to scan unstructured 5′UTRs in their absence (Pestova 
and Kolupaeva, 2002). Two alternative modes of action have been postulated for the function 
of eIF4A, eIF4B, and eIF4G during scanning: either they drive the movement of mRNA by helicase 
mediated ratcheting, with the 40S subunit unwinding the RNA structure as it moves forward; or 
where they precede 40S, unwinding the RNA structure prior to it entering the mRNA binding 
channel (Siridechadilok, 2005; Marintchev et al., 2009).  
Initiation codon recognition is highly specific for AUG triplets, usually the first downstream of 
the cap in the correct sequence context; GCC(A/G)CCAUGG, where -3 is a purine and +4 is a 
guanine (Kozak, 1991). eIF1 is essential to this process and functions to prevent Met-tRNAi base 
paring with non-AUG codons, AUG triplets which exist in a sub-optimal context, and those which 
exist <8 nucleotides from the 5′ end of the mRNA; eIF1 also functions to dissociate complexes 
which have formed at one of these incorrect sites (T. V Pestova, Borukhov, et al., 1998; Pestova 
and Kolupaeva, 2002; Pisarev et al., 2006). Codon-anticodon base pairing is inhibited in the 
“open” conformation that promotes ribosomal scanning, therefore the 40S subunit must 
undergo conformational change to achieve this. Base pairing enhances the interaction between 
the 40S subunit and eIF1A, displacing eIF1 from the P-site and “closing” the ribosomal 
conformation. Furthermore eIF1 prevents eIF2 release from the TC by repressing hydrolysis of 
GTP bound eIF2 mediated by the GTPase-activating protein (GAP) eIF5 (Unbehaun et al., 2004; 
Lomakin et al., 2003; Maag et al., 2006; Cheung et al., 2007).  
The final stage in translation initiation is the displacement of 48S associated eIFs, and joining of 
the 60S subunit to form an elongation competent 80S ribosome. This process is mediated by the 
ribosome dependent GTPase eIF5B which, in the presence of 60S, causes complete dissociation 
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of eIF2-GDP (Pisarev et al., 2006). An interaction between the C-terminal domains of eIF5B and 
eIF1A (Marintchev et al., 2003) is necessary for efficient subunit joining and promotes eIF5B-
GTP hydrolysis; resulting in dissociation of the eIF5B-eIF1A complex and formation of the 
elongation competent 80S ribosome. Figure 1.1A is a model of the pathway of canonical 
eukaryotic translational initiation (reveiwed in Jackson et al., 2010). 
 
 
A model of A) The canonical eukaryotic cap-dependent and B) HCV IRES-dependent translation 
initiation pathway (adapted from Fraser and Doudna, 2007).  
 
Figure 1.1: Canonical and HCV mediated translation initiation 
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1.2.2 Viral IRES 
 
As obligate intracellular parasites, viruses rely on the host cell machinery to translate their 
genomes. To avoid the complex, and tightly regulated, canonical initiation pathway some viruses 
utilise internal ribosome entry sites (IRES). Some viruses require a subset of eIFs to mediate cap-
independent initiation, others are able to directly recruit the 40S subunit, and some do not 
require any eIFs.  
Viral IRES were first reported for poliovirus (PV) and encephalomyocarditis virus (EMCV) in 1988 
(Jang et al., 1988; Pelletier and Sonenberg, 1988). Since then many other viral IRES have been 
reported and there is growing evidence for cellular mRNAs containing IRES, which may be 
involved in tumour survival (Martínez-Salas et al., 2012; Walters and Thompson, 2016). Viral 
IRES have since been classified into six types depending upon their requirement for host cell 
factors: picornavirus type I-V IRES (type IV IRES are also known as HCV like IRES), and intergenic 
region IRES (IGR IRES).  
Type I IRES are exclusively found in enteroviruses and are epitomised by the PV IRES. This 
archetypal type I IRES is ~450 nucleotides in length and consists of domains II-VI of the PV 5′UTR. 
PV domain I forms a cloverleaf structure which is essential for replication but does not function 
in IRES mediated translation (Andino et al., 1990; Andino et al., 1993). During PV infection the 
2A protease cleaves eIF4G to induce host cell shut off of eIF4E mediated cap-dependent 
translation (Gradi et al., 1998), therefore cap-independent translation is required to express the 
viral proteins. The minimal set of eIFs required for PV IRES mediated translation are eIF2, eIF3, 
eIF4A and the central domain of eIF4G; translation is strongly stimulated by eIF1A and eIF4B 
(Sweeney et al., 2014).  The PV IRES directly interacts with the C-terminal cleavage product of 
eIF4G, which interacts with eIF4A and eIF3 (Gradi et al., 1998; Pestova et al., 1996; Pilipenko et 
al., 1992; de Breyne et al., 2009). Recruitment of eIF4A induces conformational changes around 
the 3′ border of the IRES which has been suggested to enable 43S loading onto the domain VI 
AUG triplet (Kolupaeva et al., 2003; de Breyne et al., 2009). This AUG, however, is in poor context 
and translation is not initiated from this site. Therefore ribosome scanning proceeds through 
the ~160 nucleotide spacer region to initiate translation at the authentic AUG (Lozano and 
Martínez-Salas, 2015). 
Type II IRES are also ~450 nucleotides in length and are found in many of the Picornaviridae. The 
most well-known, and well-studied are those of EMCV and foot and mouth disease virus (FMDV). 
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The first domain of these viruses is also involved in replication and is not required for IRES 
function; however these viral 5′UTRs are formed of four domains (I-IV) rather than the six 
domains of enteroviruses (Lozano and Martínez-Salas, 2015; Gao et al., 2016). Both EMCV and 
FMDV infections induce host cell shut off and utilise an IRES to circumvent  inactivation of eIF4G 
by cleavage or phosphorylation (Belsham et al., 2000; Lee et al., 2017; Gingras et al., 1996). A 
role for EMCV 2A in sequestering eIF4E to inhibit cap-dependent translation has also been 
reported (Aminev et al., 2003). The type II IRES also harbour two in frame AUG start codons 
which, conversely to type I IRES, may both be used to initiate translation.  
The only type III IRES is found in hepatitis A virus (HAV) IRES, which is both structurally and 
functionally distinct from type I and II IRES. Strikingly it has been previously demonstrated that 
this IRES requires intact eIF4G to function, is dependent on eIF4E, and can be inhibited by 
competition with m7G cap (Ali et al., 2001; Brown et al., 1994; Borman and Kean, 1997). However 
recent studies have shown that this may not be that case and that cleavage of eIF4G by the 
FMDV L protease in fact strongly stimulates HAV IRES mediated translation, and that translation 
proceeds when eIF2α has been inactivated by phosphorylation. This suggests that in the 
presence of the FMDV L protease translation from this IRES proceeds in a similar manner to the 
type I and II IRES (Redondo et al., 2012).  
Type IV IRES, or HCV like IRES, were originally discovered in HCV and Classical swine fever virus 
(CSFV) but have since been identified in a number of picornavirus genera (reviewed in Asnani et 
al., 2015). Whilst the HCV IRES contains four domains type IV IRES typically only contain three. 
These IRES are shorter than those of type I-III, but like with type I-II IRES domain one is not 
necessary for translation and is involved in genome replication (Khawaja et al., 2015). The 
structure and function of the HCV IRES is discussed in 1.2.3. 
Type V IRES have only recently been classified and were described for the kobuvirus and 
proposed salivirus and paraturdivirus genera of the picornaviridae (Sweeney et al., 2012). They 
are of similar length (~410 nucleotides) to those of type I and II IRES and exhibit three major 
domains which are conserved throughout this class of IRES. Translation initiation proceeds 
through specific interaction with domain K, and requires the canonical factors eIF2, eIF3, eIF4A, 
and eIF4Gm.  
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Finally the IGR IRES, found in the Discistroviridae family, and exemplified by the cricket paralysis 
virus (CrPV) IRES, are a unique class of viral IRES which require no eIFs. Translation is initiated 
from a CUU, rather than AUG, triplet (Wilson et al., 2000). The CrPV IGR IRES is ~200 nucleotides 
in length and folds into three pseudoknots (Hertz and Thompson, 2011). It is located 6024 
nucleotides downstream from the 5′ end of the genome and is situated between two open 
reading frames (ORFs) (Sasaki and Nakashima, 1999).  The lack of requirement for canonical eIFs 
or initiator tRNA is unique to this class of IRES (Thompson et al., 2001).  
1.2.3 Hepaciviral IRES 
 
Type IV, or HCV-like, IRES are found in members of both the Picornaviridae and Flaviviridae, with 
the archetypal IRES being that of HCV. The 5′UTR of equine hepacivirus (EqHV), also known as 
canine hepacivirus and non-primate hepacivirus (CHV; NPHV) has also recently been described 
to function as an IRES and constitutes another type IV IRES from a hepacivirus species (Figure 
1.1A and C). The HCV 5′UTR is ~330 nucleotides long and comprises four major structural 
domains I-IV, which are comprised of SLI, SLII, SLIIa,b,c,d,e,f, a pseudoknot, and SLIV (Figure 
1.2B). Domain I consists of a short stem loop which has been demonstrated, similarly to the 
picornaviral IRES, to function in replication; playing no role in translation.  Domains II-IV 
constitute the IRES, however domains III and IV have been demonstrated to exhibit IRES activity 
in the absence of SLII (Ray and Das, 2004; Kalliampakou et al., 2002). The HCV IRES directly 
recruits the ribosomal 40S subunit and requires a minimal subset of canonical factors eIF3, eIF5, 
eIF5B, and the eIF2-GTP-Met-tRNA ternary complex (TC). There is no requirement for scanning 
in the HCV IRES, with SLIIId and the pseudoknot mediating loading of the ribosome directly onto 
the AUG start codon. The initial 42 nucleotides of the coding region also play a role in efficient 
HCV IRES mediated translation (Honda et al., 1996).  
HCV IRES mediated translation initiation begins with  direct recruitment of the 40S ribosomal 
subunit (Pestova et al., 1998) through an interaction between a GGG motif in the apical loop of 
SLIIId, and 1116CCC1118 of the 40S subunit (Matsuda and Mauro, 2014; Malygin et al., 2013). 
Mutation of this motif has been demonstrated to both reduce the affinity of the IRES for 40S 
subunit, and to severely impair translation (Kieft et al., 2001; Jubin et al., 2000). Following 
formation of this binary complex, eIF2 is recruited to the 40S subunit, via an interaction with 
eIF3 which has been suggested to  be dependent on IRES RNA-eIF3-eIF2 interactions, to correctly 
position Met-tRNA in the ribosomal peptidyl-tRNA site (P site) (Ji, 2004).  
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Figure 1.2: A Schematic representations of the predicted EqHV, and HCV, 5’UTRs 
A schematic representation of the secondary structure of the EqHV 5′UTR. Secondary structure 
was predicted using EqHV sequence NZPI (GenBank accession no. KP325401) in Mfold and a 
schematic representation of this was modelled. B) A schematic representation of the secondary 
structure of the HCV 5′UTR. miR122 seed sites are highlighted in yellow and the conserved GGG 
motif is highlighted in green, the start codon AUG is denoted in text. C) The predicted secondary 
structure of the EqHV 5′UTR as in Figure 3.1A, with enlarged sections demonstrating the 
sequence of the conserved miR122 site between SLI and SLII, the conserved GGG motif in the 
apical loop of SLIIId, and the pseudoknot. The EqHV pseudoknot was manually modelled based 
upon the Mfold prediction, the sequence of the EqHV 5′UTR in this region, previous predictions 
of the EqHV 5′UTR secondary structure, and the known structure of the HCV 5′UTR. 
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SLIIIb of the HCV IRES has been demonstrated to specifically interact with eIF3 via its apical loop, 
and a mismatched loop located in its stem (Sun et al., 2013; Sizova et al., 1998), and mutations 
in this region inhibit IRES activity (Kieft et al., 2001). Recent studies using cryo-electron 
microscopy (cryo-EM) have demonstrated that the HCV IRES interacts with the ribosome binding 
face of eIF3, causing displacement of the 40S subunit upon binding.  This functions to promote 
the accumulation of free 40S, thus favouring HCV translation (Hashem et al., 2013).  
Following ribosomal recruitment SLII contacts the ribosome to mediate a multitude of effects. 
This interaction causes a conformational change in the ribosome which closes the mRNA binding 
cleft (Spahn et al., 2001). SLII has also been implicated in the stable placement of mRNA in the 
decoding groove (Filbin and Kieft, 2011), release of eIF2 (Locker et al., 2007), the dissociation of 
eIF3j (Fraser et al., 2009), progression of 48S complexes to 80S ribosomes (Otto and Puglisi, 
2004), and manipulates the ribosome to mediate a switch between translation initiation and 
elongation, promoting the first translocation event (Filbin et al., 2013). SLII is not involved in 
positioning the AUG start codon in the P-site (Locker et al., 2007). Correct positioning of the AUG 
in the mRNA binding cleft is mediated by the pseudoknot and mutations which destabilise the 
pseudoknot, or alter the distance of the AUG start from the pseudoknot, significantly impair 
translation (Berry et al., 2010). The final step in translation initiation from the HCV IRES is 60S 
subunit joining to form an elongation competent 80S ribosome correctly positioned on the AUG 
start codon. This proceeds in the same manner as canonical, cap-dependent, initiation and is 
mediated by the ribosome dependent GTPase eIF5B (Lee et al., 2002; Pestova et al., 1998; 
Yamamoto et al., 2014).  
The only other hepaciviral IRES that has been described to date is that of EqHV (Stewart et al., 
2013), however there is only limited information available regarding the structure and function 
of this type IV IRES (Kapoor et al., 2011; Burbelo et al., 2012; Stewart et al., 2013; Scheel et al., 
2015). The EqHV 5′UTR demonstrates ~66% sequence identity with its HCV counterpart and a 
minimum free energy prediction of the 5′UTR showed a similar secondary structure 
organisation. SLII, SLIII, and the pseudoknot were predicted to exhibit secondary structure 
almost identical to that of HCV (Figures 3.1A and 4.2).  Localised sequences of high conservation 
were also observed including the SLIIId GGG motif, and the pseudoknot.  This analysis also 
revealed two major differences: a large and extended SLI, and a lack of SLIV (Burbelo et al., 2012; 
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Kapoor et al., 2011; Stewart et al., 2013). Functional analysis of the EqHV 5′UTR demonstrated 
that IRES activity was not affected by a deletion of SLI (Stewart et al., 2013). Furthermore, like 
HCV (Bradrick et al., 2006; Song et al., 2006; Jangra et al., 2010), EqHV IRES activity was enhanced 
in the presence of the 3′UTR, and the liver specific microRNA 122 (miR122); depletion of miR122 
with locked nucleic acid abrogated this effect (Scheel et al., 2015). Given the structural and 
sequence conservation exhibited between these two, closely related, viral IRES it would be 
tempting to speculate that the mechanism of translation initiation (Figure 1.1B) is conserved 
between these two viruses, however this is yet to be determined.  
1.3 RNA structure and determination 
 
1.3.1 The folding of RNA into secondary and tertiary structures 
RNA has an exceptional tendency towards folding into stable structures. As such, almost all 
RNAs, even the very shortest, form well defined and highly stable secondary structures. 
Secondary structure is the formation of helixes and loops within an RNA and is largely driven by 
two factors: bas pairing through hydrogen bonds, and base stacking. Base pairing occurs 
between AU and GC bases in the canonical Watson-Crick base pairing formation. However 
wobble (GU) base pairs are also frequently observed in native RNA structure. Triplet bases, the 
formation of base pairs between three bases, pseudoknots, kissing interactions, and other long 
range RNA-RNA interactions also contribute to the formation of RNA secondary structure. RNA 
secondary structure is inextricably linked to function. RNA stem loops have been extensively 
demonstrated to exhibit important functions, and whether a base, or motif, is in a single, or 
double, stranded conformation can significantly affect the ability of an RNA to carry out its 
function i.e. by disrupting RNA-protein interactions. RNA secondary structure is commonly 
represented in 2D (an example of which can be seen in Figure 1.2) and used to guide 
investigations into the link between RNA structure and function. To this end a suite of RNA 
secondary structure prediction tools, and programs, have been developed to predict how the 
secondary structures of RNA (discussed in 1.3.3). 
RNA tertiary structure is somewhat more complex than secondary structure and constitutes the 
3D conformation. The most common tertiary structure is the double helix, as described by 
Watson and Crick (Watson and Crick, 1953), but also include major and minor groove triplexes, 
qudraplexes, and coaxial stacking. However, the study of the 3D conformation of RNA is not 
straightforward and requires techniques such as x-ray crystallography and NMR.  
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The formation of these structures is driven by the same forces that dictate the formation of 
structure in a range of other biological molecules: hydrogen bonding, van der Waals forces, and 
the concealment of hydrophobic regions. The folding of RNA into secondary and tertiary 
structures, driven by these forces, ultimately results in energetically favourable, and stable 
conformations.  
1.3.2 Viral RNA structure 
 
Viruses are highly constrained with regards to the length, and therefore coding capacity, of their 
genomes. They must therefore employ novel methods to fully utilise the limited genetic material 
at their disposal in order to achieve replication, assembly, and release of fully infectious virus 
particles. There are a number of ways in which viruses achieve this: multifunctional proteins 
such as the HCV NS5A carry out numerous roles and thus reduce the need for individually 
encoded proteins with specific functions (Ross-Thriepland and Harris, 2015; Macdonald and 
Harris, 2004). Some viruses, such as the arenaviruses, employ ambisense genomes to increase 
their coding capacity (Auperin et al., 1984). Viruses are also able to “hijack” the cellular 
machinery to carry out viral functions; one such example being the translational machinery, as 
described in 1.2.2. RNA secondary structure is also an extremely versatile tool at the disposal of 
viruses to facilitate stages of the viral lifecycle without “wasting” precious coding capacity.  
Viruses employ RNA structure throughout their lifecycles and the structure of viral RNA can be 
as important as its sequence. As described in 1.2.2 viral IRES substitute for the m7G cap and 
canonical eIFs; their structure is paramount to their function. RNA structure in the HCV genome 
is highly conserved and essential to the viral lifecycle (Fricke et al., 2015). It has also been 
demonstrated to function in packaging of the viral genome (Stewart et al., 2016).  Human 
immunodeficiency virus 1 (HIV-1) also utilises RNA structure to package the viral genome (Clever 
et al., 1995). Genome-scale ordered RNA structure (GORS) have also been identified in positive 
sense RNA viruses and have been demonstrated to function in viral immune evasion; preventing 
the induction of interferon-β mediated though RIG-I and PKR activation (Witteveldt et al., 2013; 
Simmonds et al., 2004). In addition to the important, and necessary, functions that RNA 
structure plays throughout the viral lifecycle, the conservation of these structures further 
illustrates how important viral RNA structure truly is.  
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1.3.3 RNA structure prediction software 
As discussed in 1.3.1 and 1.3.2 RNA has an exceptional tendency to fold into stable structures 
which play an essential role in viral lifecycles. Therefore understanding viral RNA structure is 
extremely important when investigating its function. However, experimental determination of 
these structures is a difficult, and lengthy, process; especially in cases where there is not a 
current model to work from. It is therefore often not feasible to experimentally determine RNA 
structure before undertaking an investigation into its function. Consequently, the prediction of 
RNA structure, using prediction software, is widely used to guide investigations into RNA 
structure and function. Furthermore, this software can also be utilised in combination with 
experimentally acquired data, such as SHAPE data, to refine structure prediction to accurately 
model RNA secondary structure (Deigan et al., 2009).  
Two commonly used suites of prediction software are Mfold (Zuker, 2003) and RNAStrcuture 
(Reuter and Mathews, 2010), both of which are based on the Zuker algorithm for RNA structure 
prediction (Zuker, 1989) and utilise nearest neighbour free energy parameters. Furthermore, 
RNA folds in an extremely complex energy landscape which can produce myriad suboptimal 
structures and the algorithms employed by these suites of software predict a lowest free energy 
structure, and a range of structures within a given increment of free energy. The parameters of 
Watson-Crick helical regions have been well defined experimentally by investigating the 
thermodynamic properties of RNA sequences (Freier et al., 1986; Zhu and Wartell, 1997). The 
free energy algorithms, shaped by knowledge of RNA folding obtained experimentally, have 
been constantly refined and updated. This continual improvement, driven by ever increasing 
knowledge of RNA biology, has resulted in secondary structure prediction software which can 
efficiently predict RNA folding. These widely used programs are an essential tool in investigating 
RNA structure and link it to its function. 
1.3.4 Selective 2′-hydroxyl acylation analysed by primer extension (SHAPE) 
 
Numerous enzymes, and chemical reagents, have long been known to specifically modify or 
cleave nucleotides depending upon their single, or double, stranded conformation. These 
reagents have traditionally been used in combination to determine the secondary structure of 
RNA (Ziehler and Engelke, 2001). However, these methods of RNA structure probing have 
serious limitations. Many reagents lack specificity or exhibit preferential reactivity, and are base 
specific. Due to the nature of their action parallel experiments utilising different probes are 
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necessary to investigate the confirmation of every nucleotide. Furthermore, these techniques 
rely on technically challenging, and laborious, gel electrophoresis and densitometry to analyse 
the data.  
Recent advances in reagents to probe nucleotide structure have yielded a set of chemical 
reagents known as SHAPE reagents, which are now widely in use for the probing of RNA 
secondary structure (McGinnis et al., 2012; Deigan et al., 2009). These reagents represent a 
significant improvement over the traditional RNA structure probing reagents as they 
simultaneously probe every nucleotide; reactivity is independent of nucleotide type (Wilkinson 
et al., 2009). Additionally, the advent of high throughput SHAPE and analysis by capillary 
electrophoresis (Wilkinson et al., 2008) has increased both the read length, and the number of 
samples which can be consecutively analysed. The inclusion of SHAPE data as a pseudo free 
energy constraint increases secondary structure prediction accuracy; E. coli 16S RNA was 
predicted to ~95% accuracy compared with the accepted model, up from 72% for traditional 
chemical probing methods. Inclusion of SHAPE reactivity data routinely results in base pair 
prediction accuracies >90% (Rice et al., 2014; Deigan et al., 2009; Hajdin et al., 2013).  
SHAPE reagents preferentially react with the 2′-hydroxyl group of flexible (unpaired) 
nucleotides, forming bulky ester adducts with reactive bases (Figure 4.1). The reactivity of the 
2′-ribose position is strongly modulated by the adjacent 3′-phosphodiester due to 
conformational constraints. SHAPE reagents have been demonstrated to be exquisitely sensitive 
to local nucleotide flexibility because of this (Merino et al., 2005).  Following RNA labelling with 
a SHAPE reagent reverse transcriptase (RT) is employed to reverse transcribe the RNA into a 
cDNA copy; using a labelled primer to facilitate detection. The adduct formed by the SHAPE 
reagent causes termination of transcription at any reactive base. This results in different length 
cDNA transcripts which can then be separated and detected (Figure 4.1). 
In order to identify the specific reactivity of each base, and produce a SHAPE reactivity profile 
for the RNA under investigation, it is necessary to carry out a dimethyl sulfoxide (DMSO) 
negative control, and a sequencing ladder, to determine background reactivity and correctly 
align the reactivity profile with the RNA sequence. There are a number of available programs 
with which to analyse SHAPE data such as CAFA, FAST, HiTRACE, SHAPE-CE, ShapeFinder, and 
QuSHAPE  (Mitra et al., 2008; Vasa et al., 2008; Yoon et al., 2011; Pang et al., 2011; Aviran et al., 
2011; Karabiber et al., 2013). Of these available programs QuSHAPE appears to be the most 
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attractive as it produces high quality data sets with a low level of user input. Processing of the 
data obtained from the capillary electrophoresis, and alignment to the sequencing ladder, 
results in normalised reactivities which are assigned to each base and can be used to influence 
RNA structure prediction.  When used as a “soft” pseudo-free energy constraint, which guide 
rather than restrain folding (Lorenz et al., 2015), SHAPE reactivity data has been demonstrated 
to markedly increase base pairing prediction for known structures. This method significantly 
improves RNA structure predictions (Lorenz et al., 2015) and resulted in near-perfect predictions 
of RNA secondary structure when used in the RNAstructure software (Deigan et al., 2009; 
Mathews et al., 2004).  
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1.4 Hepatitis C virus 
 
1.4.1 Prevalence, transmission and pathogenicity  
 
HCV was first reported in 1989 as the major causative agent of non-A non-B hepatitis (NANBH) 
(Choo et al., 1989; Choo et al., 1990). It is a blood borne pathogen which is largely transmitted 
through contaminated needles used by intravenous drug users. However prior to widespread 
screening the majority of newly acquired infections were due to contaminated blood used for 
transfusion (Lauer and Walker, 2001). This route of transmission has now all but been eliminated 
in developed countries. Perinatal transmission is infrequent and is often associated with HIV-1 
coinfection; sexual transmission of the virus is extremely inefficient (Thomas et al., 1998; Wyld 
et al., 1997; Ohto et al., 1994).  
HCV is an extremely diverse virus and can be classified into seven distinct genotypes which vary 
by 30-35% at the nucleotide level. These are further classified into subtypes which vary by 20-
25% at the nucleotide level. HCV genotypes also demonstrate uneven geographical distribution, 
and prevalence rates of the virus as a whole vary greatly between countries. This is most striking 
in Egypt which displays a much higher rate of infection, and prevalence of genotype 4 infections 
(Frank et al., 2000).  
HCV is a global health concern with 71 million people estimated to be infected (WHO, 2017). 
Infection usually proceeds through an asymptomatic initial infection which will progress to 
chronic infection in ~75-85% of patients, with the remaining  15-25% spontaneously clearing the 
infection (Chen and Morgan, 2006). Without treatment chronic HCV infections will progress to 
liver cirrhosis and liver failure. Chronically infected patients with liver cirrhosis also have an 
increased chance of developing hepatocellular carcinoma.  
1.4.2 Organisation of the HCV genome  
 
HCV is a ~9.6 kb single stranded positive sense RNA virus. It contains one large open reading 
frame of ~9 kb which is translated into a large polyprotein which is cleaved by viral and host cell 
proteases to yield 10 individual proteins. The structural proteins: core, E1, E2, and p7, and the 
non-structural (NS) proteins: NS2, NS3, NS4A, NS4B, NS5A, and NS5B. The ORF is flanked by a 
341 nucleotide 5′UTR, which contains the viral IRES, and a 3′UTR which contains conserved 
structures involved in the synthesis of negative sense genomes (Figure 1.2A). 
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Genomic organisation of A) HCV and B) EqHV, displaying the 5′ and 3′ untranslated regions and 
the individual proteins expressed following cleavage of the polyprotein.  
 
1.4.3 The HCV viral particle and entry 
 
The HCV genomic RNA is encapsidated in a nucleocapsid particle formed of the core protein and 
enveloped in host derived membranes. It is 40-80 nm in diameter, pleomorphic, and E1 and E2 
are exposed upon the surface (Gastaminza et al., 2010; Catanese et al., 2013). HCV viral particles 
exhibit extremely low buoyant density due to their association with serum lipoproteins and are 
also known as lipoviralparticles; this has been postulated to play a role in immune evasion 
(Bartenschlager et al., 2011).  
HCV entry begins with interactions between particle associated apolipoprotein E (apoE) and 
proceeds through clathrin mediated endocytosis to fusion of the viral and endosomal 
membranes and genome release into the cytoplasm. However, whilst this may seem a familiar 
story the mechanism of HCV entry is somewhat more complex.  
Initial viral attachment to the cell membrane is mediated by particle associated apoE 
interactions with low-density-lipoprotein receptor (LDLR) and with glycosaminoglycans (GAGs) 
Figure 1.3: Hepaciviral genomic organisation 
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present on the cell surface (Monazahian et al., 1999; Agnello et al., 1999; Germi et al., 2002). 
Five cell surface receptors are required for efficient entry of the HCV particle into the cell: CD81, 
scavenger receptor class B member 1 (SRB1), claudin 1 (CLDN1), occludin (OCLN) and Niemann–
Pick C1-like 1 (NPC1L1) (Pileri et al., 1998; Scarselli et al., 2002; Evans et al., 2007; Ploss et al., 
2009; Sainz et al., 2012). Transferrin receptor 1 (TFR1) has also been demonstrated to play an 
important role after CD81 binding, although the exact role of this protein in HCV entry is yet to 
be fully elucidated (Martin and Uprichard, 2013). Following particle attachment E2 binds CD81 
and this complex is trafficked to CLDN1 tight junctions, where clathrin mediated endocytosis is 
induced (Farquhar et al., 2012). Following endocytosis, acidification of the endosome, and 
membrane fusion between the viral and endosomal membranes, the HCV genome is released 
into the cytoplasm and viral replication may begin (reviewed in Lindenbach and Rice, 2013).  
1.4.4 Polyprotein expression and processing, and replication 
 
Upon release into the cytoplasm the positive sense RNA genome of HCV can be directly 
translated. Translation is initiated by direct recruitment of the 40S ribosomal subunit by the HCV 
IRES and progresses to an 80S elongation competent ribosome positioned on the AUG start 
codon, requiring only a subset of canonical eIFs (described in 1.2.3). Translation takes place at 
the rough endoplasmic reticulum (ER) and the polyprotein is co- and post-translationally cleaved 
by cellular and viral proteases. Signal peptidase liberates core at the core-E1 junction and further 
cleavages at the E1-E2, E2-p7, and p7-NS2 junctions liberate all of the structural proteins 
(Hijikata et al., 1993; McLauchlan, 2000; Griffin et al., 2005). The NS2 auto protease cleaves at 
the NS2-NS3 junction to liberate NS2, and the remaining NS proteins are liberated by NS3-4A 
mediated cleavage (Bartenschlager et al., 1994).  
HCV replication, like other positive stranded RNA viruses, occurs in host cell derived membrane 
complexes (Mackenzie, 2005; Salonen et al., 2005). During HCV replication NS4B induces the 
formation of single, double and multi-membrane vesicles which has been termed the 
membranous web (Egger et al., 2002). This is the site of replication complexes, formed of the NS 
proteins 3-5B which are sufficient for HCV replication (Lohmann et al., 1999).  
In addition to its role in cleaving the HCV polyprotein, NS3-4A also plays a role in immune evasion 
by cleaving cellular mitochondrial antiviral signalling protein (MAVS) and toll-IL-1 receptor (TLR) 
domain-containing adaptor inducing interferon-beta (TRIF) to disrupt the RIG-I and TLR-
signalling pathways (Meylan et al., 2005; Li et al., 2005). The C-terminal domain of NS3 has also 
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been demonstrated to possess helicase activity, driving unidirectional 3′-5′ unwinding of HCV 
genomic RNA (Kim et al., 1995; Tai et al., 1996). NS4A contributes to correct folding of the NS3 
protease and also acts as a membrane anchor (Bartenschlager et al., 1995).  
NS5A is a multifunctional phosphoprotein which carries out a range of functions during the HCV 
lifecycle (reviewed in Ross-Thriepland and Harris, 2015) and the well-known culture adaptive 
mutation S2204I is located in this viral protein (Blight et al., 2000). NS5A is anchored to the 
membrane by its N-terminal helix and is an essential component of the replication complex; 
interacting with both RNA and proteins to exhibit myriad functions.  
NS5B is the viral RNA dependent RNA polymerase (RdRP) carrying out synthesis of both the 
positive sense genome and negative sense replicative intermediate, and contains the 
characteristic GDD active site; which is frequently mutated to GND/GNN to create a replication 
deficient control. Like NS5A it is also membrane anchored but this occurs in the C-terminal 
domain of NS5B. Anchoring has been shown to be essential to in vivo function (Moradpour et 
al., 2004).  
The HCV 5′ and 3′ UTRs have also been demonstrated to function in replication. SLI of the HCV 
5′UTR is essential for replication and the proximal 120 nucleotides are sufficient; however the 
full 5′UTR enhances replication (Luo et al., 2003; Friebe et al., 2001). Likewise the 150 nucleotide 
3′ portion of the 3′UTR has also been demonstrated to be essential for replication, with the 5′ 
portion shown to enhance replication (Yi and Lemon, 2003).  
1.4.5 Assembly and release 
 
The mechanism of viral assembly and release is not well understood. Particles assemble by 
budding into the ER and p7, NS2, NS3/4A, and NS5A are all involved in the recruitment of core 
to the site of viral assembly (Counihan et al., 2011). Particles are transited through the secretory 
pathway resulting in release from the cell by exocytosis (Gastaminza et al., 2008). During 
secretion the HCV particle acquires low density lipoproteins and the glycoproteins undergo post 
translational modification to contain complex glycans (Vieyres et al., 2010). There is also a role 
for p7 in protecting the particles from low pH during their maturation and secretion (Bentham 
et al., 2013; Wozniak et al., 2010; reviewed in Lindenbach and Rice, 2013).  
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1.4.6 The HCV sub genomic replicon 
 
For 10 years following the first identification of HCV, replication in cell culture systems could not 
be achieved. Therefore investigations into the molecular biology of HCV was limited to functions 
which could be reproduced in vitro such as the enzymatic activity of NS3 and 5B, and the function 
of the 5′UTR IRES. The advent of a replicative clone of HCV in cell culture represented a major 
step forward in HCV research. It has been instrumental in understanding the molecular biology 
of the virus and the development of direct acting antivirals (DAAs). In vitro replication was first 
achieved through the construction of a consensus clone sub genomic replicon (SGR) Con1b 
(Lohmann et al., 1999). The HCV SGR consists of the 5′UTR which drives expression of a reporter 
gene, the EMCV IRES which drives expression of the NS3-5B coding region, and the 3′UTR (Figure 
5.1A). 
The first cell line in which HCV replication was achieved was the human hepatoma cell line Huh7 
(Nakabayashi et al., 1982). In the intervening years Huh7, and the Huh7 derived Huh7.5, cells 
have remained the cell line of choice for much of the work in the field. Huh7.5 cells were created 
by curing Huh7 cells which stably harboured an SGR with interferon (IFN) and are defective in 
the innate immune pathway RIG-I due to a dominant negative T55I mutation which impairs RIG-
I signalling (Blight et al., 2002). 
Whilst Huh7 and Huh7.5 cells are commonly the cell lines of choice to study HCV, a number of 
liver, and non-liver, derived cell lines have been shown to support HCV replication: stomach-
derived FU97, liver derived Hep3B and Hepg2 cells, uterine Hec1B, mouse embryonic fibroblasts 
(MEFs), human embryonic kidney 293T, and cervical carcinoma HeLa cells  (Shiokawa et al., 
2014; Kambara et al., 2012; Fukuhara et al., 2012; Lin et al., 2010; Kato et al., 2005) have all been 
demonstrated to support HCV SGR replication, with a common dependence on the expression 
of miR122, a liver specific microRNA known to be essential to the HCV lifecycle (Jopling et al., 
2005).   
Whilst there are a large number of cell lines that have been demonstrated to support HCV 
replication the pool of HCV isolates that have been able to replicate in mammalian cell culture 
is somewhat limited. Only the JFH-1 isolate is able to efficiently replicate without the need for 
culture adaptive mutations. However there has been progress made regarding the diversity of 
viral genotypes that are able to replicate in mammalian cell culture with replication capable 
constructs for genotypes 1a, 1b, 2a, 3a, 4a, 5a, and 6a. However many of these isolates require 
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cell culture adaptive mutations, such as the well-known S2204I, to be introduced before 
replication can be established (Saeed et al., 2012; Kinge et al., 2014; Yu et al., 2014; Lohmann et 
al., 1999; Kato et al., 2003; Blight et al., 2003; reviewed in Lohmann and Bartenschlager, 2014).  
Whilst a wide variety of genotypes are now available  to study in cell culture, the isolation and 
study of patient derived sequences is still extremely challenging, and patient derived viruses do 
not readily replicate in cultured cells.  However the recent discovery of pro-viral properties of 
the human gene SEC14L2 has led to pan genotypic replication of patient derived samples in cell 
culture. It has been suggested that this pro-viral gene promotes HCV infection by enhancing 
vitamin E-mediated protection against lipid peroxidation (Saeed et al., 2015).  
The advent of the HCV SGR represented a huge leap forward in HCV research and has facilitated 
a litany of discoveries that have culminated in the development of pan-genotypic direct acting 
antivirals (DAAs). These new therapies have ushered in a new era of IFN free HCV therapy which 
have achieved up to 100% cure rates (reviewed in Zhang et al., 2016).  
1.5 Equine hepacivirus 
 
1.5.1 Discovery and initial characterisation of EqHV 
 
The first novel hepacivirus to be identified was canine hepacivirus (CHV) in 2011 (Kapoor et al., 
2011). Using unbiased high throughput screening respiratory samples of dogs, associated with 
respiratory illness, were screened for the presence of viral RNA. This returned a predicted amino 
acid sequence of viruses similar to flaviviruses. Further amplification revealed a highly 
convergent (99.2%) virus, closely related to HCV, which was detected in the nasal swabs of 9 
dogs; with viral copies >1x107. Further investigation of healthy dogs yielded no further detection 
of CHV, however screening of dogs that had died of unexplained gastrointestinal illness showed 
low levels (<1x103) of CHV RNA that could only be identified from liver samples, which were also 
demonstrated to contain viral RNA by in situ hybridization.   
In a follow up study conducted by the same group a luciferase-based immunoprecipitation 
system (LIPS) seroscreening approach was utilised to screen 80 dogs, 81 deer, 84 cows, 103 
horses, and 14 rabbits for the presence of CHV NS3 reactive IgG (Burbelo et al., 2012). 
Surprisingly no dog samples were seroreactive to CHV NS3, however 35% of the horse samples 
were, and genetically diverse hepaciviral RNA was detected in 8 of these samples. Due to the 
unresolved nature of the true host of the virus originally named CHV, and the genetic diversity 
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of the newly isolated viral sequences, the authors putatively named them non-primate 
hepaciviruses (NPHVs).  
In both of the aforementioned studies the viral genomes, excluding the full CHV 3′UTR, were 
sequenced and characterised based upon sequence conservation, predicted amino acid (a.a) 
sequence, and RNA secondary structure. Kapoor et al. reported the CHV genome to be at least 
9,195 nucleotides in length with a 366 nucleotide 5′UTR and a 2,942 a.a polyprotein. Whilst they 
were unable to sequence the CHV 3′UTR the authors did note the possibility of a poly(A) stretch 
at the 3′ end of the genome; an unusual finding unique amongst hepaciviruses (Kapoor et al., 
2011). poly(A) tails of variable lengths were also reported for the NPHVs (Burbelo et al., 2012). 
However a separate study by Scheel et al. reported a full length NPHV 3′UTR of 328 nucelotides, 
including a short poly(A) tract, a variable region, a poly(U/C) tract, a conserved intermediate 
region, a long poly(U) tract, and a conserved 3′X region; which resembled the HCV 3′UTR in its 
downstream sequence and structure (Scheel et al., 2015). The polyprotein cleavage map for CHV 
was predicted by alignment with HCV sequences and revealed conserved signalase, NS2/3, and 
NS3/4A cleavage motifs which would yield 10 mature proteins from the CHV polyprotein with 
conserved function with HCV: core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B. Maximum 
a.a identity was observed between CHV and HCV NS3 and NS5B (55-65%) and the lowest identity 
was between E1, NS2, and NS5A, mimicking that which is seen between HCV genotypes. This 
study also demonstrated that CHV is more similar at the a.a level to HCV than it is to GBV-B, but 
varied more from HCV than HCV genotypes do from each other (Kapoor et al., 2011). Burbelo et 
al. noted that NPHV isolates showed a moderate, 14%, sequence divergence from each other 
over the length of the genome, lower than the mean diversity observed between HCV subtypes 
(Burbelo et al., 2012).  
Initial prediction of the secondary structure of the CHV 5′UTR was conducted by Kapoor et al. 
and refined by Burbelo et al. who identified a further 17 nucleotides in the NPHV 5′UTRs and 
hypothesised that the CHV 5′UTR sequence was incomplete (Kapoor et al., 2011; Burbelo et al., 
2012). This analysis revealed that the CHV 5′UTR resembled a type IV, HCV-like, IRES and 
contained four domains (SLI, SLII, SLIIIa-f, and a pseudoknot; Figure 3.1A and B). SLII, SLIII, and 
the pseudoknot highly resembled the HCV 5′UTR structure with sequence conservation most 
prevalent in SLIIIc, e, and f. Differences in the 5′UTR structures were most notable in the 5′ region 
with a large and extended SLI in CHV which is absent in HCV. This also revealed the presence of 
an intermediate SL (herein termed SLIA) with sequence homology to the unpaired HCV miR122 
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seed site one. The CHV 5′UTR was also not predicted to contain SLIV, which has been 
demonstrated in HCV to play a role in correct ribosomal positioning (Kapoor et al., 2011; Berry 
et al., 2010). Using the multiple sequences from NPHVs Burbelo et al. further verified and refined 
the NPHV 5′UTR secondary structure. This revealed an extended SLI in comparison to CHV and 
further confirmed the conservation of sequences known to be important in ribosome binding 
and translation initiation from the HCV IRES; most notably the GGG motif in SLIIId and the 
pseudoknot region (Burbelo et al., 2012). Both studies also reported RNA secondary structure in 
the coding region of CHV/NPHVs concluding that the CHV/NPHV genomes contain GORS, 
indicative of viral persistence (Kapoor et al., 2011; Burbelo et al., 2012; Simmonds et al., 2004).  
1.5.2 Prevalence, host range, and classification, of EqHV 
 
Due to the unresolved host range of CHV/NPHVs (herein termed NPHVs) a number of studies 
set out to assess the host range and prevalence of these newly discovered viruses. These studies 
largely focused on dogs and horses as host species. Attempts to isolate NPHVs from dogs proved 
largely unsuccessful (Bexfield et al., 2014; Lyons et al., 2012; Burbelo et al., 2012; Van Der Laan 
et al., 2014) However one report isolated NPHVs  from both tracheal and liver samples of UK 
dogs (El-Attar et al., 2015). It has therefore been suggested that this may represent a recent 
cross species transmission event, or even a false transmission event (Hartlage et al., 2016). Given 
the prevalence of NPHV sequences in horses, and commercial horse serum (Postel et al., 2016), 
whether dogs represent a natural host for NPHVs warrants further investigation.  
Identification of NPHVs from dogs remains a rarity; however, studies that have focused on 
isolating NPHVs from equine species have had a consistent level of success, indicating that 
equines represent the natural host of NPHVs. For this reason newly identified viruses, which 
would previously have been denoted as CHV/NPHV, are frequently being referred to as equine 
hepaciviruses (EqHVs). This nomenclature will be used henceforth to describe hepaciviral 
isolates from both equines and dogs. EqHV has been isolated from equines worldwide with 
reports from the UK, US, Japan, China, Germany, Korea, France, Brazil, Italy, and Hungary (Lyons 
et al., 2012; Burbelo et al., 2012; Matsuu et al., 2015; Lu et al., 2016; Drexler et al., 2013; Pronost 
et al., 2016; Figueiredo et al., 2015; Reuter et al., 2014; Kim et al., 2017; Gabriella Elia et al., 
2017; Pfaender et al., 2015). However prevalence of EqHV does appear to vary between regions, 
with 34-43% seroprevalence reported for tested horses and up to 14% of seropositive horses 
also testing positive for viral RNA (Lyons et al., 2014; Burbelo et al., 2012; Matsuu et al., 2015). 
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EqHV appears to exhibit a much higher seroprevalence than HCV with a lower prevalence of 
active infection. This is suggestive that EqHV either has a more efficient route of transmission 
than HCV, or it may be that the numbers of infected horses are artificially high due to infection 
from contaminated sera (Postel et al., 2016).  
The EqHV viral isolates sequenced to date appear to demonstrate less genetic diversity than the 
closely related HCV; as such EqHV has not yet been classified into viral genotypes as are 
established for HCV. Whilst the circulation of two viral subtypes has been suggested (Pronost et 
al., 2016) viral sequences did not diverge >20% as would be expected for an HCV subtype and it 
is likely that more viral isolates will be required to definitively classify EqHV. 
1.5.3 Transmission, tissue tropism, and pathology, of EqHV 
 
The natural route of transmission of EqHV is yet to be fully elucidated. One study has 
demonstrated vertical transmission from an EqHV positive mare to foal; transmission was 
associated with high viremia at birth (Gather et al., 2016). This study also noted a greater 
susceptibility to EqHV infection following a decrease in EqHV NS3 reactive antibodies in foals, 
indicating a protective effect of antibodies transferred from mare to foal. Furthermore the 
authors also observed potential horizontal transmission of EqHV, and the infection of a foal 
which received a plasma transfusion with EqHV positive plasma. Whilst vertical transmission 
occurs for EqHV it does not appear to represent the main route of transmission; arthropod borne 
infection and contaminated medical products may therefore still represent major routes of 
EqHV infection (Burbelo et al., 2012; Postel et al., 2016).  
Whilst the route of transmission has not yet been fully elucidated, EqHV appears to display 
distinct liver tropism. EqHV RNA is most concentrated within the liver and the replicative 
intermediate negative strand genome has been exclusively identified in liver tissue (Pfaender et 
al., 2015; Scheel et al., 2015; Ramsay et al., 2015). These findings are further supported by 
evidence for increased liver enzyme levels, liver damage, and membrane rearrangements, in the 
livers of infected horses (Lyons et al., 2012; Scheel et al., 2015; Pfaender et al., 2015; Pfaender 
et al., 2017). However reports on the pathology of EqHV infection are contradictory and the true 
effect of EqHV infection is still to be determined. Whilst many studies have reported only mild 
increases in liver enzyme levels, that remain within the reference range, some have 
demonstrated significant pathology upon infection with EqHV including naturally infected 
horses with hepatitis (Reuter et al., 2014) and chronic wasting (Elia et al., 2017). One study 
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reported that horses exposed to EqHV via blood transfusions developed fulminant hepatitis, 
however co-infection with equine pegivirus (EPgV) was also present (Ramsay et al., 2015). This 
study also demonstrated liver damage in normal adult horses experimentally infected with 
EqHV; inoculation of SCID horses resulted in only mild liver disease. Chronic infection of horses 
has also been demonstrated with EqHV RNA detectable for >1 year following infection. EqHV 
also appears to be cleared much more efficiently than HCV in humans; the majority of EqHV 
infections are cleared in association with the onset of antibodies reactive to NS3 (Gather et al., 
2016; Elia et al., 2017; Scheel et al., 2015).  
The true transmission and pathology of EqHV is yet to be fully elucidated, however it appears 
likely that EqHV is a blood borne disease that has the potential to cause hepatitis in infected 
horses. EqHV is also able to establish chronic infection in horses however, in contrast to HCV, 
viral clearance appears to occur in the majority of infections. EqHV demonstrates both marked 
similarities and differences with HCV with regards to the progress of infection and the disease 
which it causes. Whilst many questions still remain to be answered, it appears as if EqHV may 
be an intriguing model with which to study HCV.  
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1.5.4 Molecular biology of EqHV – the story so far 
 
Little is known about the molecular biology of the EqHV RNA structure and proteins, how they 
function, and how they interact with the host cell. Progress has largely been impeded by a lack 
an in vitro system with which to study the viral lifecycle but progress is being made. The EqHV 
5′UTR has been extensively mapped based on sequence and phylogenetic conservation (Burbelo 
et al., 2012). Stewart et al. demonstrated that the EqHV 5′UTR functions as an IRES, and that SLI 
is not required to initiate translation (Stewart et al., 2013). A separate study also demonstrated 
that EqHV IRES activity is enhanced by miR122, and the EqHV 3′UTR (Scheel et al., 2015). 
However the in vitro secondary structure of the 5′UTR, or the reported GORS (Kapoor et al., 
2011), are yet to be experimentally confirmed. The core protein of EqHV has been suggested to 
be cleaved by signal peptidase and localises to lipid droplets, as is seen for HCV. Analogous 
mutation of key Ile and Phe residues inhibits core cleavage (Tanaka et al., 2014). The EqHV 
NS3/4A serine protease has also been demonstrated to cleave human MAVS and TRIF, like its 
HCV counterpart, and also shows specificity for both the HCV and EqHV NS5A/5B cleavage site. 
Interestingly this study also reported that two different HCV NS3/4A protease inhibitors were 
unable to inhibit the activity of the EqHV NS3/4A protein (Parera et al., 2012). Furthermore, 
EqHV infection has been demonstrated to induce membrane rearrangements in infected cells 
reminiscent of those observed during HCV infection. Whilst it has not been experimentally 
confirmed the similarity of the two viruses would suggest a role for NS4B in mediating these 
changes (Pfaender et al., 2017).  
Although research into the molecular biology of EqHV is still evidently in the early stages, 
similarities between EqHV and HCV are beginning to be elucidated. The predicted function of 
EqHV proteins is highly likely to be accurate, and the predicted activity of the 5′UTR as an IRES 
has already been confirmed. Furthermore, miR122 also plays a role in EqHV translation, and it is 
likely due to the seed site located in the EqHV IRES, although this is as yet unconfirmed. This 
would agree well with the conservation of this site observed between EqHV and HCV, and the 
liver tropism of EqHV. However, the inability of HCV inhibitors to inhibit the activity of the EqHV 
NS3/4A protease suggests that key differences between these viruses are there to be 
discovered. Whilst much research into the molecular biology of EqHV is likely to confirm 
predictions regarding conserved functions with HCV, finding differences could be key to 
understanding the differential pathology of these viruses.  
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1.6 Other newly discovered hepaciviruses 
 
Since the first isolation of HCV as the causative agent of NANBH there has been an ongoing 
search to identify animal models to study this clinically important virus. Early investigations 
focused on the identification of primate hepaciviruses but proved fruitless; no new 
hepaciviruses were isolated for over 20 years. However the use of deep sequencing in a range 
of hosts has revealed a broad range of animal hepacivirus. This recent boom in hepacivirus 
discovery has expanded this genus from 2 to 14 species in just 5 years; providing an ever growing 
pool of isolates with the potential to become the long awaited HCV animal model.  
1.6.1 Genomic organisation of the newly discovered hepaciviruses 
 
The first novel hepacivirus, since the discovery of HCV, to be isolated was equine hepacivirus 
(EqHV) in 2011 (Kapoor et al., 2011). This discovery prompted investigations to identify further 
hepacivirus species in a range of hosts by next generation sequencing. This approach led to the 
identification of hepaciviral RNA in bats, bovines, equines, rodents, a new-world primate, and 
the graceful cat shark  (Quan et al., 2012; Baechlein et al., 2015; Corman et al., 2015; Burbelo et 
al., 2012; Lyons et al., 2012; Lauck et al., 2013; Drexler et al., 2013; Kapoor et al., 2013; Shi et 
al., 2015).  
Isolation of the bat hepacivirus (BHV) 5′UTR yielded sequences of varying length with the 
shortest being 156 nucleotides and the longest 445. It is therefore likely that this 5′UTR 
represents an elongated sequence (the EqHV 5′UTR is 385 and HCV ~330 nucleotides in length) 
in comparison to other hepaciviral 5′UTRs. However secondary structure prediction shows that 
the BHV 5′UTR contains a conserved HCV-like IRES element SLIII which harbours a conserved 
GGG motif in the apical loop of SLIIId (Quan et al., 2012). The bovine hepacivirus (BovHepV) 
5′UTR is 294 nucleotides in length and is characteristic of an HCV-like IRES. SLIIIa,b,c,d,e are all 
conserved, with a GGG motif in the apical loop of SLIIId, and a miR122 seed site located directly 
upstream of SLII. However the BovHepV 5′UTR does not appear to contain a homologous SLI 
despite repeated attempts to isolate this sequence (Corman et al., 2015; Baechlein et al., 2015). 
Hepacivirus genomes isolated from bank voles demonstrated marked variability in their 5′UTRs 
which displayed characteristics of both hepaci- and pegi- virus IRES elements. One isolate (SAR-
46) displayed the typical HCV-like IRES SLIII structure with the conserved GGG motif presented 
in the apical loop of SLIIId (Drexler et al., 2013). The 5′UTR of hepaciviral isolates from deer mice 
also displayed the HCV-like IRES SLIII with SLIIIa-f and the pseudoknot all conserved. However, 
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the 5’ sequence of these UTRs could not be matched with any known sequences in genbank. All 
of the HCV-like IRES elements did however contain conserved miR122 seed sites (Kapoor et al., 
2013; Drexler et al., 2013). The 5′UTRs of both of the Guereza hepacivirus (GHV) isolates 
displayed limited homology to the other hepacivirus UTRs in their 5′ sequences, returning no 
matches to sequences in the genbank database. However the 99 nucleotides directly upstream 
of the coding region displayed analogous structural features related to SLIIId-f of HCV-like IRES 
with the characteristic conserved GGG motif presented in the apical loop of SLIIId. A conserved 
miR122 seed site was also identified within the 5′ sequence of both GHV isolates (Lauck et al., 
2013). The 5′UTR of wenling shark virus (WLSV) was not characterised but was shown to be only 
132 nucleotides in length indicating that the full 5′UTR may not have been sequenced (Shi et al., 
2015). The 5′UTRs of the Norway rat hepaciviruses (NrHVs) were not characterised (Firth et al., 
2014). 
Predictions based upon the sequences of new hepaciviral isolates have all demonstrated a 
genomic organisation which mimics that of HCV and EqHV, one large polyprotein encoding 10 
proteins: core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B. Sequence alignment and 
homology were used to identify the protein boundaries of non-structural proteins predicted to 
be cleaved by NS3/4A. Signal peptidase cleavage sites have been identified in the structural 
proteins which would yield structural and non-structural proteins of similar size to HCV, with 
predicted identical functions (Quan et al., 2012; Baechlein et al., 2015; Kapoor et al., 2013; Lauck 
et al., 2013; Shi et al., 2015). Interestingly, whilst most of the newly discovered hepaciviruses 
exhibit ORFs shorter than that of HCV (typically ~2700 a.a compared with ~3000 a.a.) the GHV 
ORF was predicted to encode a polyprotein ~3300 a.a in length. This is due to an unusually long 
and disordered NS5A protein which is over twice as long as known NS5A proteins. 
The new hepacivirus isolates, like HCV, exhibited high levels of genetic diversity within the E 
proteins and NS5A; these proteins exhibited the highest levels of sequence divergence, in some 
cases up to 85% (Kapoor et al., 2013). NS3 and NS5B exhibited the highest levels of conservation, 
up to 75.4% (Baechlein et al., 2015). Furthermore many of the viral isolates displayed sequence 
diversity from one and other reminiscent of HCV subtypes (~20%). However between species 
viral sequences exhibited expectedly higher levels of sequence divergence of >40% and up to 
70% in the case of WLSV (Shi et al., 2015).  
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All of the hepaciviruses are also predicted to have a 3′UTR. Obtaining the full sequences of 
hepaciviral 3′UTRs is difficult and thus the majority of the newly discovered viruses have not yet 
been fully characterised in this region. Some bovine isolates have been sequenced and predicted 
to form three SLs which resemble the HCV 3′UTR, however they did not contain a poly(U) stretch 
which may indicate that the sequences are incomplete (Corman et al., 2015). Furthermore one 
rodent isolate demonstrated incomplete structural similarity with the HCV X-tail with the 
terminal stem loop conserved but not the preceding structures. These data indicate that the 
3′UTR structure of these related viruses may be conserved, or at least that some structural 
features are maintained. The observed conservation throughout the majority of the genome 
would suggest that this is the case. However, more 3′UTR sequences from more isolates will 
need to be determined to confirm this.  
1.6.2 Tissue tropism, pathology, and prevalence, of the newly discovered hepaciviruses  
 
Like HCV and EqHV the newly discovered hepaciviruses exhibit liver specific tropism. The highest 
levels of genomic RNA were isolated from sera and liver tissue in all of the species investigated, 
with minimal to no viral RNA isolated from other tissues. Higher levels of viral RNA were also 
detected in liver lymph nodes. The presence of conserved miR122 seed sites in the 5′UTRs 
provides further evidence that these viruses exhibit liver tropism.  
BHV was isolated from two species of African bats with 0.6% prevalence. The authors did note 
that they were unable to assess the true prevalence, host range, or geographical distribution of 
the BHVs identified in this study, but that it can be said that they are highly genetically diverse 
and are circulating worldwide. Despite this no obvious signs of pathological disease were 
observed in any infected bats even though high viral titres (up to 3x108) were detected (Quan et 
al., 2012).  
Viral prevalence appeared to be higher in bovines, 3.2% of German cattle tested positive for 
BovHepV infection. This study also demonstrated viral persistence, with 5 cows testing positive 
over a one year period following initial detection of viral RNA; however some animals 
spontaneously cleared virus within this time frame indicating both chronic and acute infection 
of BovHepV. Whilst chronic infection was detected, no RNA positive animal exhibited significant 
differences in liver enzymes levels compared to uninfected samples. Liver degeneration or 
inflammation indicative of viral infection could not be detected in a post mortem analysis of the 
liver of an infected animal. However, viral loads of 2.92x105 were detected in the sampled liver 
30 
 
compared with 8.94x104 in the serum. Viral loads <4.15x103 were observed in other tissues and 
no virus could be isolated from milk, faeces, urine, or nasal discharge; in agreement with a liver 
specific, blood borne virus (Baechlein et al., 2015).   
In another investigation into hepaciviral infection in bovines (Corman et al., 2015), this time in 
African cattle, a higher prevalence of 8.5% was detected in 106 animals, with similar viral loads 
of 1.6x105. No tissue specific samples were available to confirm liver tropism however the data 
presented by Baechlein et al. and the presence of a conserved miR122 site in the 5′UTR would 
suggest this to be the case. Whilst Corman et al. did not present findings regarding the pathology 
of BovHepVs in African cattle they did present evidence of GORs within viral isolates; suggesting 
that they exhibit persistence.  
Rodent hepaciviruses exhibited a lower level of prevalence than that of bovines (0.8-1.9%) which 
was more similar to the prevalence of hepaciviruses in bats. Mean RNA concentrations were 
highest in the liver and RNA could be detected by in-situ hybridisation; whereas no staining was 
observed in samples negative for hepacivirus RNA by PCR, or in spleen, kidney, heart and lung 
tissues. Histopathological signs of liver inflammation were also reported as well as an 
observation that antibodies did not co-occur with RNA in most animals, indicating that bank 
voles may be able to spontaneously clear virus (Drexler et al., 2013). Another report of rodent 
hepacivirus in Norway rats observed that hepaciviral RNA was most consistently detected in liver 
tissue and the negative strand replicative intermediate was exclusively identified in liver tissue.  
Kapoor et al. also noted the existence of a conserved miR122 site in the 5′UTR of RHV indicating 
liver tropism (Kapoor et al., 2013). Lauck et al. suggested a putative liver tropism for GHV based 
upon a similar observation (Lauck et al., 2013). WLSV tropism is presumed to be specific to the 
liver as this virus was only isolated from fish liver tissue (Shi et al., 2015).  
Beyond the information regarding the viral sequences and tissue tropism obtained during the 
isolation and sequencing of this newly discovered set of viruses little is known about them. 
Excluding EqHV, no work has been undertaken to investigate the roles of the viral proteins and 
RNA structures that are predicted to function throughout the hepaciviral lifecycle.  
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1.6.3 Update to the taxonomy of the hepaciviruses  
 
The naming of newly discovered hepaciviruses has so far used the animal host to denote new 
viral species i.e. bovine-, bat-, and rodent-, hepacivirus. However this has caused some confusion 
for EqHV regarding the nomenclature for this virus (CHV, NPHV, EqHV) and no true consensus 
exists in the field.  Due to the number of new hepaciviral species being discovered, and the 
number of new isolates, an update to the taxonomy of the hepacivirus genus was proposed 
(Smith et al., 2016). This paper proposes hepaciviral species be denoted by a letter, rather than 
host species, and should encompass 14 species: hepacivirus A-N based upon the date of 
publication of the first complete sequence. Due to historical nomenclature for HCV and GBV-B 
these two viruses would be renamed hepacivirus C and hepacivirus B respectively, as opposed 
to A and B based on publication date. However CHV/NPHV/EqHV would be renamed hepacivirus 
A. Interestingly the analysis conducted in this proposal suggested that WLSV is distinct from the 
hepaciviruses, and also the closely related pegiviruses. Whilst it most closely grouped with the 
hepaciviruses the authors did not go as far as to provide a hepacivirus classification. They 
suggested that until further information about the biology and molecular biology of WSLV was 
obtained it remain as an unclassified virus in the Flaviviridae. This study confirmed that EqHV 
(hepacivirus A) is the most closely related hepacivirus, discovered to date, to HCV (Figure 1.3). 
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Phylogenetic trees using A) positions 1123–1566 and B) 2536–2959 of the virus polyprotein of all 
of the currently identified hepaciviruses indicating their species of origin and proposed new 
hepacivirus A-N classification.  
 
1.6.4 The newly discovered hepaciviruses as a model system to study HCV 
 
Given the close genetic relationship of EqHV and HCV, and apparent similarities between 
infections with regards to chronicity, it has been cited as a potential model virus with which to 
study HCV (Ramsay et al., 2015; Scheel et al., 2015).  Horses are too large to be considered an 
ideal animal for laboratory testing, however one study has demonstrated immune protection 
from reinfection with EqHV in horses (Pfaender et al., 2017). Bovines are also too large to be 
considered a viable laboratory animal and given the ethical implications of testing on primates 
GHV is also not an optimal candidate. However a number of rodent hepaciviruses have been 
discovered which would appear to provide an ideal model with which to study the full hepaciviral 
lifecycle in an immunocompetent host.  
In a recent study Billerbeck et al. used a rodent hepacivirus isolated from Norway rats (NrHV-
1/Hepacivirus G) to infect laboratory mice, achieving acute and chronic infection in which the 
virus also appeared to adapt to its new host after passaging through it. Acute infection did not 
cause disease and chronically infected mice showed minimal to mild liver inflammation 
Figure 1.4: Phylogenetic analysis of the hepaciviruses 
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(Billerbeck et al., 2017). This study also characterised the immune response to NrHV infection 
reporting a broadly directed virus-specific T cell response during acute resolving infection, and 
demonstrated that CD8+ T cell depletion rendered mice unable to clear the infection. NK cells 
were also activated upon NrHV infection, as were Tregs and this was suggested to contribute to 
the establishment of chronic infections. Overall this study has clearly demonstrated that NrHV 
infection in laboratory mice provides an immunocompetent model system with which to study 
hepaciviral infection and immunity, and may be able to contribute to the ongoing search for an 
HCV vaccine.  
Whilst the NrHV mouse model represents a major breakthrough in hepaciviral research 
NrHV/Hepacivirus G is phylogenetically distant from HCV compared with the other newly 
described hepaciviruses, and another rodent hepacivirus (hepacivirus I/RHV) is more closely 
related to HCV (Figure 1.3). Therefore infection models using other hepaciviruses may yet 
provide more informative systems.  
Furthermore, the advent of a replicative, immunocompetent, model should not diminish 
research into the other hepaciviruses, especially those which have not yet been demonstrated 
to replicate in vitro such as EqHV. Increasing understanding of the molecular biology of the most 
closely related virus to HCV still provides an invaluable tool with which to investigate this human 
pathogen. Differences identified between these two viruses may be instrumental in shaping 
future work on HCV, or in the mouse model. Furthermore, understanding the molecular biology 
of the genus as a whole may provide insights into this class of viruses that cannot be obtained 
from the study of one or two species in isolation. The scientific community must still investigate 
this novel group of viruses, and search for new ones, to increase understanding of the biology 
of hepaciviruses, HCV, and positive sense RNA viruses as a whole.  
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1.7 Project aims 
 
EqHV is the most closely related virus to HCV, however it does not match the persistence or 
pathology exhibited by HCV. The molecular biology of this virus is poorly understood and has 
not been extensively studied. EqHV research is currently being held back by the lack of a cell 
culture system with which to study its replication, and as such is limited to functions which can 
be studied independently of replication. This study therefore set out to further investigate the 
molecular biology of this newly discovered model virus by determining the secondary structure 
of the EqHV 5′UTR IRES and assigning functional attributes to structural elements, and to 
establish an EqHV SGR capable of replicating in mammalian cell culture.  
Positive strand RNA viruses are able to directly translate their genome upon release into the 
cytoplasm and this represents one of the first viral-host interactions. EqHV does not exhibit the 
same pathology as HCV, therefore identifying differences between these two closely related 
viruses may begin to provide insights into the mechanisms which underlie them. By investigating 
the structure of the EqHV 5′UTR using SHAPE, and how this relates to its function and 
interactions with host cell factors, we hoped to observe differences in translation initiation 
between EqHV and HCV, which may begin to explain differences in pathology. 
A replicative model for HCV transformed the field and has been instrumental in the advent of 
new, highly successful, DAA therapies. EqHV research is currently limited by a lack of a replicative 
model. As such an EqHV SGR able to efficiently replicate in cell culture would represent a leap 
forward not only in the field of EqHV research but also in the wider hepacivirus field. 
Understanding how EqHV replicates could provide evidence for highly conserved hepaciviral 
mechanisms, or key differences, either of which would provide insights into the HCV lifecycle 
and replication strategies of the ever expanding hepacivirus genus. We therefore attempted to 
construct a replicative EqHV SGR using two different EqHV sequences, and assayed novel cell 
lines expressing known HCV factors.  
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Chapter 2 Materials and 
Methods 
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2.1 Materials: 
 
2.1.1 Mammalian cell lines 
 
Huh7 cells are a human hepatoma cell line known to support replication of HCV (Nakabayashi 
et al., 1982; Lohmann et al., 1999). 
 Huh7.5 cells are a Huh7 derived line created through the clearing of Huh7 cells stably harbouring 
an HCV SGR; supporting higher levels of HCV replication due to a dominant negative RIG-I 
mutation (Blight et al., 2002).  
FHK cells are a foetal horse kidney cell line known to support the replication of a number of 
equine viruses and were kindly provided by Dr Hiroshi Sentsui (Nihon University, Japan) (Maeda 
et al., 2007).  
293T cells are a human embryonic kidney cell line which have been demonstrated to support 
HCV replication when engineered to express miR122 (Fukuhara et al., 2012).  
2.1.2 Bacterial strains 
 
Escherichia coli (E. coli) DH5α: Genotype; F- Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 
hsdR17 (rk-, mk-) phoA supE44 λ- thi-1 gyrA96 relA1 were purchased from Life Technologies 
Chemically competent bacteria were produced using the Z-competent kit (Zymo Research). 
2.1.3 Virus sequences 
 
Two EqHV viral sequences were used in this study 
EF369_11J; GenBank accession no. JX948116.1. 
NZPI; GenBank accession no. KP325401. 
2.1.4 SGR constructs 
 
pSGR NZPI was kindly provided for use by C. Rice (Rockefeller University). 
pSGR H-E-H was constructed at the University of Leeds by Cheryl Walter and Hazel Stewart by 
adapting the pSGR JFH as described (Targett-Adams and McLauchlan, 2005) using the EqHV 
isolate EF369_11J; GenBank accession no. JX948116.1.  
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2.1.5 Bicistronic expression constructs 
 
pGL3 RLuc/FLuc expression constructs were kindly provided for use by Kensuka Hirasawa 
(Memorial University, Newfoundland, Canada). 
2.1.6 miR122 reporter constructs 
 
pGL3 1225 and pGL3 MCS were kindly provided by Catherine Jopling (University of Nottingham).  
2.1.7 N-Methylisatoic anhydride (NMIA) 
 
NMIA was purchased from Sigma-Aldrich and resuspended in dimethyl sulfoxide (DMSO [Sigma]) 
to a concentration of 100 mM.  
2.1.8 Purified eIF3 and 40S ribosomal subunit 
 
Purified eIF3 and 40S ribosomal subunit was kindly provided for use by Dr. Nicolas Locker 
(University of Surrey). 
2.1.9 Primers 
 
Oligonucleotide primers were purchased from Integrated DNA technologies (IDT), resuspended 
in deionised water (dH2O) to 100 μM, and stored at -20°C.  
Fluorescent primers were also ordered from IDT as PAGE purified and 5′6FAM, or 5′HEX, 
fluorescently labelled. 
2.1.10 Tissue culture microscope 
 
Cultured cells were visualised with an OPTIKA XDS-2 microscope.  
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2.2 Nucleic acid manipulation 
 
2.2.1 Bacterial transformation 
 
Z-competent E. coli DH5α were transformed by addition of 10-50 ng of DNA to 50 μl of 
competent bacteria, on ice for 5 minutes, before spreading onto Luria Bertani (LB) agar plates 
with 100 μg/ml tetracycline or ampicillin. Plates were incubated at 37°C, or 30°C for bacteria 
transformed with DNA coding for the EqHV NS5A.  
2.2.2 Preparation of DNA from bacterial culture 
 
Single bacterial colonies were picked and grown in lysogeny broth (10 g/L tryptone, 10 g/L NaCl, 
5 g/L yeast extract [LB]) in a rotary shaking incubator at 200 rpm in the presence of antibiotic. 
Constructs coding for the EqHV NS3-5B region were grown for 24 hours at 30°C, all others for 16 
hours at 37°C. Bacterial cells were harvested by centrifugation at 4,000 x g for 15 min at 4°C. 
Plasmid DNA was purified by alkaline lysis using GeneJET Plasmid Miniprep kit (Thermo 
Scientific) according to the manufacturer’s protocol. For long term storage of plasmids, glycerol 
stocks of bacterial cultures were prepared from 1 ml cultures re-suspended in 30% glycerol, 70% 
LB (v/v) and stored at -80°C.  
2.2.3 Nuceleic acid quantification 
 
DNA and RNA was quantified using the absorbance at 260 nm on a NanoDrop 1000. 
2.2.4 Q5 site-directed mutagenesis 
 
All mutagenesis, including large deletions, was carried out using the NEB Q5 SDM kit according 
to the manufacturer’s instructions. Q5 SDM primers were designed in the NEBasechanger online 
tool. Primer pairs contained the desired mutation at the 5′ (forward primer) and 3′ (reverse 
primer) ends, or annealed to exclude the sequence to be removed. An initial denaturation step, 
98°C for 30 seconds, was followed by 25 cycles of 98°C for 20 seconds, 20 seconds at the 
annealing temperature recommended by the NEBasechanger tool, 72°C for 30 seconds/kb of 
amplified DNA, and a final extension at 72°C for 2 minutes. PCR products were treated with the 
kinase/ligase/DNAse (KLD) mix for 5 minutes at room temperature and transformed into 50 μl 
Z-competent E. coli DH5α. All of the constructs described of this study are archived in the Harris 
group glycerol store (Garstang 8.61, available from Prof. M Harris). 
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2.2.5 Restriction digests 
 
Restriction digests were carried out using enzymes purchased from NEB according to the 
manufacturer’s instructions. A minimum of one enzyme unit:1 μg of DNA was used for a 
minimum of one hour.  
2.2.6 Agarose gel electrophoresis  
 
DNA gels consisted of 1% (w/v) agarose in TAE buffer (40 mM Tris-HCl, 0.11% (v/v) acetic acid, 1 
mM ethylenediaminetetraacetic acid [EDTA]) with 1:10,000 SYBR Safe DNA Gel Stain 
(Invitrogen). To separate fragments samples were loaded in DNA loading buffer (1% (w/v) 
sucrose, 0.0125% (w/v) bromophenol blue in dH2O) and run in TAE buffer at 8 V/cm and 
compared to Bioline Hyperladder I markers. 
2.2.7 Gel extraction of DNA 
 
DNA bands were visualised using blue light with an orange filter and bands of interest were 
excised. DNA was purified using the QIAquick Gel Extraction kit (QIAGEN). 
2.2.8 Ligation 
 
DNA fragments were ligated at a 1:5 molar ratio (vector:insert) by mixing and incubation on ice 
for 5 minutes and made up to a final volume of 20 μl with dH2O, T4 DNA Ligase buffer, and 
10,000 units of T4 DNA ligase (NEB). Ligations were incubated at room temperature for 1 hour 
and 5 μl was transformed into Z-competent E. coli DH5α.  
2.2.9 Verification of ligation products 
 
Single colonies were picked and DNA prepared as described in 2.2.2, sequenced by Beckman 
Coulter Genomics, and aligned to the WT construct using DNA Dynamo to confirm the construct 
sequence.  
2.2.10 Linearisation of DNA 
 
To linearise pSGR constructs 10 μg of DNA was digested overnight with either XbaI (pSGR EqHV) 
or BspeI (pSGR NZPI), or AscI to linearise directly following the 5′UTR for use in pull-downs. 
Linearised DNA was purified by phenol:chloroform:isoamylalcohol (25 : 24 : 1 [pH8.0]) extraction 
by addition of an equal volume to that of the digestion. The mixture was vortexed for 1 minute 
and centrifuged at 17,000 x g for 2 minutes. The upper aqueous phase was extracted and mixed 
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with an equal volume chloroform, vortexed, centrifuged, and the upper aqueous phase again 
collected. DNA was precipitated in 2.5 samples volumes of 100% (v/v) ethanol with 0.1 sample 
volumes of 3M NaAc at -20°C for > 1 hour. DNA was pelleted by centrifugation at 20,000 x g, 
4°C, for 30 minutes and washed once in 500 μl 70% ethanol. The DNA pellet was air dried and 
resuspended in nuclease free H2O.  
2.2.11 RNA manipulation and DEPC treatment 
 
When handling RNA all surfaces were pre-treated with RNAse AWAY (Molecular BioProducts). 
Phosphate buffered saline used in RNA manipulation was treated with 0.1% (v/v) diethyl 
pyrocarbonate (DEPC) and incubated with shaking at 37°C for 16 hours, excess DEPC was 
removed by autoclaving. Nuclease free water for use in RNA manipulation was purchased from 
ThermoFisher.  
2.2.12 In vitro transcription of RNA 
 
Linearised DNA (2 μg) was used as a template in the T7 RiboMAX™ Large Scale RNA Production 
System (Promega). Reactions were incubated at 37 °C for 60 min before degradation of template 
DNA using 2 units of DNase for 30 min at 37 °C. 
2.2.13 Lithium chloride precipitation of RNA 
 
IVT RNA was precipitated using 7.5 M Lithium Chloride, 50 mM EDTA, pH 8.0 (ThermoFisher) at 
a final [LiCl] of 2.5 M and incubation at -20°C for >1 hour. RNA was pelleted by centrifugation at 
20,000 x g for 30 minutes, washed with 70% ethanol and resuspended in nuclease free H2O. 
2.2.14 RNA gel electrophoresis 
 
IVT RNA was analysed by denaturing agarose gel electrophoresis (1% (w/v) agarose, 1X MOPS 
(40 mM 3-(N-morpholino)-propanesulfonic acid [pH 7.0], 10 mM sodium acetate, 1 mM EDTA), 
4.7% (v/v) formaldehyde), supplemented with 1:10,000 SYBR Safe DNA Gel Stain (Invitrogen). 
RNA samples were diluted in RNA loading buffer (47.5% (v/v) formamide, 9 mM EDTA, 0.0125% 
(w/v) SDS, xylene cyanol and bromophenol blue), denatured at 65°C for 10 minutes and loaded 
onto gels. Gels were run for 1 hour at 70 V and visualised under blue light illumination, compared 
with a ssRNA ladder (NEB). 
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2.3 Tissue culture 
 
2.3.1 Mammalian cell lines 
 
All mammalian cells used in this study were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; Sigma), 10% (v/v) foetal bovine serum (FBS), 100 IU/ml penicillin, 100 μg/ml 
streptomycin and 1% (v/v) non-essential amino acids (Lonza) in a humidified incubator at 37°C  
with 5% CO2. Cells were passaged at 70-80% confluency by washing with PBS and incubation 
with 0.5 mg/ml trypsin-EDTA (Sigma). Trypsin was inactivated by addition of excess complete 
DMEM and seeded into culture flasks, or plates, for further passage or experimentation.  
2.3.2 Freezing cell stocks 
 
Cultured cells were frozen for long term storage at -80°C in full media supplemented with 10% 
DMSO, 40% FBS (v/v).  
2.3.3 Retroviral transduction 
 
Psuedotyped virus containing the gag/pol HIV capsid and VSVg glycoproteins, with the gene of 
interest packaged via the psi packaging signal, were created by transfection of 4 μg of plasmids 
coding for the gag/pol, glycoprotein, and psi flanked gene of interest, into 4x105 293T cells in a 
10 cm2 dish using PEI (as described in 2.3.6). Supernatant was collected 3 days post transfection, 
clarified at 1200 x g for 5 minutes and filtered through a 0.45 μm filter, to collect pseudotyped 
particles.  
Mammalian cells were transduced by addition of 6 ml of the collected supernatant, and 4 ml full 
DMEM, to 4x105 cells in a 10 cm2 dish. After 24 hours of incubation media was replaced with 3:7 
ml supernatant:full DMEM and this was repeated every 24 hours up to 72 hours. The 
supernatant was removed and replaced with full media supplemented with 5 μg/ml at 72 hours. 
This was conducted for both miR122 and SEC14L2 in Huh7, FHK, and 293T cells.  
2.3.4 Maintenance of mammalian cells expressing miR122, SEC14L2, or the PIV5 V protein 
 
For cells transduced to express miR122 or SEC14L2 media was supplemented with 5 μg/ml 
puromycin every second passage to ensure maintenance of miR122 expression. Cells expressing 
the PIV5 V protein were passaged in media supplemented with 500 μg/ml neomycin.  
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2.3.5 RNA electroporation 
 
For either translation or replication assays cells were harvested by centrifugation following 
trypsin treatment and washed twice with ice cold PBS. Cells were counted and a final suspension 
of 5x106 created in ice cold DEPC treated PBS. 400 μl of cell suspension was mixed with 2 μg RNA 
in a chilled electroporation cuvette (Geneflow) and cells were electroporated at 950 μF, 260 V 
for 25 msec (BioRad Gene Pulser). Cells were immediately recovered in complete media, seeded 
into culture plates and incubated at 37°C, 5% CO2 until lysed for assay. 
2.3.6 Nucleic acid transfection 
 
DNA and RNA were both transfected using polyethylenimine (PEI) into 4x105 cells. Nucleic acid 
(2 μg) was diluted in 100 μl optimem (Sigma) and mixed with 10 μl 1 mg/ml PEI and incubated 
for 10 minutes at room temperature. During this time cells were washed twice with PBS. 
Following incubation 600 μl complete media was added to the transfection mix and this was 
immediately added to the washed cells. Transfected cells were incubated for 2 hours at 37°C, 
5% CO2, washed twice with PBS and complete media was added.  
2.3.7 Firefly luciferase assays 
 
Plates seeded with cells from electroporations (96 well, 2x105 cells) or transfections (6 well, 
4x105) were harvested for luciferase activity by washing in PBS and lysis in Passive Lysis Buffer 
(PLB; Promega). For replication assays cells were harvested at 4, 24, 48, and 72 hours post 
transfection (h.p.t), for translation assays using SGRs cells were harvested 6 h.p.t, and for 
translation assays using the bicistronic constructs cells were harvested 24 h.p.t. For 96 well 
plates cells were lysed in 30 μl PLB and 6 well plates 100 μl.  Samples were stored at -20°C until 
analysis. For samples obtained from a 6 well plate 30 μl of sample was transferred to a 96 well 
plate for assay with 50 μl of Luciferase Assay Reagent (Promega). Light emission was monitored 
on a BMG plate reader. 
2.3.8 Dual Luciferase assay 
 
Cells were treated as described for 6 well plates in 2.3.7 and assayed using the dual-luciferase 
reporter assay system (Promega) using 50 μl of each reagent with light emission monitored on 
a BMG plate reader.  
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2.3.9 Selection of stable cell lines 
 
Following transfection of SGR RNA cells were placed under selection with: 5 μg/ml puromycin, 
10 μg/ml blasticidin, or 500 μg/ml neomycin, depending upon the resistance gene located in the 
SGR (Table 5.3) until discreet colonies had formed, or all cells had died.  
 
2.4 In vitro methods 
 
2.4.1 Selective 2′hydroxyl acylation and analysis by primer extension (SHAPE) 
 
IVT RNA (12 pmol) was resuspended in 20 μl 0.5x TE buffer, incubated at 95°C for 2 minutes and 
cooled on ice for 2 minutes. Following this 103 μl ddH2O, 45 μl 3.3x folding buffer (333 mM 
HEPES, 20 mM MgCl2, 330 mM NaCl), and 2 μl RNAse inhibitor (RNAse OUT), was added and 
incubated for 30 minutes at 37°C. After incubation the mixtures were evenly split into positive 
and negative reactions to which 8 μl of 100 mM NMIA (positive [to a final concentration of 10 
mM]) or DMSO (negative) was added. Mixtures were incubated for 50 minutes at 37°C and 
precipitated in 4 μl 5 M NaCl, 2 μl 100 mM EDTA, 1 μl 20mg/ml glycogen, 18 μl ddH2O, and 350 
μl 100% ethanol at -80°C for 30 minutes. RNA was pelleted by centrifugation at 20,000 x g for 
30 minutes at 4°C, aspirated, dried, and resuspended in 10 μl 0.5x TE buffer.  
For both the positive and negative reactions 5 μl of this RNA was incubated with 1 μl 10 μM FAM 
labelled fluorescent primer, and 6 μl ddH2O at 85°C for 1 minute, 60°C for 10 minutes, and 30°C  
for 10 minutes. A master mix of 4 μl superscript IV (SSIV) RT buffer, 1 μl 100 mM DTT, 0.5 μl 100 
mM dNTPs, 0.5 μl RNAse OUT, 1 μl ddH2O, and 1 μl SSIV RT, was added to each reaction and 
incubated for 30 minutes at 55°C.  
For the sequencing ladder reaction 6 pmol unfolded IVT RNA in 7.5 μl 0.5x TE buffer, 1 μl 10 mM 
HEX labelled primer, and 2 μl ddH2O was incubated at 85°C for 1 minute, 60°C for 10 minutes, 
and 30°C  for 10 minutes and a master mix of 4 μl SSIV RT buffer, 1 μl 100 mM DTT, 0.5 μl 100 
mM dNTPs, 0.5 μl RNAse OUT, 1 μl ddGTP, and 1 μl SSIV RT, was added before incubation for 30 
minutes at 55°C.  
All RT extensions were heated at 95°C for 3 minutes, and cooled on ice with 2 μl 2 M HCl for 2 
minutes. cDNA was precipitated in 4 μl 3 M NaAc, 4 μl 100 mM EDTA, 1 μl 20 mg/ml glycogen, 
and 60 μl 100% ethanol for 30 minutes at -80°C, pelleted by centrifugation, aspirated and 
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resuspended in 40 μl deionised formamide (Hi-Fi formamide). Samples were pooled with 20 μl 
of ladder and stored at -80°C.   
2.4.2 Gel Based SHAPE 
 
SHAPE reactions were carried out as described in 2.4.1. However, primers were first labelled 
with ỵATP-33P through the addition of 5 μl H2O, 2 μl 10x Poly nucleotide kinase (PNK) buffer, 2 
μl PNK, and 11 μl ỵATP-33P to 1 μl (60 pmol) of unlabelled primer. Reactions were incubated for 
30 minutes at 37°C, and 20 minutes at 65°C. Labelled primers were precipitated in 4 μl 5 M NaCl, 
2 μl 100 mM EDTA, 18 μl ddH2O, and 350 μl 100% ethanol at -80°C for 30 minutes, pelleted by 
centrifugation at 20,000 x g for 30 minutes at 4°C, aspirated, dried, and resuspended in 50 μl 1 
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES). For the SHAPE reaction 3 μl 
of primer was used. Primer extensions were separated by running on a polyacrylamide 
sequencing gel (5 ml 10x TBE, 20g Urear, 9 ml 40% acrylamide, 35 ml H2O, 400 μl APS, 10 μl 
TEMED) for 3 hours at 40 watts. Gels were dried and exposed to a phosphor screen for one week 
and imaged using a FujiFilm FLA-500 imager  
2.4.3 SHAPE footprinting 
 
SHAPE footprinting was carried out as described in 2.4.1 however following folding of the IVT 
RNA, and prior to NMIA/DMSO treatment, 300 nM eIF3, or 40S ribosomal subunit, was added 
and incubated for 20 minutes at 37°C.  
2.4.4 SHAPE data analysis 
 
SHAPE fragment analysis was conducted by capillary electrophoresis by DNA sequencing and 
services, Dundee University. SHAPE data was analysed in the program QuSHAPE (Karabiber et 
al., 2013) and RNA structure prediction was carried out using the RNAstructure software (Reuter 
and Mathews, 2010) using the SHAPE reactivity profile as a pseudo free energy constraint. RNA 
secondary structure was modelled in VaRNA.  
2.4.5 Pull downs 
 
To pull-down EqHV 5′UTR binding partners from Huh7 cells the Pierce™ Magnetic RNA-Protein 
Pull-Down Kit was used. IVT EqHV 5′UTR RNA was 3′ biotinylated using the Pierce RNA 3´ End 
Desthiobiotinylation Kit according to the manufacturer’s instructions. Huh7 cells were lysed in 
Thermo Scientific Pierce IP Lysis Buffer and total protein concentration determined using a 
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NanoDrop. Biotinylated EqHV 5′UTR RNA (50 pmol) was bound to Nucleic-Acid Compatible 
Streptavidin Magnetic Beads and used as bait to pull-down from the Huh7 cell lysate (>2mg/ml). 
In place of a final elution step beads were resuspended in 50 μl wash buffer and stored at -80°C 
to be sent for tandem mass tag (TMT) mass spectrometry analysis.  
2.4.6 TMT mass spectrometry 
 
TMT mass spectrometry was carried out Kate Heesom (University of Bristol Proteomics Facility) 
and analysed against a bead only negative control sample. 
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Chapter 3  
A structural and functional 
analysis of the EqHV 5′UTR 
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3.1 Introduction 
 
The EqHV 5′UTR is a 385 nucleotide sequence located at the 5′ end of the EqHV genome. It has 
been predicted to comprise of three main structural domains, SLI, SLII, and SLIII (comprising 
domains SLIIIa,b,c,d,e,f), and a pseudoknot (Figure 3.1A and Figure 3.1C).  Previous work on the 
EqHV 5′UTR demonstrated that, like its HCV counterpart, it functioned as a viral IRES. Initiating 
translation in a cap-independent manner in mammalian cells in the context of both a bicistronic 
reporter construct, and an HCV SGR in which the HCV 5′UTR was replaced with that of EqHV 
(Stewart et al., 2013). This work also demonstrated that a ΔSLI deletion had no significant effect 
on translation efficiency from the EqHV IRES. In addition to this, work conducted by Scheel et al. 
investigated the effect of the presence of the EqHV 3′UTR, and miR122, on IRES activity. This 
work demonstrated that IRES activity was significantly enhanced by either the presence of the 
EqHV 3′UTR, or miR122, in a monocistronic system. Conversely, sequestration of miR122 using 
a locked nucleic acid (LNA) significantly decreased IRES efficiency (Scheel et al., 2015).  
The EqHV 5′UTR shares 66% sequence identity and a predicted high degree of structural 
similarity with the HCV 5’UTR (Kapoor et al., 2011). Translation of the viral genome is an essential 
part of the viral lifecycle and represents one of the first virus-host interactions during the 
establishment of infection. Translation initiation from the HCV 5′UTR IRES is a well-studied, and 
well understood, process. How the structural elements of this type IV IRES contribute to its 
function have been well established (reviewed in Fraser and Doudna, 2007). Domains II-IV 
constitute the IRES with domain I involved in replication, playing no role in IRES function. SLIIIb 
has been shown to interact with the ribosome binding face of eIF3, SLIIId with the 40S ribosomal 
subunit, and the pseudoknot positions the AUG start in the ribosome binding cleft (Berry et al., 
2010).  
Previous studies were able to demonstrate that the EqHV 5′UTR possessed IRES activity, and 
identified viral and host cell factors which influenced its activity. However, neither conducted 
an in depth study regarding how the individual domains, and conserved sequences, of the 5′UTR 
contribute to IRES activity. This chapter will therefore describe the design, construction, and 
analysis, of a series of EqHV 5′UTR structural mutants, in comparison to the WT.  
RNA secondary structure prediction is a fast and widely used method to investigate viral RNA 
structure where no experimental data exists, in order to analyse conserved structures and guide 
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mutational analysis. However, this does not come without its limitations (reveiwed in Schroeder, 
2009). One such limitation, pertinent to this study in particular, is the inability of many programs 
to reliably predict pseudoknots. Whilst some programs are designed specifically for this function 
each has its own limitations which would rendered them unsuitable for the purposes of this 
study. Therefore, the well-known and widely used program Mfold, a free energy based 
prediction software, was selected (Zuker, 2003). 
The first section of this chapter (3.2.1) describes the predicted structure of the EqHV 5′UTR and 
how this correlates with that of HCV. The predicted conformation of a number of structural 
deletions introduced into the EqHV 5′UTR are also described.  
As the structure of the 5′UTR, which guided the mutational analysis, was predicted it was 
important to experimentally determine the structure of the EqHV 5′UTR, and the structural 
mutants, to provide a more detailed insight into EqHV translation initiation to begin to build a 
model of EqHV IRES-dependent translation initiation.  
There are a number of ways to analyse RNA secondary structure in vitro. One such approach is 
the use of RNAses with different specificities (i.e. single and double stranded). This method 
utilises parallel analysis of cleavage patterns, resolved on denaturing polyacrylamide gels, to 
assess the single, or double stranded conformation of RNA (Nilsen, 2013). An alternative 
approach to RNA secondary structure determination is the use of chemical agents and enzymes 
and functions by acting on bases sensitive to chemical and enzymatic attack; however this labour 
intensive method is most powerful in comparison with a model of secondary RNA structure 
generated from an alternative experimental approach (Ziehler and Engelke, 2001). Whilst both 
of these approaches provide a wealth of structural information about the RNA structure under 
investigation, they both have significant limitations. Therefore SHAPE analysis (described in 
1.3.4) was chosen for use in this study.  
SHAPE analysis utilises chemical probing reagents which selectively acylate the ribose in the 
backbone of flexible (unpaired) nucleotides within a structure.  These chemical adducts prevent 
reverse transcription (RT) progression at a reactive base resulting in RT extension terminations. 
By using a labelled primer to conduct the RT step cDNA fragments can be analysed, in 
conjunction with a sequencing ladder, to determine which bases exhibit high levels of 
terminations, and are thus likely unpaired. This experimental methodology  therefore has a 
significant advantage over other RNA structure probing methods as every base is simultaneously 
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reacted with, and therefore its structure interrogated, in one reaction; theoretically allowing the 
capture of information regarding the base pairing state of every single nucleotide with one 
experiment. The advantages of SHAPE are further extended by the advent of “high throughput” 
SHAPE (Wilkinson et al., 2008). This method utilises fluorescent labels to allow the cDNA 
fragments to be analysed by capillary electrophoresis, excluding the need for laborious and 
technically challenging sequencing gels. Furthermore, analysis by capillary electrophoresis 
allows for the consecutive analysis of up to 96 samples. The use of data obtained from SHAPE 
analysis in the guide of RNA secondary structure prediction has been shown to be extremely 
accurate. The use of SHAPE data as a “soft” pseudo-free energy constraint increased the 
prediction accuracy of the 16S E. coli RNA structure from 72% for traditional chemical probing 
methods to ~95%. Inclusion of SHAPE reactivity data routinely results in base pair prediction 
accuracies >90% (Rice et al., 2014; Deigan et al., 2009; Hajdin et al., 2013); put together these 
advances in chemical probing reagents, and detection, makes SHAPE an extremely powerful and 
relatively high throughput method to investigate RNA secondary structure (the current state of 
SHAPE is reviewed in Kenyon et al., 2014). 
Section 3.2.2 of this chapter describes the experimental process of the SHAPE analysis used in 
this study. Subsequent sections describe the structural analysis of the WT (3.2.3) ΔSLI (3.2.4) 
ΔSLI+II (3.2.5) ΔSLIII (3.2.6) ΔSLIIIb (3.2.7) and ΔSLIIId (3.2.8) EqHV 5′UTR, as a complementary 
system to further our understanding of the role which structure plays in the function of the EqHV 
5′UTR IRES. 
Bicistronic reporter constructs have long been used to investigate the activity of nucleic acid 
which has been postulated to function as an IRES. The principle of such constructs is two 
cistrons, each under independent translational control. Translation of the first is driven by the 
m7G cap, with the second potentially driven by the putative IRES under investigation (reviewed 
in Terenin et al., 2017). By assessing the relative translation of each cistron it is possible to draw 
conclusions regarding the IRES activity of the sequence being investigated.  
Section 3.2.9 of this chapter describes the analysis of WT EqHV 5′UTR IRES function, and 
structural mutants, in the context of a classical RLuc/FLuc bicistronic construct, and the effect 
that miR122 has on the activity of the EqHV IRES in this context.  
Whilst bicistronic reporter constructs have been widely used for the analysis of viral IRES activity, 
and have many advantageous properties in this regard, there are also a large number of 
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disadvantages regarding their use (reviewed in Terenin et al., 2017). It is known that aberrant 
translation of the second cistron can be driven by cryptic promoter sequences and splicing 
events resulting in false positive IRES activity, especially in the case of cryptic promoters in HCV. 
It is difficult to establish comprehensive controls for assays utilising a bicistronic system. 
Furthermore miR122 has been demonstrated to protect HCV viral RNA from the endonuclease 
XrnI (Thibault et al., 2015), a function which may be ablated by internal positioning of the IRES. 
Due to the known pitfalls of bicistronic assays in general, and the potential for HCV specific 
problems to arise in EqHV due to their similarity, further analysis of the EqHV IRES using an 
alternative system was deemed necessary. Both monocistronic, and SGR, systems have been 
used to assay EqHV 5′UTR IRES activity (Stewart et al., 2013; Scheel et al., 2015) and were 
considered as potential candidates for this study. Both constructs position the 5′UTR at the 
proximal 5′ end, as in the viral genome, facilitating a more relevant interaction with miR122. 
Both systems can also include the 3′UTR, which has been shown to upregulate translation. 
However, the SGR was chosen as it is the more physiologically relevant of the two. 
Section 3.2.10 of this chapter describes the analysis of the aforementioned structural mutants 
in the context of an EqHV SGR, investigating the differences observed between the activity of 
the IRES in the bicistronic and SGR constructs. The effect of miR122 on translational activity, and 
the EqHV sequence that is mediating such effects, is also described.  
As there are fundamental differences in the pathology of EqHV and HCV and it has not, as yet, 
been possible to establish replication of EqHV in vitro it was postulated that the inability of EqHV 
to cause significant disease may be linked to its inability to replicate in mammalian cell culture. 
Therefore it may be that the predicted structural differences observed between these two viral 
IRES are affecting their functions and, as translation is one of the earliest interactions between 
the virus and host cell on the path to establishing replication, the ability of EqHV to establish 
infection. This could therefore limit its pathogenic potential and ability to replicate in 
mammalian cell culture. It was therefore essential to further investigate the IRES function of the 
EqHV 5′UTR as this could shed light on the fundamental differences between these two viruses 
and provide information on why HCV so efficiently establishes a disease with such a significant 
pathology.   
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3.2 Results 
 
3.2.1 Predicting the structure of the EqHV 5′UTR and structural mutants 
 
The secondary structure of the EqHV 5′UTR has previously been described and has been 
predicted to contain three main structural domains: SLI, SLII, SLII (comprising SLIIIa,b,c,d,e,f), 
and a pseudoknot (Kapoor et al., 2011; Burbelo et al., 2012). The HCV 5′UTR has been well 
characterised and is known to contain four main structural domains: SLI, SLII, SLII (comprising 
SLIIIa,b,c,d,e,f), SLIV and a pseudoknot. An independent prediction of the EqHV 5′UTR was 
conducted for this study using the NZPI EqHV 5′UTR sequence (GenBank accession no. 
KP325401) in the RNA prediction software Mfold (see appendices for Mfold predicted 
structures). A schematic representation in comparison to the known HCV 5′UTR structure can 
be seen in Figure 3.1A and Figure 3.1B.  
This agreed well with previously published predictions of the secondary structure (Kapoor et al., 
2011; Burbelo et al., 2012) indicating the presence of all three main structural domains. One 
difference observed here was the lack of an intermediate SL that has previously been predicted 
to reside between SLI and SLII, 5′ to the miR122 seed site (herein termed SLIA). Whilst this SL 
has previously been predicted for EqHV the Mfold predictions conducted here did not indicate 
the presence of SLIA. Furthermore SLIA demonstrates high sequence comparison with the, 
unpaired, miR122 seed site one of HCV and was therefore omitted from the structural prediction 
to maintain a more “HCV like” 5′UTR. In comparison with the HCV 5′UTR the secondary structure 
is largely similar throughout SLII and SLIII; however, 5′ relative to SLII there are some marked 
differences. Most notably is the large and extended SLI of EqHV which is 57 nucleotides larger 
than HCV SLI, comparable in size to SLII, and the lack of SLIV. With regards to sequence specific 
features there are some interesting observations to be made. The HCV 5′UTR contains two 
miR122 seed sites; however, just one seed site, corresponding to seed site two, is conserved in 
the EqHV 5′UTR. This conservation indicates that miR122 plays a role in the EqHV lifecycle. 
However, this incomplete conservation may suggest that it either plays an alternative, or less 
important, role than in HCV.  
Furthermore five out of the six nucleotides which form the apical loop of SLIIId are conserved 
between these two viruses (UUGGGC/U) with EqHV containing a C at position 6 in the loop and 
HCV a U. Whilst the apical loop is 100% conserved amongst HCV isolates, due to previous studies 
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demonstrating that the GGG motif interacts with the 40S ribosomal subunit during HCV 
translation initiation, and that only the GGG motif is conserved amongst other 
Hepacivirus and Pestivirus species, this study focussed only on the conserved GGG motif. 
Predicting the existence of a pseudoknot by conventional RNA secondary structure prediction 
software is difficult and often unreliable. As such, the existence of such a structure was not 
initially predicted by Mfold. However, by closely examining the sequence of this region in the 
context of the predicted secondary structure of SLI, SLII, and SLIII it became clear that the 
existence of a pseudoknot was possible. From the beginning of the stem of SLIIIe through to the 
end of the predicted pseudoknot base pairing region there is 84% sequence conservation 
between HCV and EqHV. However, the apical loop of SLIIIe is 100% conserved with HCV and 7 of 
the 8 nucleotides in the apical loop of SLIIIf are conserved. The predicted stem of the EqHV 
pseudoknot only exhibits 55% sequence identity with HCV. However, closer inspection revealed 
that the equivalent regions in these two viruses both have 9 nucleotide long sequences which 
are able to form canonical base pairs. Base pairing in this region would not preclude the 
formation of either SLIIIe or SLIIIf and would correctly position the conserved bases involved in 
the pseudoknot to form said interactions.  Therefore a pseudoknot was modelled onto the EqHV 
5′UTR using the HCV pseudoknot as a guide; this can be seen in Figure 3.2C.  
 
 
 
 
 
 
 
 
 
 
 
53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) A schematic representation of the secondary structure of the EqHV 5′UTR. Secondary structure 
was predicted using EqHV sequence NZPI (GenBank accession no. KP325401) in Mfold and a 
schematic representation of this was modelled. B) A schematic representation of the secondary 
structure of the HCV 5′UTR. miR122 seed sites are highlighted in yellow and the conserved GGG 
motif is highlighted in green, the start codon AUG is denoted in text. C) The predicted secondary 
structure of the EqHV 5′UTR as in Figure 3.1A, with enlarged sections demonstrating the 
sequence of the conserved miR122 site between SLI and SLII, the conserved GGG motif in the 
apical loop of SLIIId, and the pseudoknot. The EqHV pseudoknot was manually modelled based 
upon the Mfold prediction, the sequence of the EqHV 5′UTR in this region, previous predictions 
of the EqHV 5′UTR secondary structure, and the known structure of the HCV 5′UTR. 
Figure 3.1: A Schematic representations of the predicted EqHV, and HCV, 5’UTRs 
 
A B 
C 
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Whilst it has been demonstrated to possess IRES function, to date, no functional attributes have 
been assigned to any individual domains of the EqHV 5′UTR. An in depth analysis of the structural 
features of the EqHV 5′UTR was therefore undertaken to assess how these contributed to its 
function as an IRES. Based upon the secondary structure that had been predicted (Figure 3.1) a 
panel of structural deletion mutants were designed which encompassed deletions of SLI, SLI+II, 
SLIII (excluding SLIIIe and f), SLIIIb, or SLIIId. Mfold was again utilised, following the design of said 
mutants, to predicted whether the deletion of any of these segments would impact the overall 
secondary structure of the 5′UTR and thus have effects on translation that were not specific to 
the structure being investigated (all Mfold predicted structures can be seen in Appendices 
Figures 8.1-8.8). 
Deletions were introduced using Q5 SDM (NEB) according to the manufacturer’s instructions, 
with mutagenesis primers designed in the online tool NEBaseChanger. Figure 3.2 is a schematic 
representation of all mutants which have been modelled on the predicted Mfold structure, and 
which also include the predicted pseudoknot. SLI is the main structural difference between the 
EqHV and HCV 5′UTRs and a deletion removing this SL has previously been made in the context 
of a bicistronic reporter system, and a chimeric EqHV/HCV SGR which contained the EqHV 5′UTR, 
and HCV 3′UTR and polyprotein. This deletion caused no significant effect on translation 
(Stewart et al., 2013). In this previous study the secondary structure of the EqHV 5′UTR was 
predicted to contain SLIA, as such deletion of SLI would result in a 5′UTR structurally similar to 
that of HCV, where SLIA is presumed to be homologous to HCV SLI. As this study does not predict 
the formation of SLIA, and utilises a consensus 5′UTR, this deletion (ΔSLI) was included to further 
investigate what effect SLI has on translation driven by the EqHV IRES.  
SLIII has been shown, in HCV, to be the most important domain with regards to IRES-dependent 
translation. Therefore SLI+II were removed in combination, leaving only SLIII (ΔSLI+II), and SLIII 
was deleted (ΔSLIII), with SLIIIe, f, and the pseudoknot retained, to determine if this was also 
true for EqHV IRES function. SLIIIb, in HCV, has been demonstrated to interact with eIF3 during 
translation initiation, interacting with the ribosome binding face in order to sequester eIF3.  This 
interaction prevents the formation of 43S complexes, increasing the availability of free 40S 
ribosomal subunits required for translation initiation from the HCV IRES (Hashem et al., 2013). 
This sub domain was therefore deleted (ΔSLIIIb) to investigate whether SLIIIb may have a similar 
function during translation from the EqHV IRES. Finally SLIIId, specifically the GGG motif located 
in the apical loop, has previously been demonstrated to interact with the 40S ribosomal subunit 
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during HCV translation initiation, positioning the ribosome at the AUG start codon. SLIIId was 
therefore deleted (ΔSLIIId) in its entirety to investigate whether translation from the EqHV IRES 
was able to proceed in its absence. This panel of deletions allows for a more detailed 
understanding of translation initiation from the EqHV IRES to be established to begin to 
understand if this proceeds in the same fashion as in HCV.  
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Schematic representations of the predicted structures of A) ΔSLI, B) ΔSLI+II, C) ΔSLIII, D) ΔSLIIIb, 
and E) ΔSLIIId. The secondary structure of all 5′UTR deletions was predicted in Mfold, and a 
schematic representation, including the modelled pseudoknot, was drawn to represent each (as 
in Figure 3.1). The miR122 seed site is highlighted in yellow and the conserved GGG motif in 
green, the AUG start codon is denoted by text.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B A 
C D 
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Figure 3.2: A schematic representation of the structural deletion mutations 
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3.2.2 The execution of SHAPE experiments  
 
SHAPE fragment analysis was conducted using capillary electrophoresis by DNA sequencing and 
services, Dundee University (a schematic can be seen in Figure 3.3). Data analysis was carried 
out using QuSHAPE (Karabiber et al., 2013) and structure predictions were carried out in 
RNAstructure (Reuter and Mathews, 2010) reading the SHAPE reactivities as a pseudo free 
energy constraint to produce an RNA secondary structure based upon the experimental data. 
Using the experimental set up described here we were able to produced high quantity, high 
quality, RNA which could be used to reproducibly obtain high quality SHAPE reactivity profiles 
covering the majority of the EqHV 5’UTR. 
Initially gel-based SHAPE was utilised in order to confirm that elongation was being achieved 
using the designed primers (Appendices Figure 8.9) which were designed to bind in the luciferase 
gene ~100 bases downstream of the AUG start. Primers were radioactively labelled with yATP-
33P and used in place of fluorescently labelled primers as described in 2.4.1, using 5 mM NMIA 
rather than 10 mM. Extensions were analysed by separation on a SHAPE sequencing gel. Gels 
were exposed to a phosphor screen for one week and imaged using a FujiFilm FLA-500 imager 
(Figure 3.4). Whilst this process was not optimised to achieve high quality reads that would be 
suitable for SHAPE analysis, it was sufficient to demonstrate that the designed primers could 
successfully be used for elongation. As such these primers were synthesised with FAM and HEX 
fluorescent labels for use in high-throughput SHAPE using capillary electrophoresis.     
Initial high-throughput SHAPE analysis was conducted using 5 mM NMIA, as was used in the gel-
based SHAPE. However, this concentration of NMIA returned a sub-optimal trace in which 
reactivity was low toward the 5′ end of the UTR and did not achieve sufficient signal to 
determine the individual SHAPE reactivities of these bases (Figure 3.5A). Therefore higher 
concentrations of NMIA were used to optimise reactivity and provide consistent reactivity 
through the entire UTR. Two concentrations (10 and 15 mM) of NMIA (Figures 3.5B and 3.5C) 
were trialled. This optimisation revealed that 15 mM NMIA resulted in too high a level of 
reactivity, resulting in a trace which frequently exceeded the detection limit and was therefore 
not considered acceptable. However, the use of 10 mM NMIA returned a trace which had 
consistently detectable reactivity, did not frequently exceed the detection limit, and maintained 
a reactivity profile through to the 5′ end of the UTR. This concentration of NMIA was therefore 
taken forward to analyse the secondary structure of the EqHV 5′UTR, and mutants. 
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A schematic representation of A) NMIA reacting with a flexible ribose moiety in RNA (Sheppard, 
2005) and B) SHAPE experimental flow through. NMIA is represented in red, with fluorescently 
labelled primers shown in green. RT extensions are shown as black lines.  
 
  
A 
B 
Figure 3.3: Schematic representation of SHAPE 
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Figure 3.4: Determination of SHAPE primer extension using gel based SHAPE 
SHAPE experiments using 5 mM NMIA were carried out on the full length 5′UTR in either the 
bicistronic or replicon constructs and extensions were separated in a sequencing gel in 
comparison to a ladder. Each band represents a primer extension termination event with darker 
bands representing sites of frequent termination. 
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Figure 3.5: Optimisation of NMIA concentrations for high-throughput SHAPE 
Capillary electrophoresis sequencing traces for the full length EqHV 5′UTR in the context of the 
replicon construct using A) 5 mM, B) 10 mM, and C) 15 mM NMIA. The top, red, trace is the NMIA 
(positive) reaction trace. The blue trace is the DMSO (negative) reaction trace. The green and 
pink traces represent the sequencing ladders for the positive and negative reactions respectively. 
Each peak represents an individual nucleotide and vertical red lines indicate a nucleotide for 
which the reactivity has exceeded the detection threshold.  
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3.2.3 SHAPE analysis of the WT 5′UTR  
 
The WT 5′UTR of EqHV has been conclusively demonstrated to function as an IRES and is able to 
efficiently drive expression in the context of bicistronic reporter constructs, monocistronic 
expression constructs, and an SGR (Stewart et al., 2013; Scheel et al., 2015). However the RNA 
secondary structure has, to date and to our knowledge, only ever been predicted and never 
experimentally confirmed. Therefore determining the secondary structure of the EqHV 5′UTR 
served two purposes: Firstly to provide the first experimental description of the secondary 
structure of this viral IRES, and secondly to demonstrate that the UTR used in the experiments 
described in Chapter 3 matched that of the predicted structure, providing a reference structure 
with which to compare the 5′UTR mutants.  
SHAPE experiments were carried out on the WT 5′UTR in both the SGR and bicistronic construct. 
SHAPE analysis was carried out on the UTR in both these constructs to ensure that the deletion 
mutations caused the same effect on the overall 5′UTR structure in both constructs. The values 
obtained from SHAPE were used in the prediction of RNA secondary structure as a pseudo free 
energy constraint in the prediction software RNAstructure (Reuter and Mathews, 2010). 
Due to inaccuracies in structure prediction introduced by the presence of pseudoknots, and the 
predicted presence of a pseudoknot in the EqHV 5′UTR and the potential for this to disrupt 
structure prediction in its immediate vicinity, SLIIIe, f, and the pseudoknot were manually 
modelled, with the SHAPE reactivities mapped on to the structure. Whilst this approach 
discounted SHAPE reactivities in this region with regards to structure prediction, it was 
considered an appropriate method to tackle the issues caused by such structures, providing an 
accurate representation of RNA secondary structure in this region; especially when the 
sequence and structural similarities to HCV in this region are taken into account. 
Figure 3.6 is an experimental model of the EqHV 5′UTR RNA secondary structure, in the context 
of an SGR. This was created using the experimental and prediction methodologies outlined in 
this chapter. Figure 3.7A is the same model with the SHAPE reactivity profile overlaid onto the 
structure (due to experimental limitations reactivity values for nucleotides 371-387 are not 
available). This, to our knowledge, represents the first experimentally confirmed model of the 
EqHV 5′UTR. The experimental structure agrees well with the predicted structure presented in 
Figure 3.1, with the exception of the presence of SLIA. Figure 4.3B shows an enlarged image of 
SLIA, and the miR122 seed site (96CACUCC101) which shows that the loop of SLIA was NMIA 
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reactive and would be predicted to be unpaired; confirming the existence of this intermediary 
SL. The miR122 seed site was NMIA reactive at its 5′ end with a reduction in NMIA activity seen 
sequentially toward the 3′ end.  
Apart from SLIA, the structure of the EqHV 5′UTR agrees well with the overall predicted 
structure. Figures 3.7C and D show an enlarged view of SLIIIb, and SLIIId respectively. Both 
structural domains are here shown to form in the EqHV 5′UTR, with both structures matching 
extremely well with SHAPE reactivities. Both apical loops, 249ACUUU253 and 307UUGGGC312, 
showed extremely high SHAPE reactivities which match well with the structures. Finally SLIIIe, f, 
and the pseudoknot, are enlarged in Figure 3.7E. SLIIIe demonstrated intermediate SHAPE 
reactivities across its apical loop, agreeing with the structure, and 357ACCUGCCGG365 showed low 
to intermediate reactivities, again agreeing will with the structure; indicating they are base 
paired. There is, however, a lack of SHAPE reactivity in the apical loop of SLIIIf (excluding 349G 
and 350C) which appears to contradict the existence of this loop. However, low SHAPE reactivities 
in this region have previously been published for HCV (Angulo et al., 2016). 349GCGAG353 are also 
predicted to form base pairs with 367CUCGU371 as part of the pseudoknot and would therefore 
exhibit low NMIA reactivity in this confirmation. Furthermore, 336U-A372 is 84% identical to the 
corresponding HCV sequence, with complete conservation in the apical loops of SLIIIe and SLIIIf 
(excluding 354G), and all of the bases which are predicted to form the pseudoknot. Due to this 
high level of conservation with the known structure of HCV, and the observation of similar 
SHAPE reactivities observed between the two viruses, this structure likely represents the 
biological secondary structure of this region of the EqHV 5′UTR.  
The structure represented in Figure 3.6 and 3.7 are expected to represent an accurate depiction 
of the structure of the EqHV 5′UTR which has been modelled based on a combination of 
predicted secondary structure, experimental data, and comparison with conserved regions from 
HCV. This study presents, to our knowledge, the first experimental structure of the EqHV 5′UTR. 
Due to the accuracy of this model, and to allow for ease of comparison, the reactivity profiles of 
the WT bicistronic 5′UTR, and all mutants, were fitted onto the structure presented in Figure 
4.2, or the respective predicted confirmation of each deletion mutant, based upon this structure 
and the Mfold analysis. The EqHV 5′UTR in the bicistronic reporter construct was also subject to 
SHAPE investigation using the same method outlined above. The results of these experiments 
can be seen in Figure 3.8. This analysis showed good agreement with the 5′UTR SHAPE 
reactivities from the SGR. Similarly, the apical loop of SLIA was highly reactive, and the miR122 
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seed site showed decreasing reactivity in the 5′ to 3′ direction, but was overall less reactive to 
NMIA than the SGR seed site. The apical loops of SLIIIb and SLIIId were both highly reactive, with 
some increase in reactivity in the base paired nucleotides, however this did not occur on a large 
scale and most likely represents experimental variation. Reactivities in SLIIIe, f, and the 
pseudoknot also agreed well with the data obtained from the SGR. It can be concluded that the 
5′UTR secondary RNA structure does not differ significantly between the bicistronic construct 
and the SGR (a comparison of the SHAPE reactivity profiles between the SGR and bicistronic 
construct can be seen in Appendices Figure 8.10).  
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A schematic representation of the EqHV 5′UTR RNA secondary structure. SHAPE analysis of the 
EqHV 5′UTR in the SGR was carried out and these data read as a pseudo free energy constraint 
in RNAstructure to predict the secondary structure. The pseudoknot was manually mapped and 
the base pairs predicted to form in this structure are represented as blue lines.  
 
 
 
 
 
 
Figure 3.6: The secondary structure of the EqHV 5’UTR 
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The secondary structure of the A) WT 5′UTR B) SLIA and the miR122 seed site C) the apical portion 
of SLIIIb D) SLIIId and E) SLIIIe, f, and the pseudoknot in the SGR as predicted by RNA structure 
using experimentally obtained SHAPE reactivity values as a pseudo free energy constraint. SHAPE 
reactivities are represented on a colour scale from white (low reactivity – predicted paired) to 
red (high reactivity – predicted unpaired) a representative scale denoting reactivity increments 
of 0.1 is displayed. Every 10th nucleotide is number labelled and the number labelling in B, C, D, 
and E, corresponds to the number labelling in A. 
Figure 3.7: Experimental structure of the WT 5′UTR in SGR 
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The secondary structure of the A) WT 5′UTR B) SLIA and the miR122 seed site C) the apical portion 
of SLIIIb D) SLIIId and E) SLIIIe, f, and the pseudoknot in the bicistronic construct mapped onto 
the WT EqHV 5′UTR in the SGR as in Figure 4.3. SHAPE reactivities are represented on a colour 
scale from white (low reactivity – predicted paired) to red (high reactivity – predicted unpaired) 
a representative scale denoting reactivity increments of 0.1 is displayed. Every 10th nucleotide is 
number labelled and the number labelling in B, C, D, and E corresponds to the number labelling 
in A. 
Figure 3.8: Experimental structure of the EqHV 5′UTR in the bicistronic construct 
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3.2.4 SHAPE analysis of the ΔSLI 5′UTR 
 
In either the SGR (Figure 3.9) or bicistronic construct (Figure 3.10) the deletion of SLI did not 
appear to cause any major structural rearrangements. One striking observation is the overall 
structural similarity that the EqHV ΔSLI 5′UTR appears to share with the HVC 5′UTR. However, 
upon closer inspection of the sequence of SLIA, and the comparable HCV sequence, there 
appears to be no significant conservation. In fact SLIA more closely corresponds to the miR122 
seed site 1 in HCV. This intermediary SL appears to constitute a divergence in structure, rather 
than a conservation. The ΔSLI 5′UTR retains all of the structural features as in the WT (excluding 
SLI which was deliberately removed) and this deletion does not appear to cause any aberrant 
effects on the overall structure. One interesting observation that can be made upon closer 
inspection of the miR122 seed site in the SGR (Figure 3.9B) is an apparent reversal in the trend 
observed in Figure 3.7B and 3.8B in that this site is less reactive at the 5′ than the 3′ end of the 
sequence. However, the data for all of the other structural features appears to be in good 
agreement. The miR122 seed site in the bicistronic construct (Figure 3.10B) retains the 5′ to 3′ 
loss of NMIA reactivity in the miR122 seed site seen in WT and the SHAPE reactivities in Figure 
3.10 agree well with the SGR ΔSLI data. As with the WT there are some differences between the 
SGR and bicistronic reactivity data, these are not, however, predicted to cause any structural 
changes and are likely due to experimental variability.  
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The secondary structure of the A) ΔSLI 5′UTR B) SLIA and the miR122 seed site C) the apical 
portion of SLIIIb D) SLIIId and E) SLIIIe, f, and the pseudoknot in the SGR mapped onto the ΔSLI 
structure as predicted from the WT EqHV 5′UTR in the SGR in Figure 4.3. SHAPE reactivities are 
represented on a colour scale from white (low reactivity – predicted paired) to red (high reactivity 
– predicted unpaired) a representative scale denoting reactivity increments of 0.1 is displayed. 
Every 10th nucleotide is number labelled and the number labelling in B, C, D, and E corresponds 
to the number labelling in A. 
Figure 3.9: Experimental structure of EqHV ΔSLI 5′UTR in the SGR 
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The secondary structure of the A) ΔSLI 5′UTR B) SLIA and the miR122 seed site C) the apical 
portion of SLIIIb D) SLIIId and E) SLIIIe, f, and the pseudoknot in the bicistronic construct mapped 
onto ΔSLI structure as predicted from the WT EqHV 5′UTR in the SGR as in Figure 4.5. SHAPE 
reactivities are represented on a colour scale from white (low reactivity – predicted paired) to 
red (high reactivity – predicted unpaired) a representative scale denoting reactivity increments 
of 0.1 is displayed. Every 10th nucleotide is number labelled and the number labelling in B, C, D, 
and E corresponds to the number labelling in A. 
Figure 3.10: Experimental structure of EqHV ΔSLI 5′UTR in the bicistronic construct 
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3.2.5 SHAPE analysis of the ΔSLI+II 5′UTR 
 
SHAPE reactivities for ΔSLI+II mapped extremely well onto the predicted structure for both the 
SGR (Figure 3.11) and bicistronic (Figure 3.12) constructs. Highly reactive bases largely mapped 
to unpaired regions, and low reactivity to paired regions. The patterns of reactivity also 
appeared to be largely similar between both constructs within the main structural regions which 
are focussed on in this study; excluding SLIA and the miR122 seed site which were deleted as 
part of this mutation. The apical loops of both SLIIIb (Figure 3.11B and 3.12B) and SLIIId (Figure 
3.11C and 3.12C) remained highly reactive, and the pattern of reactivity seen in SLIIIe, f, and the 
pseudoknot (Figure 3.11D and 3.12D) was similar to WT. These data indicate that the deletion 
of SLI+II in either the bicistronic construct, or in the SGR, resulted in a 5′UTR consisting only of 
SLIII and the pseudoknot as they are in the WT 5′UTR.  
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The secondary structure of the A) ΔSLI+II 5′UTR B) the apical portion of SLIIIb C) SLIIId and D) 
SLIIIe,  f, and the pseudoknot in the SGR mapped onto the ΔSLI+II structure as predicted from the 
WT EqHV 5′UTR in the SGR in Figure 4.3. SHAPE reactivities are represented on a colour scale 
from white (low reactivity – predicted paired) to red (high reactivity – predicted unpaired) a 
representative scale denoting reactivity increments of 0.1 is displayed. Every 10th nucleotide is 
number labelled and the number labelling in B, C, and D corresponds to the number labelling in 
A. 
Figure 3.11: Experimental structure of EqHV ΔSLI+II 5′UTR in the SGR 
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The secondary structure of the A) ΔSLI+II 5′UTR B) the apical portion of SLIIIb C) SLIIId and D) 
SLIIIe,  f, and the pseudoknot in the bicistronic construct mapped onto the ΔSLI+II structure as 
predicted from the WT EqHV 5′UTR in the SGR as in Figure 4.7. SHAPE reactivities are represented 
on a colour scale from white (low reactivity – predicted paired) to red (high reactivity – predicted 
unpaired) a representative scale denoting reactivity increments of 0.1 is displayed. Every 10th 
nucleotide is number labelled and the number labelling in B, C, and D corresponds to the number 
labelling in A. 
Figure 3.12: Experimental structure of EqHV ΔSLI+II 5′UTR in the bicistronic construct 
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3.2.6 SHAPE analysis of the ΔSLIII 5′UTR 
 
Whilst it was predicted to retain both SLI and SLII in the same confirmation as the WT, and care 
was take to retain the sequences involved in the formation of the pseudoknot, it was possible 
that this large structural deletion could potentially disrupt the global structure of the 5′UTR; 
especially due to its proximity to the pseudoknot. However, across SLI+II SHAPE reactivities 
mapped well onto the structure obtained from the WT analysis, with well-defined areas of 
reactivity and non-reactivity which corresponded well with unpaired and paired regions, 
respectively, for both the SGR (Figure 3.13) and bicistronic (Figure 3.14) constructs. In both of 
these constructs SLIA was also maintained and the miR122 seed site showed intermediate 
reactivity across its entirety (Figures 3.13B and 3.14B). Although this does not completely agree 
with the data shown for the WT, reactivity here fits well with this region being single stranded 
and so the differences observed are not considered detrimental to the overall secondary 
structure. The apical loop of SLIIIe also demonstrated intermediate reactivity across its entirety 
and the apical loop of SLIIIf was largely unreactive (Figures 3.13C and 3.14C), as it is for the WT 
(Figure 3.7E). There was some increase in SHAPE reactivity across the base paired sequence 
220CUGCCG226 which could potentially have induced a change to the structural organisation of 
the pseudoknot. However these values are indicative of intermediate to low reactivity, as are 
those in 227U 228U 231G 232U, therefore a complete disruption of base pairing is highly unlikely. For 
the bicistronic construct the pseudoknot region demonstrated a slight increase in reactivity 
(Figure 3.14C) but to a lesser extent than the SGR (Figure 3.13C), allowing for the conclusion that 
structure in this region was also retained.  
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The secondary structure of the A) ΔSLIII 5′UTR B) SLIA and the miR122 seed site and C) SLIIIe, f, 
and the pseudoknot in the SGR mapped onto the ΔSLIII structure as predicted from the WT EqHV 
5′UTR in the SGR in Figure 4.3. SHAPE reactivities are represented on a colour scale from white 
(low reactivity – predicted paired) to red (high reactivity – predicted unpaired) a representative 
scale denoting reactivity increments of 0.1 is displayed. Every 10th nucleotide is number labelled 
and the number labelling in B and C corresponds to the number labelling in A. 
 
Figure 3.13: Experimental structure of EqHV ΔSLIII 5′UTR in the SGR 
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The secondary structure of the A) ΔSLIII 5′UTR B) SLIA and the miR122 seed site and C) SLIIIe, f, 
and the pseudoknot in the bicistronic construct mapped onto the ΔSLIII structure as predicted 
from the WT EqHV 5′UTR in the SGR as in Figure 4.9. SHAPE reactivities are represented on a 
colour scale from white (low reactivity – predicted paired) to red (high reactivity – predicted 
unpaired) a representative scale denoting reactivity increments of 0.1 is displayed. Every 10th 
nucleotide is number labelled and the number labelling in B and C corresponds to the number 
labelling in A. 
Figure 3.14: Experimental structure of EqHV ΔSLIII 5′UTR in the bicistronic construct 
76 
 
3.2.7 SHAPE analysis of the ΔSLIIIb 5′UTR 
 
The SHAPE reactivities for both the SGR (Figure 3.15) and bicistronic (Figure 3.16) constructs 
were in good agreement with those seen across SLI and SLII for the WT (Figure 3.7), indicating 
maintenance of these structures in ΔSLIIIb. A reduction in the reactivity in the apical loop of SLII 
was observed in the SGR, however some of these bases still exhibited intermediate reactivity 
and, given the agreement demonstrated for the other regions in the 5′ portion, it was not 
deemed that this reduction in reactivity would result in a significant structural rearrangement. 
SLIA was also maintained, displaying the characteristic reduction in reactivity in the miR122 seed 
site (Figures 3.15B and 3.16B) that is evident in almost all of the other constructs analysed. The 
apical loops of SLIIIa and c remained highly reactive in ΔSLIIIb, with a highly reactive single 
stranded region linking them. Furthermore, reactivities in SLIIId for both constructs (Figures 
3.15C and 3.16C) agreed well with the WT (Figure 3.7D) and maintained high reactivity in the 
apical loop. SHAPE reactivity values for SLIIIe and f were also in good agreement with those in 
the WT, as were those for the bases predicted to form the pseudoknot. These data show that 
the overall structure of SLIII is maintained upon the deletion of SLIIIb, with this deletion 
producing a truncated SLIII where SLIIIa and SLIIIc are linked by a single stranded region in place 
of SLIIIb. 
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The secondary structure of the A) ΔSLIIIb 5′UTR B) SLIA and the miR122 seed site C) SLIIId and D) 
SLIIIe, f, and the pseudoknot in the SGR mapped onto the ΔSLIIIb structure as predicted from the 
WT EqHV 5′UTR in the SGR in Figure 4.3. SHAPE reactivities are represented on a colour scale 
from white (low reactivity – predicted paired) to red (high reactivity – predicted unpaired) a 
representative scale denoting reactivity increments of 0.1 is displayed. Every 10th nucleotide is 
number labelled and the number labelling in B, C, and D corresponds to the number labelling in 
A. 
Figure 3.15: Experimental structure of EqHV ΔSLIIIb 5′UTR in the SGR 
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The secondary structure of the A) ΔSLIIIb 5′UTR B) SLIA and the miR122 seed site C) SLIIId and D) 
SLIIIe, f, and the pseudoknot in the bicistronic construct mapped onto the ΔSLIIIb structure as 
predicted from the WT EqHV 5′UTR in the SGR as in Figure 4.11. SHAPE reactivities are 
represented on a colour scale from white (low reactivity – predicted paired) to red (high reactivity 
– predicted unpaired) a representative scale denoting reactivity increments of 0.1 is displayed. 
Every 10th nucleotide is number labelled and the number labelling in B, C, and D, corresponds to 
the number labelling in A. 
Figure 3.16: Experimental structure of EqHV ΔSLIIIb 5′UTR in the bicistronic construct 
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3.2.8 SHAPE analysis of the ΔSLIIId 5′UTR 
 
The GGG motif has been shown to be involved in proper folding of the HCV 5′UTR (Jubin et al., 
2000) therefore demonstrating correct folding of this 5′UTR in the absence of SLIIId, and the 
GGG motif, was essential.  
For both the SGR (Figure 3.17) and bicistronic (Figure 3.18) constructs the SHAPE reactivity 
profile through SLI+II matched well with that of WT. SLIA was again maintained and this region 
and demonstrated a, now somewhat characteristic, reduction in reactivity from 5′ to 3′ of the 
miR122 seed site (Figure 3.17B and 3.18B). SLIIIa, b, and c were all maintained, with high 
reactivities in their respective apical loops (a detailed view of SLIIIb can be seen in Figures 3.17C 
and 3.18C). Similarly to ΔSLIIIb, the deletion of SLIIId appeared to simply result in a single 
stranded “linker” region which bridged the gap where SLIIId previously was. This region was 
shown to be highly NMIA reactive in both constructs. Finally, SLIIIe and SLIIIf appeared to be well 
maintained, with similar SHAPE reactivity profiles both between constructs and in comparison 
to WT (Figure 3.17D and 3.18D) and 185CCGGCAGGU193/357ACCUGCCGG365 maintained low 
reactivity, indicating decreased structural freedom. These results demonstrate that the 
predicted secondary structure of the ΔSLIIId 5′UTR (Figure 4.13) is a good representation of its 
structure in vitro.  
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The secondary structure of the A) ΔSLIIId 5′UTR B) SLIA and the miR122 seed site C) SLIIIb and D) 
SLIIIe, f, and the pseudoknot in the SGR mapped onto the ΔSLIIId structure as predicted from the 
WT EqHV 5′UTR in the SGR in Figure 4.3. SHAPE reactivities are represented on a colour scale 
from white (low reactivity – predicted paired) to red (high reactivity – predicted unpaired) a 
representative scale denoting reactivity increments of 0.1 is displayed. Every 10th nucleotide is 
number labelled and the number labelling in B, C, and D corresponds to the number labelling in 
A. 
Figure 3.17: Experimental structure of EqHV ΔSLIIId 5′UTR in the SGR 
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The secondary structure of the A) ΔSLIIId 5′UTR B) SLIA and the miR122 seed site C) SLIIIb and D) 
SLIIIe, f, and the pseudoknot in the bicistronic construct mapped onto the ΔSLIIId structure as 
predicted from the WT EqHV 5′UTR in the SGR as in Figure 4.13. SHAPE reactivities are 
represented on a colour scale from white (low reactivity – predicted paired) to red (high reactivity 
– predicted unpaired) a representative scale denoting reactivity increments of 0.1 is displayed. 
Every 10th nucleotide is number labelled and the number labelling in B, C, and D corresponds to 
the number labelling in A. 
Figure 3.18: Experimental structure of EqHV ΔSLIIId 5′UTR in the bicistronic construct 
82 
 
3.2.9 Investigating the activity of EqHV 5′UTR mutants in a bicistronic construct 
 
In order to assay the IRES activity of the 5′UTR deletion mutants, each was introduced into an 
RLuc/FLuc pGL3 bicistronic expression construct by Q5 SDM (NEB). Bicistronic expression 
constructs are widely used for analysing IRES activity and express two reporter genes from which 
translation is driven in a cap and IRES-dependent fashion, respectively. Upon transfection into a 
cell the construct is transcribed into capped mRNA encoding both reporter genes, separated by 
the IRES under investigation. Translation of RLuc was driven by the m7G cap and FLuc by the IRES 
(Figure 3.19A).  
To assess IRES activity from these constructs, 1.5x105 Huh7, FHK, or 293T cells were transfected 
with 2 μg DNA and assayed for dual luciferase activity 24 hours post transfection (h.p.t). For each 
mutant, and cell line, the ratio of FLuc:RLuc was calculated and used as a measure of relative 
efficiency of translation from the IRES in relation to that of the m7G cap. A pGL3 plasmid which 
contained no IRES was used to control for read through from RLuc to FLuc in the absence of an 
IRES. Each experiment was subject to a minimum of N=3 biological repeats and a student’s T test 
calculated to determine statistical significance.  
ΔSLI showed no significant impact on translation in either Huh7 (Figure 3.19B), FHK (Figure 
3.19C), or 293T (Figure 3.19D) cells. This is in good agreement with previously published data 
(Stewart et al., 2013) on the translational efficiency of the ΔSLI 5′UTR and indicates that SLI does 
not play a role in translation from the EqHV IRES. Whilst the effect of the ΔSLI deletion was 
consistent through all three cell lines which were tested, the ΔSLI+II deletion exhibited different 
effects in each cell line. Whilst ΔSLI+II significantly inhibited translation in both Huh7 and FHK 
cells, the degree of inhibition was far greater in FHK cells. The same deletion in 293T cells 
exhibited no significant reduction in translation; however there was a trend toward inhibition 
(p=0.059). Taken together these data indicate that the presence of SLI+II influences the ability 
of the EqHV 5′UTR to initiate translation. However, the variability in the effect that the ΔSLI+II 
deletion had on translation efficiency between the cells lines may indicate that SLII is not playing 
a direct role in translation initiation from the EqHV IRES.  
The deletion of SLIII, however, caused an almost complete ablation of translation with >95% 
inhibition in all three cell lines tested. ΔSLIIIb, on the other hand, demonstrated much less of an 
effect on EqHV IRES function which, similarly to ΔSLI+II, was significant only in Huh7 and FHK 
83 
 
cells but not in 293T cells. This indicated that SLIIIb is not necessary for IRES function and that it 
may not be directly involved in translation initiation. Finally, ΔSLIIId exhibited complete ablation 
of translation with >99% inhibition in all three cell lines tested. Taken together these data 
suggest that SLI+II, and SLIIIb, are not required for EqHV IRES mediated translation but that SLIII, 
specifically SLIIId, is necessary. 
 In order to investigate the effect of miR122 on translation from the EqHV IRES, FHK and 293T 
cells, which do not express miR122, were transduced to overexpress this liver specific microRNA. 
The transduced cells were selected, and maintained, in 5 μg/ml puromycin to ensure that a 
population of cells expressing miR122 was maintained. To confirm that these puromycin 
resistant cells were expressing miR122 and had not simply acquired puromycin resistance, two 
reporter plasmids, pGL3 MCS and pGL3 1225, were utilised. pGL3 1225 is a miR122 responsive 
plasmid which contains a perfect miR122 seed site within the luciferase reporter gene, which is 
cleaved upon binding to miR122 resulting in downregulation of expression. pGL3 MCS does not 
contain such a site and was used to control for any differences in transfection efficiency that 
may arise from the over expression of miR122. Both constructs were transfected into FHK 122 
and 293T 122 cells, harvested 24 h.p.t, and assayed for luciferase activity. Figure 3.20 represents 
a minimum of N=3 biological repeats for both cell lines and demonstrates that expression of 
miR122, in either cell line, did not have any significant effect on transfection efficiency (Figure 
3.20A). Both the FHK 122 and 293T 122 cell lines were confirmed to express miR122, as 
evidenced by the significant reduction in luciferase activity in the miR122 expressing cell lines 
(Figure 3.20B).  
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A) A schematic representation of the pGL3 bicistronic construct containing the WT EqHV 5′UTR. 
B, C, and D) pGL3 N (where N represents either WT or mutant EqHV, or a control plasmid 
containing no IRES) was transfected into B) Huh7 C) FHK, or D) 293T cells, harvested 24 h.p.t and 
assayed for dual luciferase activity. All values are represented as a ratio of FLuc:RLuc and this is 
used as a representative measure of IRES activity. All data was subject to a student’s T test in 
comparison to the WT value for each respective cell line. Stars represent statistically significant 
values and N/S represents values which were not significant. 
Figure 3.19: EqHV mutant IRES activity in an RLuc/FLuc bicistronic construct 
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A) A control luciferase reporter pGL3 MCS or B) the miR122 responsive pGL3 1225 was 
transfected into FHK, FHK 122, 293T, and 293T 122 cell lines and assayed 24 h.p.t for luciferase 
activity. Data was subject to a student’s T test comparing each construct against its 
corresponding transfection into the 122 cell line. Stars highlight statistically significant 
differences whilst N/S represents values which were not significant.  
 
 
 
 
 
 
 
 
 
 
 
A B 
Figure 3.20: Assay of miR122 expression in FHK and 293T cells 
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Following confirmation that the 122 cell lines were expressing miR122 all 5′UTR mutants, WT, 
and control plasmid, were transfected into the FHK 122 and 293T 122 cell lines, harvested 24 
h.p.t, and assayed for dual luciferase activity as previously described (Figure 3.21 A and B). The 
same trends were observed in the miR122 expressing cell lines as was observed in the parental 
cell lines (Huh7 cells were omitted from these experiments as they endogenously express 
miR122). However it could have been possible that the expression of miR122 was effecting each 
mutant to an equal extent, thus masking any effect of miR122 on translation. Therefore the 
translation efficiency of the WT 5′UTR in the parental cell lines was compared to its efficiency in 
the miR122 expressing cell lines in both FHK, and 293T cells (Figures 3.21C and D). These data 
showed that efficiency of translation from the WT IRES is not influenced by the presence of 
miR122 in either FHK or 293T cells, indicating that miR122 is unable to influence translation 
efficiency from the EqHV IRES in the context of a bicistronic expression system.  
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pGL3 N (where N represents either WT or mutant EqHV, or a control plasmid containing no IRES) 
was transfected into A) FHK 122 and B) 293T cells, harvested 24 h.p.t, and assayed for dual 
luciferase activity. All values are represented as a ratio of FLuc:RLuc and this is used as a 
representative measure of IRES activity. All data was subject to a student’s T test in comparison 
to the WT value for each respective cell line. Stars represent statistically significant values and 
N/S represents values which were not significant. WT translation values from C) FHK and FHK 
122 and D) 293T and 293T 122 cells were compared. Values were normalised to % of the WT 
value in the parental cell line and a student’s T test carried out to determine statistical 
significance. N/S represents non-significant values.  
Figure 3.21: The effect of miR122 on EqHV IRES activity in a bicistronic construct 
 
88 
 
3.2.10 Investigating the activity of EqHV 5′UTR mutants in an SGR 
 
Whilst there are many advantages to assaying IRES activity in the bicistronic system, there are 
also many disadvantages to this method of analysis (as discussed in 3.1). Notably, from the 
observations made in 3.2.9, the EqHV 5′UTR IRES activity did not seem to be influenced by the 
presence of miR122, as has previously been reported (Scheel et al., 2015). The authors also 
reported an enhancement of translation from the EqHV 5′UTR IRES in the presence of the EqHV 
3′UTR, which is not present in the bicistronic construct.  
It is common practice in the field of HCV research, when conducting replication assays using 
SGRs, to assay an early time point, typically 4-6 hours post electroporation (h.p.e), as a measure 
of input translation to control for electroporation efficiency. It has previously been shown that 
the EqHV 5′UTR is able to efficiently drive expression of a reporter gene in the context of an SGR, 
which is detectable 5 h.p.e. Each of the 5′UTR mutants described in Figure 3.2, and the WT, were 
therefore introduced into pSGR NZCI (described in 5.2.4), which contains a codon optimised 
CpG/UpA low FLuc reporter gene (a schematic of which can be seen in Figure 3.22A) in order to 
create an alternative means of assaying EqHV IRES activity. This construct represents a more 
physiologically relevant system by which to investigate the EqHV 5′UTR as it is located at the 
proximal 5′ end of the construct as it would be in the viral genome, as opposed to its internal 
position in the bicistronic construct. The 3′UTR is also present in this construct, unlike in the 
bicistronic construct, ~10 Kb downstream of the 5′UTR; again mirroring the organisation of the 
viral genome.  
All structural deletion mutants, and the WT 5′UTR, were synthesised by GENEART and 
introduced into the pSGR by molecular cloning. An XbaI site directly upstream of the 5′UTR and 
an AscI site located at the beginning of the CpG/UpA low luciferase reporter gene were utilised 
to introduce the 5′UTR into pSGR NZCI. In order to assay IRES activity in this context SGR RNA 
was in vitro transcribed from linearised DNA using the ribomax T7 transcription kit (promega) 
according to manufacturer’s instructions. Huh7 and FHK (by electroporation), and 293T cells, 
were all transfected with 2 μg RNA, harvested at 6 h.p.t and assayed for firefly luciferase activity. 
A mock transfection was carried out with RNAse free water to control for background luciferase 
activity and each experiment was subject to a minimum of N=3 biological repeats; a student’s T 
test was carried out to determine statistical significance.  
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In either Huh7 (Figure 3.22B), FHK (Figure 3.22C), or 293T (Figure 3.22C) cells ΔSLI did not 
demonstrate any significant effect on translation from the EqHV 5′UTR IRES; indicating SLI is not 
involved in EqHV translation. Deletion of SLI+II (ΔSLI+II) demonstrated a significant reduction in 
translation compared to WT in all three cell lines tested, however this effect was enhanced in 
Huh7 cells (~25% efficiency) compared to both FHK and 293T cells (~50% efficiency). These data 
indicate that the absence of SLI+II has a large impact on translation; however the relative 
inhibition of translation, compared with significant size of the deletion created for this mutant, 
may suggest that the impact of the ΔSLI+II deletion may not be due to a direct involvement in 
translation. In all cell lines tested here deletion of SLIII, SLIIIb, or SLIIId caused a complete 
ablation of translation, equivalent to mock transfection levels. Taken together these data 
indicate that SLIII is necessary, and SLIII and the pseudoknot are sufficient, for EqHV 5′UTR IRES 
function. ΔSLI+II is still able to initiate translation whilst ΔSLIII, ΔSLIIIb, or ΔSLIIId completely 
ablate translation. Therefore it can be concluded that SLIII, and more specifically SLIIIb and SLIIId 
all play direct and necessary roles in the initiation of translation from the EqHV IRES in the 
context of an SGR.  
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A) A schematic representation of SGR NZCI containing the WT EqHV 5′UTR. B, C, D) SGR NZCI N 
(where N represents either the WT or mutant EqHV 5′UTR) or mock (no RNA) was transfected 
into B) Huh7 C) FHK and D) 293T cells. Cells were harvested 6 h.p.t and assayed for firefly 
luciferase activity. All values are represented as a percentage of the RLU for the WT EqHV 5′UTR 
and this is used as a representative measure of IRES efficiency (with WT taken as 100% activity). 
All data was subject to a student’s T test in comparison to the WT value for each respective cell 
line. Stars represent statistically significant values and N/S represents values which were not 
significant.  
Figure 3.22: EqHV mutant IRES activity in an SGR 
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In order to assay the effect of miR122 on translation from the EqHV IRES the miR122 expressing 
cell lines described in 3.2.9 were transfected with all 5′UTR mutants and the WT EqHV 5′UTR, or 
mock treated, as described above (Figure 3.23A and B). The same trends were observed in the 
miR122 expressing cell lines as was observed in the parental cell lines (Huh7 cells were omitted 
from these experiments as they endogenously express miR122). However it could have been 
possible that the expression of miR122 was effecting each mutant to an equal extent, thus 
masking any differences. Therefore the translation efficiency of the WT 5′UTR in the parental 
cell lines was compared to its efficiency in the 122 cells (Figure 3.23C and D). This analysis 
showed that the overexpression of miR122 in both FHK and 293T cells resulted in a significant 
enhancement of translation to 228% and 129% of WT in the parental cell lines, respectively. In 
light of this result the miR122 seed site was changed to the corresponding miR124 seed site by 
Q5 SDM, and introduced into the full length 5′UTR (termed NZCI 124). SGR NZCI 124 RNA was 
transfected into FHK and 293T (+/- 122) cells in order to assess whether the effect that miR122 
had on translation was mediated by an interaction with the miR122 seed site (Figure 3.24). In 
both the FHK 122 and 293T 122 cell lines NZCI 124, unlike the WT, was unresponsive to the 
presence of miR122 when compared to its IRES activity in the parental cell lines. Taken together 
with Figure 3.23C and D, these data indicate that EqHV IRES activity is enhanced by the presence 
of miR122, and that enhancement is mediated by the miR122 seed site located directly upstream 
of SLII.  
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A) FHK 122 and B) 293T 122 cells were transfected, with 2 μg RNA or 2 μl RNAse free water 
(mock) and assayed for firefly luciferase activity 6 h.p.e/t. All values are represented as a 
percentage of the RLU for the WT EqHV 5′UTR and this is used as a representative measure of 
IRES efficiency (with WT taken as 100% activity). All data was subject to a student T test in 
comparison to the WT value for each respective cell line. Stars represent statistically significant 
values and N/S represents values which were not significant. C, D) WT translation values from C) 
FHK and FHK 122 and D) 293T and 293T 122 cells was compared. Values were normalised to % 
of the WT value in the parental cell line and a student’s T test carried out to determine statistical 
significance.  
Figure 3.23: The effect of miR122 on EqHV IRES activity in an SGR 
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A) FHK and FHK 122 and B) 293T and 293T 122 cells were transfected with 2 μg SGR NZCI 124 
and assayed for firefly luciferase activity 6 h.p.t and normalised to NZCI 124 in the respective 
parental cell line. All data was subject to a student’s T test in comparison to the WT value for 
each respective cell line to determine statistical significance. N/S represents values which were 
not significant.  
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Figure 3.24: The effect of miR122 on NZCI 124 
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3.3 Discussion 
 
3.3.1 Predicting the structure of the EqHV 5′UTR, and structural mutants 
 
The secondary structure of the EqHV 5′UTR predicted for this study agrees well with previously 
published predictions (Kapoor et al., 2011; Burbelo et al., 2012),indicating the presence of three 
main structural domains (SLI, SLII, and SLIII) and a pseudoknot. However, the presence of the 
putative SLIA was omitted here due to the structural divergence from HCV that this would 
represent and, as such, did not directly influence decision making with regards to the deletions 
which were made. Furthermore, due to limitations of RNA structure prediction software 
(discussed in 3.1) it was not possible to predict the existence of a pseudoknot within the EqHV 
5′UTR. However using previously published EqHV 5′UTR predictions, and the HCV 5′UTR as a 
model, it was possible to map the EqHV 5′UTR sequence onto a potential pseudoknot.  
To probe the role that the structural domains of the EqHV 5′UTR played in translation a panel of 
deletion mutants were created which systematically removed major structural components, 
based on the predicted structure. To reduce the possibility that these deletions exhibited 
indirect effects on translation by causing major structural changes in the 5′UTR, the secondary 
structure of each mutant was predicted in the same manner as the full 5′UTR. These predictions 
indicated the deletions would only exhibit the desired local effect on the secondary RNA 
structure and provided confidence that effects on translation would be directly influenced by 
each respective deletion.  
3.3.2 Experimental determination of the EqHV 5′UTR RNA secondary structure 
 
This chapter describes the first experimentally confirmed structure of the EqHV 5′UTR. In good 
agreement with the predicted structure (Figure 3.1) the EqHV 5′UTR contains three main 
structural domains (SLI, SLII, and SLIII). Whilst the existence of a pseudoknot has not been 
experimentally confirmed the high level of conservation with the corresponding region of the 
HCV 5′UTR (84% sequence identity across 336U-A372), SHAPE reactivities which resemble those 
previously published for the HCV pseudoknot (Angulo et al., 2016), the conservation of function 
(discussed below), and the conservation of structure, especially throughout SLIII, exhibited 
between these two viruses provides compelling evidence for the existence of this structure in 
the EqHV 5′UTR. Therefore the existence of a pseudoknot in the EqHV 5′UTR is highly probable.  
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Using experimental SHAPE data to inform structure predictions based on free energy is a highly 
accurate method of secondary structure prediction, with 97% of the E. coli 16S ribosome RNA 
base pairs being predicted, in comparison to the accepted structure, using this method (Deigan 
et al., 2009). This provides confidence that Figure 3.6 represents the correct confirmation of the 
RNA secondary structure of the EqHV 5′UTR. This section will discuss the structure of the WT 
5′UTR, as was experimentally confirmed from the SGR, as it most closely resembles the 5′UTR 
positioning in virus and therefore is most likely to represent the 5′UTR as it exists in nature.  
3.3.3 The structure of EqHV SLI, SLIA, and SLII 
 
 SLI is a large, 73 nucleotide, stem loop spanning 2C-G75 with an apical loop, 39G-U42, which 
demonstrated high SHAPE reactivity. Interestingly, the bulges in SLI show low SHAPE reactivity 
and would thus be considered to be predicted base paired. However, the relatively slow reaction 
rate of NMIA could explain this apparent disparity between the SHAPE data and the structure 
(Merino et al., 2005). If the bulges in SLI are transiently, and rapidly, switching between two 
confirmations, i.e. paired and unpaired, NMIA may not have enough time to properly react with 
the unpaired confirmation. These regions would therefore exhibit low SHAPE reactivity in this 
experimental set up. The high reactivity of the SLI apical loop suggests that any conformational 
changes occurring within SLI do not impact its overall stability.  
This study has also confirmed the existence of SLIA, a small stem loop which resides in between 
SLI and SLII, 5′ of the miR122 seed site (81C-G94). The intervening region between SLI and SLIA 
(76G-U80) is unpaired and the SHAPE reactivity profile agrees well with this. There is a short stem 
of 4 bases followed by a 6 nucleotide apical loop (85U-A90) with the following four nucleotides 
closing the stem. The nucleotides in the apical loop show high to intermediate reactivity, with 
the base paired nucleotides in the stem exhibiting low reactivity, indicating that this structure is 
stable within the 5′UTR.  The single stranded region between SLIA and SLII, which contains the 
miR122 seed site (96C-C101), however appears to have a less straightforward relationship 
between its existence as a single stranded region in the structure, its SHAPE reactivity profile, 
and its role in translation. The miR122 seed site was demonstrated to interact with miR122 to 
enhance translation, and therefore is available for binding and would be predicted to be 
unpaired. However, whilst the structure shown in Figure 4.3B shows the miR122 seed site as 
single stranded, the SHAPE reactivity profile for this region indicates that  96CAC98 are NMIA 
reactive, and therefore flexible and predicted unpaired, but that 99UCC101 are unreactive and 
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thus demonstrate properties of base paired nucleotides with regards to their SHAPE reactivities. 
However, given the structures that exist either side of the miR122 seed site (SLIA and SLII) and 
that the unpaired bases available to interact with the miR122 site would not be able to pair with 
this sequence to extend these SLs, and the functional data demonstrating that the miR122 seed 
site is available to interact with miR122, it is highly likely that this site is unpaired.  
SLII spans 79 nucleotides, 101C-G179. It contains two bulges, one large and one small, a 
mismatched loop on the right hand side of the stem, and a 5 nucleotide apical loop (138G-A142). 
Like SLI the bulge, and flexible, regions of the stem have low NMIA reactivity. However, due to 
the high reactivity demonstrated in the apical loop, this SL is also likely to be highly stable. There 
is a possibility that these single stranded regions do not exhibit reactivity toward NMIA due to 
RNA breathing as discussed for SLI, and similarly that any conformational changes occurring 
within SLII do not impact its stability. 
3.3.4 The structure of EqHV SLIII  
 
SLIII is the largest of the structural features of the EqHV 5′UTR spanning 164 nucleotides 194C-
G332, and contains 6 sub domains that make up its overall structure (SLIIIa, b, c, d, e, and f). The 
paired region 185CCGGCAGGU193/357ACCUGCCGG365 (Figure 4.3E) was not considered to be a part 
of SLIII as these bases are predicted to play a role in the formation of the pseudoknot and are, 
as such, classified within this structural feature.  
SLIIIa (215U-A230) is here demonstrated to consist of a stem of 6 base pairs with an apical loop of 
4 bases (221A-A224), the stem has a low reactivity to NMIA, indicative of a base paired region, with 
the apical loop exhibiting high reactivity. SLIIIb (232A-U271) is the largest sub domain of SLIII 
spanning 41 nucleotides. SLIIIb contains one large bulge towards the base of the stem, and an 
apical loop (249A-U253) consisting of 6 nucleotides which exhibit high reactivity to NMIA. SLIIIc 
(274G-C283) sits opposite SLIIIa and consists of a three base pair stem and a 4 nucleotide apical 
loop (276C-G280) which also demonstrates high NMIA reactivity similar to SLIIIa and SLIIIb.  
SLIIId (297G-C322) has a 10 base pair stem with an apical loop consisting of 6 nucleotides (307U-
C312), crucially this apical loop contains the highly conserved GGG motif. This study demonstrates 
that this motif is indeed presented in the apical loop of SLIIId, as was predicted, and that it is 
highly reactive to NMIA. These data provide further evidence towards a conserved mechanism 
of translation initiation between EqHV and HCV as deletion of this domain causes a complete 
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ablation in translation. It was hypothesised that this effect was due to the removal of the GGG 
motif which was likely interacting with the 40S ribosomal subunit to position it at the AUG start. 
Therefore the demonstration that this motif is presented in the apical loop, and is single 
stranded, means that it is available to interact with the 40S subunit and may represent a 
conserved mechanism of hepaciviral translation initiation.  
SLIIIe (333G-U344) consists of a three base pair stem with a 6 nucleotide apical loop (336U-G341). 
Reactivities throughout the stem and loop agree well with the structure as shown. Finally SLIIIf 
(345G-G356) possesses the shortest stem of the structural domains of SLIII of just two base pairs. 
The apical loop (347U-G354) is 8 nucleotides in length and is largely NMIA unreactive, however this 
loop has been shown to be relatively NMIA unreactive in published SHAPE data for the HCV IRES 
(Angulo et al., 2016) and is predicted to interact with downstream sequences to form the 
pseudoknot, which is described in 3.3.5.  
Whilst the large majority of the SHAPE reactivity profile across SLIII agrees well with the 
structure, especially across base paired regions and in the apical loops, bulges within SLIII, 
similarly to SLI and SLII, are largely unreactive or exhibited low to intermediate reactivity. As 
discussed for SLI and SLII the highly structured nature of the rest of SLIII, coupled with the high 
NMIA reactivity of all of the apical loops, indicate that SLIII is a stable structure which folds as is 
shown in Figure 3.6. The most likely cause of the discrepancies between structure and SHAPE 
data exhibited here is RNA breathing which does not allow NMIA enough time to fully react with 
the bases in the bulges, rendering them NMIA unreactive. However, the overall structure and 
reactivity of the apical loops would suggest that SLIII is highly stable and the potential internal 
rearrangements in structure do not affect the overall confirmation of SLIII.  
3.3.5 The structure of the EqHV pseudoknot 
 
The pseudoknot remains a predicted structure, and has not been experimentally confirmed in 
this study, however there is strong evidence for its existence from the SHAPE analysis, and 
confirmed structure, of the 5′UTR. The pseudoknot as predicted consists of a stem of 9 base 
pairs forming between 185CCGGCAGGU193/357ACCUGCCGG365, and 6 nucleotides from the apical 
loop of SLIIIf 348UGCGAG353 interacting with 367CUCGUA372. The EqHV sequence encompassing 
the start of the SLIIIe apical loop to the end of the predicted pseudoknot (336U-A372) shares 84% 
sequence conservation with the HCV sequence from the equivalent region and 100% across 
348UGCGAG353 and 367CUCGUA372; predicted to base pair as part of the EqHV pseudoknot and 
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known to form such interactions in the HCV pseudoknot. Whilst the stem only displays 55% 
sequence identity across the two viruses it is important to note that whilst they may not 
maintain a conserved sequence, each virus has a perfectly complementary 9 nucleotide 
sequence located in the same equivalent location within the 5′UTR. SHAPE reactivities across 
this region provide further evidence that a pseudoknot is being formed. 
185CCGGCAGGU193/357ACCUGCCGG365 has no to low NMIA reactivity across its entirety agreeing 
with base pairing at these sites.  
SLIIIf demonstrates a low SHAPE reactivity profile throughout its apical loop, excluding 350C. 
However if the pseudoknot is forming as predicted 348UGCGAG353  of the SLIIIf apical loop would 
be base paired with 367CUCGUA372, therefore low SHAPE reactivity in this region is in good 
agreement with the existence of the pseudoknot. In this configuration 347U and 353G would be 
not be base paired and thus should exhibit high NMIA reactivity. However, low NMIA reactivity 
has previously been demonstrated for HCV, which is known to form a pseudoknot, and therefore 
low reactivity of these bases does not exclude the formation of such a structure. Based on the 
SHAPE data presented here, conservation between EqHV and HCV throughout the pseudoknot 
region, and that the other secondary structure features which have been experimentally 
confirmed and do not preclude the formation of the pseudoknot, it is hypothesised that this 
structure exists in the EqHV 5′UTR as shown in Figure 3.6.  
The data obtained from the SHAPE analysis of the EqHV 5′UTR, combined with structure 
prediction using this data as a pseudo free energy constraint, and conserved structural, 
sequence, and functional, features between EqHV and HCV has resulted in the first 
experimentally confirmed secondary structure model of the EqHV 5′UTR (Figure 3.6). This 
structure is extremely likely to contain a pseudoknot at its 3′ end, prior to the AUG start. This 
complements the functional study described in Chapter 3, supporting the hypotheses made 
regarding the process of EqHV IRES mediated translation, and provides further evidence to 
support the hypothesis of a conserved mechanism of hepaciviral translation.  
3.3.6 EqHV 5′UTR ΔSLI and ΔSLI+II structural deletions have no overall impact on 5′UTR 
secondary structure 
 
To confirm that the functional effects that structural deletions had on EqHV IRES mediated 
translation were specifically caused by deletion of a structure, and not more general structural 
effects that the deletion caused, it was necessary to confirm the structures of the WT and 
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mutant EqHV 5′UTRs in each construct. This also confirmed that differences observed in 
translation from the bicistronic and SGR constructs was not due to differential UTR folding in 
these different contexts. The structure of the 5′UTR in the SGR is extensively discussed in 3.3.2-
3.3.5. Comparisons of mutant 5′UTR structures will be made to the 5′UTR structure in the SGR 
as this represents the most physiologically relevant context in which the structure of the 5′UTR 
was mapped. A model for each mutant was created based on the Mfold prediction (appendices 
Figures 8.1-8.8), and combined with the experimentally confirmed structure to create an 
updated prediction of mutant structures from those depicted in Figure 3.2. SHAPE reactivity 
values were then mapped onto these structures in order to assess whether they significantly 
differed from the WT across the relevant regions. Structural predictions using the experimental 
SHAPE values as pseudo free energy constraints were also generated, and agreed well with those 
depicted here; for ease of comparison, as no significant structural changes were predicted, the 
confirmed WT structure with the mutations manually introduced, and SHAPE values mapped on, 
are here shown. 
The WT 5′UTR SHAPE reactivities for the bicistronic construct mapped well onto the structure 
determined from the SGR WT 5′UTR. No major differences between the two constructs were 
observed and the overall secondary structure is not altered when the 5′UTR was in the context 
of the bicistronic construct. Importantly, the miR122 seed site, SLIIIb, SLIIId, and the pseudoknot 
exhibited extremely similar SHAPE reactivity profiles. Some nucleotides exhibited increased 
reactivity in the bicistronic UTR, however there were no defined regions that exhibited major 
differences in reactivity, and thus no structural differences are expected. Importantly, when 
taking into consideration the functional data, the miR122 seed site exhibited very little change 
between the SGR and bicistronic constructs. Absolute reactivity was slightly lower in the 
bicistronic than in the SGR, however there was no change in classification of nucleotides 
throughout and nucleotides predicted to be paired/unpaired in the SGR showed the same trends 
in the bicistronic construct. These data demonstrate that the difference in miR122 
responsiveness observed between these two constructs is due to the positioning of the 5′UTR, 
rather than different structural arrangements. This supports the hypothesis that the 
enhancement of translation upon expression of miR122 is due to XrnI protection.  
ΔSLI had no impact on IRES function in comparison to the WT 5′UTR and it was therefore not 
expected to cause any major structural changes outside of the deletion of SLI. This was 
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confirmed by SHAPE as all of the major structural features displayed reactivity profiles which 
resembled the WT 5′UTR and were suggestive of a maintenance of structure.  
ΔSLI+II had an extremely variable effect on IRES efficiency, which ranged from mean efficiencies 
of ~23%-100% of WT. Two hypotheses were posed to explain this variation in function: Firstly 
that SLII may have an indirect role to play in translation and therefore the effect of its deletion 
had varying effects on translation. Secondly that ΔSLI+II caused the remaining structure to adopt 
two, or more, different confirmations with different translation competency, with the ratio of 
these different confirmations favoured under different conditions. However, the SHAPE 
reactivity profile was consistent with that of SLIII in WT, and across the two constructs. If 
different confirmations of the 5′UTR were present large differences would have been expected 
to be seen between the SHAPE reactivity profiles of ΔSLI+II and the WT 5′UTR, with regions 
adopting different NMIA reactivity profiles between different confirmations. As no such regions 
were present these data rule out the possibility that ΔSLI+II causes the 5′UTR to adopt a number 
of different confirmations and supports the hypothesis of an accessory role of SLII in translation. 
It does not however account for why the variation occurs and why the ΔSLI+II 5′UTR exhibits 
such variability. A more detailed investigation into the role of SLII in translation, and the host 
cell factors with which it interacts, would be needed to identify differences between the cell 
lines that may account for the variable translation phenotypes observed. 
3.3.7 The effect of SLI+II on EqHV 5′UTR IRES function 
 
The role of structural features of the EqHV 5′UTR IRES were here investigated in two 
complimentary systems. In order to fully appreciate the effect on translation that each deletion 
had, and subsequently the role that structure plays in translation, these data must be looked at 
in combination.  
ΔSLI, regardless of the cell line or construct in which it was tested, caused no significant impact 
on translation. Therefore it is possible to conclude that, in agreement with the work published 
by Stewart et al  this SL, which is the only major structure of the EqHV 5′UTR not present in HCV, 
does not have a role to play in translation initiation (Shi and Lai, 2006). It has been demonstrated 
that the HCV SLI functions in replication and that domains II-IV of the HCV 5′UTR constitute the 
IRES (Friebe et al., 2001; Lukavsky, 2009). Due to the structural similarities observed between 
EqHV and HCV, and the data presented here, and published by others (Stewart et al., 2013; 
Scheel et al., 2015), a conclusion naturally follows that SLI functions during EqHV replication in 
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similar way to that of HCV SLI. However, without a system to study replication of EqHV, this 
cannot yet be confirmed. Furthermore, it is possible that SLI of EqHV and HCV do not represent 
equivalent structures within the respective 5′UTRs. It may be the case that the EqHV SLIA 
represents the equivalent structure to HCV SLI and, if function is conserved, it is SLIA which plays 
a role in EqHV replication with SLI carrying out another, unknown, function. Whilst this 
hypothesis does not rule out a role for EqHV SLI in replication, it is something that would need 
to be considered in future experiments.  
Whilst the data for ΔSLI was in agreement across all five cell lines, and both constructs, the data 
for ΔSLI+II was less straightforward.  Translation efficiency varied greatly between cell lines and 
constructs alike. ΔSLI+II exhibited 61% mean activity of WT in Huh7 cells transfected with the 
bicistronic construct compared with 25% mean activity in Huh7 cells electroporated with the 
SGR, a similar trend was seen in the 293T cells where ΔSLI+II caused no significant effect on 
translation in the bicistronic construct but a 51% reduction in activity in the SGR. The converse 
was observed in FHK cells as mean IRES activity rose from 23% of WT in the bicistronic construct 
to 51% in the SGR in this cell line. There was no consistent effect on translation observed 
between each method of delivery, i.e. transfection or electroporation, and therefore this can be 
ruled out as the cause of the observed differences in IRES activity. The degree of variability 
between constructs and cell lines for this mutant means that definitive conclusions regarding its 
role in translation are difficult to draw. There was no consistent trend to be observed between 
either the construct in which the UTR was assayed, or which cell line was assayed. As such, 
different cell host factors or construct specific effects do not appear to be the cause of the 
variation. However, one definitive conclusion that can be drawn from this data is that SLI+II do 
not play an essential role in translation as, whist their deletion resulted in mean translation 
efficiency ranging from 23-100% of WT, a complete ablation of translation was not observed 
under any conditions. When this data is combined with our, and others, findings that SLI is not 
involved in EqHV IRES mediated translation it may be the case that SLII, whilst not essential, 
serves an accessory function which enhances translation from the EqHV IRES. The data 
presented here is in agreement with previous studies demonstrating that HCV SLII may not be 
required for IRES function (Wang et al., 1994; Reynolds et al., 1996; Kamoshita et al., 1997; 
Kolupaeva et al., 2000). However, the inhibitory effect on IRES activity in the absence of SLII may 
suggest that a conserved function may exist between HCV and EqHV in contacting the ribosome. 
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The role that miR122 may be exhibiting in translation from the ΔSLI+II 5′UTR is discussed in 
3.3.10. 
3.3.8 Structural deletions in EqHV 5′UTR SLIII have no overall impact on 5′UTR secondary 
structure 
 
ΔSLIII caused complete ablation of translation in all cell lines tested and there are two potential 
explanations for this phenotype: Firstly that SLIII is necessary for translation and its deletion 
therefore ablates this function. Secondly that the deletion of this large SL caused a structural 
rearrangement that abolished translation, especially given the close spatial relationship 
between SLIII and the pseudoknot. However, when mapped onto the ΔSLIII structure the data 
supports the hypothesis that SLIII is necessary for IRES function. SLI+II are clearly retained with 
the stems, and apical loops, showing reactivity profiles in good agreement with the WT. The 
flexible region in SLII did become highly reactive upon the deletion of SLIII, compared to 
unreactive in the WT. If the hypothesis regarding breathing and formation of unstable structural 
intermediates which are not conducive to NMIA reactivity is true, SLIII could be mediating such 
events and as such its deletion stabilises the confirmation as shown in Figure 3.7. However, as 
SLII is not necessary for IRES function, increased flexibility in this region is highly unlikely to cause 
complete ablation of translation. Interestingly these data indicate a role for SLIII effecting the 
flexibility of SLII, suggesting potential effects on tertiary structure caused by SLIII.  
Due to the proximity of the structures it was most likely that, if they were to exist, aberrant 
effects of ΔSLIII on the 5′UTR structure would affect the pseudoknot. It is known that the 
pseudoknot plays an extremely important role in HCV translation, positioning the AUG start in 
the mRNA binding cleft (Berry et al., 2010). Great care was taken in the design of this mutant to 
preserve SLIIIe and SLIIIf, and the initial stem of the pseudoknot, to preserve correct folding. 
However, it could not be ruled out that such a large deletion would have aberrant effects on the 
formation of the pseudoknot and thus be responsible for the ablation of translation. The SHAPE 
data in this region of ΔSLIII was in good agreement with that which was seen for the WT, and 
the slight observed differences do not appear large enough to elicit any major effect on the 
structure of the pseudoknot. Interestingly the miR122 seed site exhibits higher SHAPE reactivity 
throughout the sequence for the ΔSLIII mutant compared to WT, indicating that this region may 
be more flexible than in the WT 5′UTR. This could be being mediated by the increased flexibility 
in SLII. However a functional attribute cannot be assigned to this change in reactivity as 
translation does not occur from this mutant.  
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ΔSLIIIb exhibited variable effects between the two constructs tested, and it appeared as if SLIIIb 
was not essential to IRES function in the bicistronic construct, but necessary in the SGR. These 
different translation phenotypes could have been attributed either to different folding of this 
mutant in the two constructs resulting in different phenotypes, or to differential requirements 
for structural features in the bicistronic and SGR constructs; whereby the function of SLIIIb was 
not completely necessary in the bicistronic construct due to 40S ribosomal subunits being 
released from the end of cistron one and accumulating at the ΔSLIIIb IRES. This spatial 
arrangement could substitute for the proposed function of SLIIIb in binding eIF3 to prevent 43S 
accumulation and promote free 40S, assuming conserved function between EqHV and HCV. If 
the latter were the case then this would indicate that SLIIIb is indeed necessary for IRES function 
and that the ability of the ΔSLIIIb mutant to initiate translation was merely an artefact of the 
experimental set up. Figure 3.15 and Figure 3.16 demonstrate that SHAPE reactivities between 
the two constructs for the ΔSLIIIb mutant are largely similar. SLIIIa and SLIIIc are retained and 
SLIIIb is replaced by a single stranded “linker” region which is highly reactive to NMIA. The overall 
structure of SLIII is retained and the deletion of SLIIIb does not appear to have any significant 
impact on the pseudoknot. Some differences in reactivities were observed in SLII in the SGR; 
however, this study has already demonstrated that SLII is not necessary for IRES function and so 
slight effects seen here would not be expected to ablate translation.  
Finally ΔSLIIId caused complete ablation of translation in both the bicistronic and SGR constructs. 
It was hypothesised that this was due to the removal of the GGG motif which is proposed to 
interact with the 40S ribosomal subunit to position it at the AUG start codon for translation. 
However, it was possible that this ablation of translation was merely due to improper folding of 
the 5′UTR mediated by this deletion. The GGG motif in the apical loop of SLIIId has been 
previously demonstrated to impact correct folding of the HCV 5′UTR (Jubin et al., 2000). If the 
former of these two hypothesis was true it would provide further evidence that there exists a 
conserved mechanism of hepaciviral translation initiation. Determining the structure of this 
mutant 5′UTR was therefore essential. Upon inspection of the reactivity profile of ΔSLIIId it can 
be seen that it is in good agreement with the WT 5′UTR across all of the main structural elements 
investigated in this chapter. The overall structure of SLIII, and the pseudoknot, appear to be 
maintained, as do SLI, SLII, and SLIA. There are some slight differences to be observed in SLI and 
SLII. As for previous mutants these slight differences in reactivity profile do not appear to cause 
any overall structural changes to the UTR. Given their location in the 5′ half of the UTR, which is 
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not necessary for IRES function, they are highly unlikely to be able to completely ablate 
translation. As expected the deletion of SLIIId, similarly to ΔSLIIIb, resulted in a single stranded, 
highly NMIA reactive, “linker” region where SLIIId used to reside. This region already possessed 
some flexibility due to the single stranded region directly downstream of SLIIId, and thus it would 
not be expected that a minor increase in flexibility here would be able to ablate translation. The 
retention of all of the other major structural features, especially with regards to the pseudoknot 
and SLIII, indicates that no rearrangements of structure have occurred and confirms a specific 
block to translation mediated by the deletion of SLIIId. This finding provides further evidence 
that SLIIId, specifically the GGG motif, is interacting with the 40S ribosomal subunit to initiate 
translation; a function conserved between EqHV and HCV.  
  
3.3.9 The effect of SLIII on EqHV 5′UTR IRES function 
 
ΔSLIII consistently ablated translation to mock/control levels across all cells lines irrespective of 
the construct in which it was assayed. These data show that SLIII plays a direct and essential role 
in translation from the EqHV IRES, as it does in HCV. Whilst no sequence or structural deletions 
were made to SLIIIe or f, when the ΔSLIII data is viewed in combination with that obtained for 
ΔSLI+II it would appear as if SLIII and the pseudoknot comprise the minimal EqHV IRES.  
Translation efficiency from ΔSLIIIb exhibited variation between Huh7, FHK, and 293T cells for 
the bicistronic construct with regards to the efficiency of translation; however, in the context of 
the SGR, translation was completely ablated in all three cell lines. For the bicistronic construct 
mean translation efficiencies were 54% and 56% of WT in Huh7 and FHK cells respectively and, 
although not statistically significant, 80% of WT in 293T cells. Whilst the degree of efficiency was 
variable between these three cell lines it is evident that the deletion of SLIIIb did not completely 
ablate translation in the context of the bicistronic construct. This is in stark contrast to the 
complete lack of translation exhibited from this mutant in the same cell lines when it was in the 
context of the SGR. This poses many questions about the role of this structure in EqHV 
translation as data from the bicistronic assays would suggest that it is non-essential whereas the 
SGR data indicates that it is. The disagreement between the two sets of data may be due to 
experimental differences in regards to the two constructs. The proximity of the UTR to the cap-
dependent first cistron could result in the accumulation of initiation factors, and ribosomal 
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subunits, which would be able to interact with the remaining structural elements of the 5′UTR 
that would not have been able to, or which would have occurred far less frequently, in the SGR. 
During translation from the HCV IRES SLIIIb has been shown to recruit eIF3 by interacting with 
its ribosome binding face, thus preventing the accumulation of 43s complexes and promoting 
the availability of 40S subunits (Sun et al., 2013; Hashem et al., 2013). If this same mechanism 
were to be taking place in EqHV then proximity of the 5′UTR to a site of active translation i.e. 
cistron one, could be acting to carry out this function in the absence of SLIIIb. In this scenario, 
following the detection of the stop codon of cistron one, recruitment of the release factor, and 
dissociation of the two ribosomal subunits from the mRNA, there would be an accumulation of 
40S ribosomal subunits at the end of cistron one and thus at the ΔSLIIIb UTR. This could therefore 
avoid the requirement of eIF3 interactions with SLIIIb, and allow translation to proceed from 
this mutant IRES. However when the 5′UTR was located in its more natural position, at the 
proximal 5′ end of the SGR, SLIIIb may be absolutely required to either free 40S from eIF3, or 
recruit eIF3 and the 40S subunit to the 5′UTR for translation initiation and therefore, in its 
absence, translation would be ablated.  
Finally translation from ΔSLIIId (SLIIId contains a conserved GGG motif in its apical loop) was 
completely ablated in all cell lines tested in both the bicistronic, and SGR constructs (Figure 3.19 
and Figure 3.22). The conserved GGG motif could be the key factor in understanding the clearly 
essential nature of SLIIId in translation from the EqHV 5′UTR IRES, and our understanding of 
translation initiation in HCV allows us to draw such conclusions. The GGG motif in the apical loop 
is completely conserved amongst HCV isolates and is conserved in the related Hepaci- and Pesti-
viruses  (Jubin et al., 2000). In HCV this motif has been shown to directly interact with the 40S 
subunit, positioning it at the AUG start during translation initiation (Matsuda and Mauro, 2014; 
Malygin et al., 2013; Angulo et al., 2016). Due to the structural similarities observed between 
the 5′UTR of these two closely related viruses (Figure 3.1), the observed similarities in relation 
to the function of 5′UTR structural domains, and the presence of the conserved GGG motif both 
in sequence and position in the UTR, it is not unreasonable to assume a conserved mechanism 
of translation between EqHV and HCV. If this is the case then the ΔSLIIId deletion would remove 
the site of interaction between the EqHV 5′UTR and the 40S subunit, therefore preventing 
ribosome recruitment to the AUG start and preventing the formation of a translation complex.  
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Taken together these data show that SLI is not involved in translation initiation from the EqHV 
5′UTR IRES and, whilst not necessary for IRES function SLII may play a role in efficient translation 
initiation. Furthermore these data suggest that SLIII and the pseudoknot comprise the necessary 
minimal EqHV IRES. There is likely a conserved mechanism of translation initiation between HCV 
and EqHV. 
3.3.10 The role of miR122 in translation from the EqHV 5′UTR IRES – a tale of two constructs 
 
miR122 is a liver specific microRNA which is essential to HCV replication, however it has also 
been demonstrated to play a role in translation and RNA stability (Jangra et al., 2010; Thibault 
et al., 2015; Jopling et al., 2005). Whilst HCV contains two miR122 seed sites within its 5′UTR, 
EqHV only contains one, located directly 5′ of SLII. This corresponds to seed site two in HCV 
(Figure 3.1). It has previously been demonstrated that the overexpression of miR122, in cell lines 
in which it is not endogenously expressed, upregulates translation from the EqHV 5′UTR IRES 
which can be knocked down using LNAs (Scheel et al., 2015). However, whilst this effectively 
demonstrated the effect of miR122 on EqHV translation, the site of interaction with the UTR was 
merely assumed. Therefore this study aimed to firstly confirm the enhancing effect of miR122 
on EqHV translation, and secondly demonstrate the site of interaction.   
Upon transfection of bicistronic constructs into cells engineered to overexpress miR122 no 
obvious effect could be observed (Figure 3.21). In order to confirm whether or not miR122 was 
exhibiting an effect on translation the WT 5′UTR translation data from said miR122 expressing 
cells was normalised to the corresponding data from the parental cell line (Figure 3.21). This 
showed that no significant difference in translation efficiency could be seen upon the expression 
of miR122 for either FHK or 293T cells. One hypothesis for this lack of responsiveness is that 
translation from the EqHV 5′UTR IRES is simply not influenced by the presence of miR122; 
however this explanation seemed extremely unlikely given published data, and the array of 
functional similarities observed here between HCV and EqHV. It was therefore much more likely 
that the miR122 is unable to carry out the function which enhances EqHV translation when the 
5′UTR is assayed in the bicistronic construct.  
To answer this question the same miR122 expressing cell lines were assayed using the SGR. 
When a comparison of the WT values was conducted between the cell lines, as described above, 
for the SGR it became clear that the presence of miR122 significantly enhanced translation 
(Figure 3.23). This indicated that the effect of miR122 was dependent on the construct in which 
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it was assayed. When Scheel et al demonstrated miR122 mediated enhancement of EqHV 
translation they did so in a monocistronic reporter, in which the 5′UTR is located at the proximal 
5′ end. It was therefore likely that the effect of miR122 on translation is dependent on the 
positioning of the 5′UTR. It is therefore hypothesised that miR122 may be exhibiting a stabilising 
effect on the EqHV 5′UTR, potentially protecting it from the XrnI endonuclease, as has been 
demonstrated for HCV (Thibault et al., 2015). 
It was also observed that the efficiency of ΔSLI+II appeared to decrease in the miR122 expressing 
cells in comparison to the WT, from ~50% mean translation efficiency in FHK and 293T cells to 
~20% in FHK 122 and 293T 122 cells (Figure 3.22 and Figure 3.23). It was possible that the 
presence of miR122 was actively inhibiting translation. However this deletion mutant was the 
only one that exhibited such an effect, and was also the only one in which the deletion removed 
the miR122 seed site. This therefore meant that the most likely explanation was that the 
observed reduction in efficiency was due to the lack of a miR122 seed site.  This would result in 
translation from the WT 5′UTR being enhanced by miR122 with ΔSLI+II not, resulting in a 
perceived reduction in translation efficiency compared with WT. When the ΔSLI+II values from 
miR122 expressing cells are compared to the WT values from the respective parental cell lines 
they demonstrate a mean efficiency of 46% and 43% in FHK and 293T cells, respectively, 
compared with 52% and 53% for ΔSLI+II values from the parental cell lines. However, the 
differences between the sets of data obtained from the parental and miR122 expressing cells is 
not statistically significant for either cell line. This confirms the hypothesis that ΔSLI+II was 
simply unresponsive to the presence of miR122 rather than actively downregulated.  
To confirm that these observations were caused by the lack of the miR122 seed site, rather than 
another, unknown, feature which resided within SLI+II a miR122 to miR124 seed site mutant 
was created and assayed in the FHK and 293T parental and miR122 expressing cells (Figure 3.24). 
No significant difference was observed in translation efficiency from SGR NZCI 124 in the 
presence of miR122 in either cell line. This confirmed that enhancement of translation from the 
EqHV 5′UTR IRES is mediated by an interaction between miR122 and the miR122 seed site. This 
can be ablated by complete removal, or mutation, of this seed site. However whether the 
activity of miR122 is dependent on the location of this seed site was not investigated in this 
study and further work would be required to demonstrate this.  
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Taken together these data show that miR122 mediated enhancement of EqHV 5′UTR IRES 
activity is dependent on two factors, the positioning of the 5′UTR at the proximal end of the 
construct from which translation is being measured, and the presence of a miR122 seed site, 
which is naturally located directly 5′ of SLII. 
This structural study has provided the first experimental description of the secondary structure 
of the EqHV 5′UTR and has confirmed the existence of three main structural domains SLI, SLII, 
and SLIII(a ,b ,c ,d ,e , and f). The data in this study also indicate that a pseudoknot is highly likely 
to form at the 3′ end of the EqHV 5′UTR. Furthermore it has been demonstrated that structural 
deletions of major 5′UTR structures do not affect overall folding and structure, and confirms that 
translation phenotypes observed for these mutants are specific to the function of the deleted 
structural domain. Therefore, when taken together with the functional analysis of the EqHV 
5′UTR it is possible to conclude that SLI+II are not necessary for translation, and that SLIII and 
SLIIId are absolutely necessary. The necessity of SLIIIb has not yet been confirmed, however the 
hypothesis that SLIIIb is only not necessary in the bicistronic construct due to the internal 
location of the IRES, and its proximity to the end of cistron one, provides a reasonable 
explanation for this. Further investigation to confirm this hypothesis is required. 
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4.1 Introduction 
 
The data presented in Chapter 3 demonstrated that SLIII is the main determinant of translation 
from the EqHV 5′UTR IRES. Furthermore, these data demonstrated an essential role for SLIIIb 
and SLIIId in translation. A further analysis of the role which sequence plays in the function of 
SLIII was therefore carried out to investigate the ability of EqHV SLIII to interact with the host 
cell translational machinery. 
It is known that eIF3 and the 40S ribosomal subunit specifically interact with HCV SLIIIb and 
SLIIId, respectively. The ribosomal binding face of eIF3 interacts with the apical loop, and a 
mismatched loop of SLIIIb (Sun et al., 2013; Hashem et al., 2013). A more specific determination 
of interaction has been demonstrated between the 40S ribosome and HCV SLIIId. The conserved 
GGG motif in SLIIId specifically interacts with 1116CCC1118 of the 40S subunit (Matsuda and Mauro, 
2014; Malygin et al., 2013). Mutations made within the apical loops of HCV SLIIIb and SLIIId have 
been demonstrated to significantly impair translation activity from the HCV IRES. It was 
hypothesised that the apical loops of EqHV SLIIIb and SLIIId also interact with eIF3 and the 40S 
ribosomal subunit and that these interactions could be interrupted by apical loop mutations. 
Section 4.2.1 describes EqHV SLIIIb and SLIIId apical loop mutants and the effects they have on 
translation from the EqHV IRES. 
SHAPE footprinting is a method of SHAPE analysis (described in 4.2.1) in which a predicted 
interacting partner is introduced into the reaction, following folding and before the addition of 
the SHAPE reagent. This method has been used to predict eIF3 interactions with HCV SLIIIb (Sun 
et al., 2013) and HCV SLIIId interactions with the 40S ribosome (Angulo et al., 2016). 
Furthermore, analysis of RNA-protein interactions requires minimal additional optimisation over 
that which is required for the conventional SHAPE experiments. Therefore if a SHAPE 
experimental protocol has been previously optimised for a specific RNA, as was the case in this 
study, SHAPE footprinting provides a relatively straightforward experimental progression to 
provide a more detailed insight into the characteristics of the RNA in question.  
Section 4.2.2 of this Chapter describes SHAPE footprinting experiments carried out on the WT 
EqHV 5′UTR, and the apical loop mutants, to assess their ability to interact with purified eIF3 and 
40S ribosomal subunit.   
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Whilst SHAPE footprinting provides good evidence for a protein-RNA interaction, this approach 
utilises purified proteins for the analysis and is therefore not suitable to identify a large number 
of interacting partners. Furthermore this technique infers interaction by assessing the ability of 
a protein to protect unpaired nucleotides from reaction with the SHAPE reagent. This means 
that proteins that associate with a protein in a complex, and therefore are not involved in a 
direct interaction with the RNA, would not be able to be identified. To identify which 
components of the translational machinery are associated with the EqHV 5′UTR, tandem mass 
tag mass spectrometry (TMT MS) was utilised (Thompson et al., 2003) 
Section 4.2.3 describes pull-down assays performed using biotinylated EqHV 5′UTR as bait, and 
the interacting partners identified by TMT MS. 
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4.2 Results 
 
4.2.1 Sequence specific mutations in EqHV SLIIIb and SLIIId disrupt translation 
Functional analysis had demonstrated that SLIIIb, and SLIIId, play key roles in translation from 
the EqHV IRES. It was hypothesised that this was due to interactions with eIF3 and the 40S 
ribosomal subunit, respectively. Apical loop mutations of SLIIIb and SLIIId in HCV have previously 
been demonstrated to reduce translation efficiency to 50%, and <5% respectively, and these 
loops have previously been demonstrated to interact with eIF3 and the 40S subunit. (Jubin et 
al., 2000; Barría et al., 2009; Kieft et al., 2001; Sun et al., 2013; Angulo et al., 2016). To investigate 
whether the apical loops of EqHV SLIIIb and SLIIId were mediating interactions with host cell 
factors during translation initiation, causing inhibition of translation upon their deletion, 
sequence specific mutations were introduced into SLIIIb (250CUU252 to 250GUC252) and SLIIId 
(309GGG311 to 309AGU311). 309GGG311 to 309AGU311 is a mutation that has been previously 
characterised for HCV and ablates both translation and 40S ribosomal subunit interaction. 
Mutations were introduced into the SGR by Q5 SDM (NEB). As described in 3.2.10 RNA was in 
vitro transcribed and transfected into Huh7 (Figure 4.1A), FHK (Figure 4.1B) and 293T (Figure 
4.1C) cells, and assayed for FLuc activity 6 h.p.t. All experiments were conducted to N=3 and a 
student’s T test calculated for all data in comparison to WT translation. Data are represented as 
a percentage of the WT IRES activity, which is set at 100%. The GUC mutant caused a significant 
impairment of translation to 40% of WT in the Huh7 cells, 76% in FHK cells, and 64% in 293T 
cells. Unlike the ΔSLIIIb mutation, GUC did not cause a complete ablation of translation in any of 
the cell lines tested, indicating that the overall structure of SLIIIb is more important to EqHV 
translation that the sequence of the apical loop. The AGU mutant, on the other hand, caused an 
almost complete ablation of translation in all three cell lines tested to a mean efficiency of 13% 
of WT in Huh7, 17% in FHK, and 10% in 293T cells. Indicating that the sequence of the apical loop 
of SLIIId is a key determinant of EqHV IRES activity. 
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NZCI N (where N represents either WT or mutant EqHV) or mock (no RNA) was transfected into 
A) Huh7 B) FHK and C) 293T cells, harvested 6 h.p.t and assayed for firefly luciferase activity. All 
values are represented as a percentage of the RLU for the WT EqHV 5′UTR and this is used as a 
representative measure of IRES efficiency (with WT taken as 100% activity). All data was subject 
to a student’s T test in comparison to the WT value for each respective cell line. Stars represent 
statistically significant values. 
 
Figure 4.1: Translation activity of SLIIIb and SLIIId apical loop mutations 
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4.2.2 SHAPE footprinting analysis 
 
The functional data in Figure 4.1 suggested that the GUC and AGU mutations could be disrupting 
SLIIIb and SLIIId interactions with the host cell translational machinery. Based on our knowledge 
of the HCV IRES it was hypothesised that the interacting partners were eIF3 and the 40S 
ribosomal subunit, respectively. To test this hypothesis SHAPE footprinting analysis of SLIII was 
conducted with either purified eIF3 or 40S ribosomal subunit (provided by N. Locker, University 
of Surrey).  In a conventional SHAPE experiment the reactivity of any given base is solely 
dependent upon the flexibility of its 2′OH group. However, the addition of purified protein, 
before the addition of NMIA, alters this. If the protein and RNA interact, the reactivity of each 
base toward NMIA becomes dependent not only upon the flexibility of its 2′OH, but also upon 
protection by the interacting protein. Therefore if a previously NMIA reactive base interacts with 
the protein it will preclude NMIA binding and shift from a reactive to unreactive base. A 
schematic representation of this altered SHAPE protocol can be seen in Figure 4.2.  
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A schematic representation of the SHAPE footprinting experimental flow through with the 
addition of protein following RNA folding and before addition of NMIA. NMIA is represented in 
red, with fluorescently labelled primers shown in green. RT extensions are show as black lines.  
 
 
 
 
 
Figure 4.2: A schematic representation of the SHAPE experimental procedure 
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4.2.3 The EqHV 5′UTR interacts with eIF3 and the 40S ribosomal subunit 
 
Using SHAPE footprinting the ability of SLIIIb and SLIIId to interact with eIF3 and the 40S 
ribosomal subunit was investigated. EqHV SGR containing the WT 5′UTR was in vitro transcribed 
and subject to SHAPE footprinting analysis with 300 nM of purified eIF3 (Figure 4.3), or 40S 
ribosomal subunit (Figure 4.4). All experiments were conducted to N=3 and a student’s T test, in 
comparison to no protein, was conducted for each base in SLIIIb (for eIF3 footprinting) or SLIIId 
(for 40S footprinting) to determine if any statistically significant change in NMIA reactivity had 
occurred. 
The apical loop of SLIIIb (65ACUUU69) is highly NMIA reactive when analysed in a traditional 
SHAPE experiment (Figures 5.3A and B). However, upon the addition of eIF3 NMIA reactivity is 
significantly reduced across all 5 bases in the apical loop, in comparison to no eIF3 (Figure 4.3C 
and D and Table 4.1). No other statistically significant changes in NMIA reactivity are observed 
in SLIIIb in the footprinting assay.  These data indicate that eIF3 is able to specifically interact 
with the apical loop of EqHV SLIIIb.  
Similarly the apical loop of SLIIId (123UUGGGC128) is highly NMIA reactive in a traditional SHAPE 
experiment (Figure 4.4A and B and Table 4.2). However, upon the addition of 40S ribosomal 
subunit NMIA reactivity is significantly reduced across all 6 bases in the apical loop, in 
comparison to no 40S (Figure 4.4C and D and Table 4.2). These data indicate that the 40S 
ribosomal subunit is able to specifically interact with the apical loop of EqHV SLIIId. Interestingly, 
there is also a statistically significant increase at 129C, the first base 3′ of the apical loop. This is 
similar to the non-significant increase (p=0.13) in NMIA reactivity exhibited at 71A (increase in 
mean NMIA reactivity of 0.2 to 2.6) of SLIIIb (Figure 4.3D).   Both increases in reactivity occur at 
bases immediately downstream of the site of interaction and could therefore be caused by 
residual bound protein on the apical loops causing extension of the RT to terminate and thus 
giving a false positive NMIA reactivity.  
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A) SHAPE analysis of SLIII of the EqHV 5′UTR B) Enlarged image of SLIIIb from the SHAPE analysis 
in A. B) eIF3 SHAPE footprinting analysis of SLIII of the EqHV 5′UTR C) Enlarged image of SLIIIb 
from the footprinting analysis in C. Red stars indicate bases which exhibited a statistically 
significant reduction in NMIA reactivity when footprinting with eIF3 was conducted, compared 
to no eIF3. SHAPE reactivities are represented on a colour scale from white (low reactivity – 
predicted paired) to red (high reactivity – predicted unpaired) a representative scale denoting 
reactivity increments of 0.1 is displayed. Number labelling corresponds to domain III only and 
number labelling in B and D correspond to number labelling in A and C. 
 
 
 
 
 
 
 
 
Table 4.1: SHAPE reactivity values for the apical loop of WT SLIIIb +/- eIF3 
 
  
Figure 4.3: Shape footprinting reveals an interaction between the apical loop of EqHV SLIIIb 
and eIF3 
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A) SHAPE analysis of SLIII of the EqHV 5′UTR B) Enlarged image of SLIIId from the SHAPE analysis 
in A. C) 40S ribosomal subunit SHAPE footprinting analysis of SLIII of the EqHV 5′UTR D) Enlarged 
image of SLIIId from the footprinting analysis in C. Red stars indicate bases which exhibited a 
statistically significant reduction in NMIA reactivity when footprinting with 40S was conducted, 
compared to no 40S; green stars represent an increase. SHAPE reactivities are represented on a 
colour scale from white (low reactivity – predicted paired) to red (high reactivity – predicted 
unpaired) a representative scale denoting reactivity increments of 0.1 is displayed. Number 
labelling corresponds to domain III only and number labelling in B and D correspond to number 
labelling in A and C. 
 
 
 
Table 4.2: SHAPE reactivity values for the apical loop of WT SLIIId +/- 40S ribosomal subunit 
 
 
 
 
 
 
 
Figure 4.4: Shape footprinting reveals an interaction between the apical loop of EqHV SLIIId 
and the 40S ribosomal subunit 
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4.2.4 Mutations in SLIIIb and SLIIId can disrupt EqHV 5′UTR interaction with eIF3 and the 40S 
ribosomal subunit 
 
Both eIF3 and the 40S ribosomal subunit significantly altered the NMIA reactivity of bases in the 
apical loops of SLIIIb and SLIIId and can be said to be exhibiting an interaction. It was therefore 
hypothesised that the reduction, and complete ablation, of translation from the GUC and AGU 
mutations (Figure 4.1), was caused by these mutations disrupting the interactions demonstrated 
in Figures 4.3 and 4.4. To test this hypothesis, these mutants were subject to the same SHAPE 
footprinting assays as in 4.2.3.  
Unlike the WT (Figure 4.3) the SLIIIb GUC mutant exhibited very little change in NMIA reactivity 
across the apical loop of SLIIIb in eIF3 SHAPE footprinting. Only 126C exhibited any significant 
change. However, whilst this base did exhibit a significant reduction in mean NMIA reactivity 
compared to WT, from 2.68 to 0.77, a SHAPE reactivity value over 0.7 is widely considered to be 
highly reactive. Therefore 126C is still considered to be highly reactive to NMIA and as such would 
not be considered to be protected from NMIA in this assay (Figure 4.5 and Table 4.3). These data 
indicate that eIF3 is not able to interact with the GUC mutant to protect the apical loop from 
NMIA reaction. The GUC mutant disrupts the interaction between the apical loop of SLIIIb, and 
eIF3. 
Similarly, the SLIIId AGU mutant exhibited no significant difference in NMIA reactivity in all bases 
in its apical loop, apart from two, in a footprinting assay using 40S ribosomal subunit compared 
to WT. The change in NMIA reactivity seen in 124U actually represents an increase in NMIA 
reactivity. As with 126C, 124U and 127U are still both considered to be highly reactive to NMIA in 
both the WT, and the AGU footprinting assay (Figure 4.6 and Table 4.4). Therefore, whilst there 
is a significant change, the differences seen here do not impact the conclusion that the 40S 
ribosomal subunit is not able to interact with the SLIIId AGU mutant. 
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A) SHAPE analysis of SLIII of the EqHV 5′UTR B) Enlarged image of SLIIIb from the SHAPE analysis 
in A. C) eIF3 SHAPE footprinting analysis of SLIII of the EqHV GUC 5′UTR D) Enlarged image of 
SLIIIb from the footprinting analysis in C.  Red stars indicate bases which exhibited a statistically 
significant reduction in NMIA reactivity when footprinting with eIF3 was conducted, compared 
to WT no eIF3. SHAPE reactivities are represented on a colour scale from white (low reactivity – 
predicted paired) to red (high reactivity – predicted unpaired) a representative scale denoting 
reactivity increments of 0.1 is displayed. Number labelling corresponds to domain III only and 
number labelling in B and D correspond to number labelling in A and C. 
 
Figure 4.5: A mutation in the apical loop of EqHV SLIIIb prevents interaction with eIF3 
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Table 4.3: SHAPE reactivity values for the apical loop of GUC SLIIIb +eIF3 in comparison to 
WT without eIF3 
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A) SHAPE analysis of SLIII of the EqHV 5′UTR B) Enlarged image of SLIIId from the SHAPE analysis 
in A. C) 40S ribosomal subunit SHAPE footprinting analysis of SLIII of the EqHV AGU 5′UTR D) 
Enlarged image of SLIIId from the footprinting analysis in C. Green stars indicate bases which 
exhibited a statistically significant increase in NMIA reactivity when footprinting with 40S was 
conducted, compared to WT no 40S; red stars indicate a decrease. SHAPE reactivities are 
represented on a colour scale from white (low reactivity – predicted paired) to red (high reactivity 
– predicted unpaired) a representative scale denoting reactivity increments of 0.1 is displayed. 
Number labelling corresponds to domain III only and number labelling in B and D correspond to 
number labelling in A and C. 
 
Figure 4.6: A mutation in the apical loop of EqHV SLIIId prevents interaction with the 40S 
ribosomal subunit 
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Table 4.4: SHAPE reactivity values for the apical loop of AGU SLIIIb +40S ribosomal subunit in 
comparison to WT no 40S 
 
 
 
  
126 
 
4.2.5 The EqHV 5′UTR interacts with host cell translational machinery necessary for HCV 
translation 
 
To confirm the interactions observed in 4.2.3, and to determine other mammalian initiation 
factors with which the EqHV 5′UTR interacts, pull-down assays were conducted using Huh7 cell 
lysate and the EqHV 5′UTR RNA as bait. The identity of interacting partners was then determined 
by tandem mass tagged (TMT) mass spectrometry (MS [TMT MS]) (University of Bristol). Pull 
downs were carried out using the Pierce™ Magnetic RNA-Protein Pull-Down Kit according to the 
manufacturer’s instructions. Three groups of proteins are described here: eIFs (Table 4.1), 40S 
ribosomal (Table 4.2), and 60s ribosomal (Table 4.3) proteins. Only proteins identified at an 
abundance ratio of sample:bead only control >1 were considered to have been specifically 
pulled down by the WT 5′UTR and are displayed here.  
As discussed in 1.2.3 the HCV IRES interacts with a subset of the canonical initiation factors, and 
the 40S and 60S ribosomal subunits, to initiate translation in a cap-independent fashion. This 
process does not require eIF4G or eIF4E, and absolutely requires eIF2, eIF3, eIF5B, and the 
ribosomal subunits to initiate translation. The functional analysis of the EqHV IRES described in 
Chapter 3 indicates that the function of the individual IRES domains is conserved between these 
two closely relate viruses, and that the mechanism of translation initiation may be conserved. 
Therefore the EqHV IRES would also require interaction with the same eIFs as HCV, and 40S and 
60S subunits, to initiate translation. The TMT MS data shown in Table 4.5, Table 4.6, and Table 
4.7 are in good agreement with this hypothesis and demonstrate that the EqHV IRES does not 
interact with eIF4G or eIF4E, doe interact with the eIFs required for HCV IRES mediated 
translation initiation, as well as the 40S and 60S ribosomal subunits required to initiate 
elongation.  
This analysis demonstrates the ability of the EqHV 5′UTR to pull-down, and therefore interact 
with, the complete set of eIFs and ribosomal subunits required for HCV IRES mediated 
translation. These data provide compelling evidence for a conserved mechanism of translation 
initiation between HCV and EqHV (discussed in 4.3.3).  
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A list of eIFs identified to interact with the EqHV 5′UTR from pulldown-TMT MS analysis. FDR 
confidence is the False discovery rate confidence (high=1% medium=5%). Abundance ratio is the 
ratio protein abundance for the WT 5′UTR pull-down to the bead only control. 
 
Table 4.5: eIF interacting partners of the EqHV 5’UTR  
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A list of 40S ribosomal proteins identified to interact with the EqHV 5′UTR from pulldown-TMT 
MS analysis. FDR confidence is the False discovery rate confidence (high=1% medium=5%). 
Abundance ratio is the ratio protein abundance for the WT 5′UTR pull-down to the bead only 
control. 
 
Table 4.6: 40S ribosomal interacting partners of the EqHV 5′UTR  
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A list of 60s ribosomal proteins identified to interact with the EqHV 5′UTR from pulldown-TMT 
MS analysis. FDR confidence is the False discovery rate confidence (high=1% medium=5%). 
Abundance ratio is the ratio protein abundance for the WT 5′UTR pull-down to the bead only 
control. 
 
Table 4.7: 60S ribosomal interacting partners of the EqHV 5’UTR 
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4.3 Discussion 
 
4.3.1 eIF3 interacts with the apical loop of EqHV 5′UTR SLIIIb during IRES mediated translation 
 
As discussed in 3.3.8 the proximity of the EqHV IRES to the end of cistron one in the bicistronic 
construct may have been compensating for the function of SLIIIb in the ΔSLIIIb mutant IRES, 
therefore only the SGR was used to further investigate the role of SLIIIb in EqHV IRES mediated 
translation. Here a 250CUU252 to 250GUC252 mutation was introduced into the apical loop of SLIIIb 
to investigate if this mutation could also knock down translation in the same way as ΔSLIIIb 
(Figure 4.1). Whilst this mutation did not completely ablate translation it did reduce activity to 
40-70% of WT. eIF3 has previously been demonstrated to protect the apical loop of HCV SLIIIb 
in SHAPE footprinting. The translation efficiency of a deletion of the apical portion of HCV SLIIIb 
resulted in 34% translation efficiency of WT, similar to that observed in Huh7 cells for the GUC 
mutant (Sun et al., 2013). This study also demonstrated 214AAU216, which resides within a 
mismatched loop in the HCV SLIIIb, interacts with eIF3. However this loop is not conserved within 
EqHV SLIIIb in the structure described in this study (Figure 4.2). Therefore, it was hypothesised 
that the reduced IRES efficiency seen in the GUC mutant was caused by this mutant’s inability 
to interact with eIF3 via the apical loop.  
SHAPE footprinting analysis confirmed that eIF3 was indeed interacting with the apical loop of 
EqHV SLIIIb, causing a significant reduction in NMIA reactivity in this region. However, unlike 
studies conducted on eIF3-HCV 5′UTR interactions, no significant reduction in NMIA reactivity 
was observed for any other base in the apical portion of SLIII. This evidence suggests that eIF3 
exclusively interacts with the apical loop of EqHV SLIIIb. However, the apical loops of SLIIIa, and 
SLIIIc, are completely conserved between HCV and EqHV, suggesting that they share a conserved 
function. Mutation of these SLs in HCV reduced translation to <10% of WT with the deletion of 
SLIIIa resulting in <5.5 fold affinity for eIF3. These data therefore raise some interesting 
questions about the role of SLIIIb in interacting with eIF3 in EqHV IRES-dependent translation. 
HCV SLIIIb has been extensively shown to interact with eIF3 to facilitate efficient translation. The 
SHAPE footprinting conducted here confirmed that eIF3 specifically interacts with the apical loop 
of EqHV SLIIIb, so it was therefore of no surprise that deletion of this subdomain ablates 
translation. However the 250GUC252 mutation, which disrupts the interaction of eIF3 and SLIIIb, 
does not completely block translation. It is therefore possible that another interaction site exists. 
Given the lack of any significant alteration to NMIA reactivity throughout SLIII upon eIF3 binding 
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it may be the case that eIF3 is interacting with a structural motif of SLIII which is in a base paired 
confirmation. This would preclude NMIA from reacting in the natural confirmation and thus 
protection by eIF3 would not be observable by this method. Furthermore, the SLIIIabc junction 
has been demonstrated, for HCV, to be an important determinant of eIF3 interaction and 
translation efficiency (Odreman-Macchioli et al., 2000). The EqHV ΔSLIIIb mutant encompassed 
a deletion of the entirety of SLIIIb, therefore disrupting the SLIIIabc junction and this could 
provide an explanation for the differences observed between ΔSLIIIb and 250GUC252 in their ability 
to initiate translation. Whilst these data suggest a role for the SLIIIabc junction in EqHV 
translation, it does appear to rule out any specific interactions between SLIIIa, or SLIIIc, and eIF3. 
It is hypothesised that both sequence and structural features are involved in EqHV SLIII – eIF3 
interactions during translation initiation. eIF3 specifically interacts with the apical loop of SLIIIb 
to enhance IRES activity, but this is not the main determinant of translation with regards to eIF3. 
There are two hypotheses for what this main determinant may be. Either eIF3 interacts with 
SLIIIb in a structure specific manner; or eIF3 interacts with the SLIIIabc junction. A more detailed 
mutational analysis to investigate these possibilities, as well as the roles of SLIIIa and SLIIIc, could 
answer these questions. Alternative methods of RNA structure probing, such as enzymatic 
cleavage analysis, could also be used to further our understanding of EqHV 5′UTR interactions 
with eIF3. 
4.3.2 40S ribosomal subunit interacts with 309GGG311 during IRES mediated translation 
 
As discussed in 3.3.2 the ΔSLIIId mutation completely ablated translation from the EqHV IRES 
and this was hypothesised to be due to the absence of the conserved GGG motif within the 
apical loop (Figure 4.2). In order to test this a 309GGG311 to 309AGU311 mutation, previously 
demonstrated to reduce HCV translation to ~10% of WT translation was introduced into pSGR 
NZCI (Jubin et al., 2000; Otto and Puglisi, 2004; Barría et al., 2009). The data shown in Figure 4.1 
demonstrate that a similar effect can be observed for mutation of the GGG triplet in EqHV, with 
translation efficiency <20% of WT, and as low as 10%.  
This GGG motif has been demonstrated, in HCV, to interact with 1116CCC1118 of the 40S ribosomal 
subunit, exhibiting a protective effect in SHAPE footprinting. Conversely the 40S ribosome has 
been demonstrated to have a protective effect on 266GGG268 in the HCV apical loop (Angulo et 
al., 2016) with the corresponding HCV AGU mutant negating these effects. It was therefore 
hypothesised that, due to the similar functional effects demonstrated for this mutation, the 
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EqHV 309GGG311motif also interacts with the 40S subunit. SHAPE footprinting analysis confirmed 
that 40S ribosomal subunit had a protective effect on the apical loop of EqHV SLIIId, with all 
bases in the apical loop exhibiting a significant reduction in NMIA reactivity in this experiment. 
No bases exhibited a loss of NMIA reactivity upon the addition of 40S subunit to the AGU mutant 
5′UTR. Whilst the corresponding experiments for protection of 1116CCC1118 by EqHV SLIII were not 
conducted, the structural, sequence, and functional conservation of these bases between EqHV 
and HCV is strongly indicative that 309GGG311 of EqHV SLIIId interacts with 1116CCC1118 of the 40S 
ribosomal subunit. .  
Interestingly, for both eIF3 and 40S SHAPE footprinting, an increase in NMIA reactivity was 
observed in bases immediately downstream of the interaction site. However it is believed that 
this is an artefact of the experimental setup. RNA was not phenol chloroform extracted to 
remove protein following NMIA reaction. This step was not included due to loss of sample and 
downstream detection issues. It was expected that the high temperature used for RT would 
prevent any protein RNA interactions forming during the extension and therefore not affect the 
experiment. However, low levels of binding during the extension could have occurred and thus 
halted RT progression, resulting in a high number of transcription stops at this point and a false 
positive NMIA peak. This appears to be the most likely cause of the increase in NMIA reactivity 
and this explanation fits well with the lack of significance exhibited in the eIF3 footprinting. 
Furthermore it is not believed that this artefact had an impact on the overall data obtained from 
the footprinting analysis as there was a clear and reproducible decrease in NMIA activity in the 
apical loops. Protein binding detection as a false positive NMIA signal would cause bases to 
appear highly NMIA reactive.  
4.3.3 The EqHV 5′UTR interacts with all of the factors required for HCV translation initiation 
 
The HCV IRES requires only a subset of initiation factors to efficiently initiate translation of its 
polyprotein. The 40S ribosomal subunit is directly recruited to the IRES through a specific 
interaction with SLIIId, and correct folding of the pseudoknot correctly positions the AUG start 
in the mRNA binding cleft. eIF3 is recruited through a specific interaction with SLIIIb, and this 
ternary complex (TC) associates with eIF2/GTP/Met-tRNA to form the 48S particle. Following 
hydrolysis of GTP eIF2 releases Met-tRNA, and is itself released from the 48S complex. eIF5B 
then facilitates a further GTP hydrolysis reaction which allows binding of the 60S subunit, 
resulting in the assembly of an 80S ribosome capable of initiating translation (Ji, 2004). As can 
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be observed in Table 4.1 the EqHV WT 5′UTR is able to pull-down a number of eIF3 subunits, 
including eIF3a which has been demonstrated to be the most important in HCV IRES activity (Sun 
et al., 2013). A number of eIF2 subunits, and eIF5B, were also pulled down. This demonstrated 
that the EqHV 5′UTR was interacting all of the initiation factors involved in the expression of the 
HCV polyprotein from the IRES. Interestingly eIF1A was not shown to associate with the EqHV 
5′UTR. This interaction was demonstrated for HCV by (Jaafar et al., 2016) who also suggested an 
updated mechanism of translation initiation whereby the HCV binds an assembled pre initiation 
complex (PIC).  
The EqHV 5′UTR is also shown to be in associated with a number of 40S (Table 4.2) and 60S 
(Table 4.3) ribosomal proteins. These data therefore demonstrate that the EqHV 5′UTR is 
specifically interacting with eIF3 and the 40S ribosomal subunit, and that the 80S ribosome is 
highly likely to assemble on the EqHV AUG start following eIF2 and eIF5b binding.  
4.3.4 A predicted model of EqHV translation initiation 
 
In this study a complimentary functional and structural analysis of the EqHV 5′UTR IRES was 
undertaken which demonstrated that SLI is not involved in IRES mediated translation, SLII is not 
essential but enhances translation, and that SLIII is absolutely necessary. The apical loop of SLIIIb 
interacts with eIF3 and whilst this interaction is not necessary for IRES function the presence of 
SLIIIb is crucial. SLIIId is absolutely required for IRES activity and this is due to a conserved GGG 
motif which interacts with the 40S ribosome. The EqHV 5′UTR also interacts with all of the 
factors involved in HCV translation initiation. 
Based upon the data presented here it is proposed that EqHV and HCV share a conserved 
mechanism of translation initiation. The data presented here provides a compelling argument 
for this functional conservation and this also potentially represents a conserved mechanism of 
hepaciviral translation initiation (Figure 1.1B). However, investigations into the mechanisms 
employed by the other newly discovered hepacivirus is needed to confirm this.  
 
 
 
134 
 
 
 
 
Chapter 5 Rational 
modification of an EqHV 
sub-genomic replicon to 
enhance replicative capacity 
 
 
 
 
 
135 
 
5.1 Introduction 
 
Sub-genomic replicons (SGRs) are widely used to study an array of positive-sense RNA viruses 
including picorn-, alpha-, and flavi- viruses. The principles of an SGR are that the structural 
proteins of a given virus are replaced with a reporter gene so that virus replication can be studied 
in the absence of virus particle production. Such constructs have provided extremely useful tools 
to research dangerous pathogens which are required to be handled only at high containment 
levels. This has increased research access to, and therefore knowledge of, these viruses as their 
SGRs can be handled at lower containment levels than infectious virus.  
SGRs are a widely used system to study the replication of HCV, and the function of its non-
structural proteins. The HCV genome is ~10 Kb in length with 5′ and 3′ UTRs. Expression of the 
large polyprotein is driven by the HCV 5′UTR IRES and is cleaved by cellular, and viral, proteases 
to yield 10 proteins. The first four constitute the structural genes (core, E1, E2, and p7) and the 
remaining six the non-structural genes (NS2, NS3, NS4A, NS4B, NS5A, NS5B). The HCV proteins 
NS3-5B constitute the minimal components for HCV replication. The HCV SGR consists of the 
5′UTR, which drives expression of a reporter gene, followed by the EMCV IRES which drives 
expression of the non-structural genes NS3-5B, and finally the HCV 3′UTR. A GDD-GND/N 
mutation in in the active site of NS5B is commonly used in the field as a replication deficient 
negative control (Lohmann et al., 1999).  
Replication of the HCV SGR is assayed in two main ways: stable and transient. Stable replication 
(also referred to as stable cell lines) utilises an antibiotic resistance gene in place of the structural 
genes which, following transfection of IVT HCV SGR RNA into cells, can be selected to maintain 
a population of cells which harbour the SGR. Transient replication utilises a reporter gene, 
commonly firefly luciferase (FLuc), with chemilumiscent or fluorescent properties which can be 
quantified to assess levels of replication. Both systems have inherent advantages and 
disadvantages: stable cell lines can often support the replication of viral isolates for which 
replication cannot be detected in a transient assay, and can be used to select for mutations 
which enhance replication in mammalian cells. However they are time consuming to create, and 
select against deleterious mutations. On the other hand transient SGR assays allow for the study 
of viral growth kinetics, and the effects of deleterious or replication suppressive mutants, but 
virus isolates with low levels of replication may not be able to be detected transiently.  
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Traditionally the reporter gene used for HCV SGRs has been Feo, a fused firefly 
luciferase/neomycin phosphotransferase gene (FLuc/Neo), as this allows stable cell lines to be 
selected for whilst also providing a system to easily detect active replication both in the transient 
system and in the stable cell line. However, other reporter genes such as puromycin resistance, 
blasticidin resistance, fluorescent proteins, and Neo and Fluc in isolation have also been used. 
Recently it was discovered that a CpG and UpA low FLuc gene was able to increase detection of 
transient HCV SGR replication by 100 fold (Atkinson et al., 2014).  
The advent of the HCV SGR represented a huge leap forward in HCV research and has facilitated 
a litany of discoveries that have culminated in the development of pan-genotypic direct acting 
antivirals (DAAs) which have ushered in a new era of IFN-free HCV therapy with remarkable 
success (reviewed in Zhang et al., 2016). However, HCV still remains a global health concern and, 
currently, no models exist for comparative study. EqHV is the most closely related virus to HCV, 
but exhibits no significant pathology in its natural host, equines. It therefore has the potential 
to provide illuminating data regarding how, and why, such closely related viruses exhibit such 
disparity in their disease causing capabilities. Therefore I set out to establish an EqHV SGR 
capable of efficient replication in mammalian cell culture to provide such a system.  
Sections 5.2.1, 5.2.2, and 5.2.3 of this Chapter describe the construction and assay of a “first 
generation” EqHV sub-genomic SGRs using isolate EF369_11J; GenBank accession no. 
JX948116.1. Sections 5.2.4, and 5.2.5 of this chapter describe the construction and assay of SGRs 
derived from the consensus NZPI sequence (GenBank accession no. KP325401). 
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5.2 Results 
 
5.2.1 First generation EqHV, and chimeric, SGRs 
 
The original EqHV SGR was constructed in the image of the widely used HCV SGRs described in 
5.1, and had an identical organisation (Figure 5.2A). The NS3-5B region of EqHV (isolate 
EF369_11J; GenBank accession no. JX948116.1) was PCR amplified and introduced into the JFH-
1 HCV SGR construct, in place of the HCV NS3-5B region by H. Stewart and C. Walter (University 
of Leeds). The reporter gene used here was the Feo gene, so that both transient and stable 
replication could be investigated. The EMCV IRES drove translation of EqHV NS3-5B, and this 
was followed by the HCV 3′UTR. This construct was given a three letter designation H-E-H with 
each letter representing the 5′UTR, polyprotein, and 3′UTR, with H representing the HCV 
sequence and E the EqHV sequence (Figure 5.2A). Therefore the construct designated pSGR H-
E-H would contain the HCV 5′UTR, EqHV polyprotein, and the HCV 3′UTR. This nomenclature is 
used throughout this chapter to refer to all of the chimeric SGRs constructed. In order to 
investigate replication of the EqHV SGRs it was first necessary to create a replication deficient 
clone equivalent to those used for HCV. The accepted replication deficient control for HCV 
replication is an NS5B RNA dependent RNA polymerase (RdRP) active site (GDD) mutation to 
GND/GNN. EqHV also contains the classical GDD motif in its NS5B RdRP, therefore a GDD Æ GNN 
mutation was introduced by Q5 SDM (NEB) to create a replication deficient control for 
replication assays. It was hypothesised that, like for many HCV isolates, EqHV would require 
culture adaptive mutations to replicate in cell culture. It has become common to artificially 
introduce adaptive mutations into HCV sequences in an attempt to facilitate their replication in 
cell culture. A common mutation, S2204I, has been demonstrated to significantly enhance HCV 
replication. Alignment of the EqHV and HCV polyprotein sequences revealed a conserved serine 
in the EqHV NS5A protein (S2180) equivalent to S2204 (Figure 5.1). An SÆI mutation was 
introduced at this point (S2180I) to try and achieve EqHV replication in cell culture. To test the 
replicative ability of SGR H-E-H 2 μg IVT RNA was transfected by electroporation into Huh7, or 
Huh7.5, cells and assayed for firefly luciferase activity at 4, 24, 48, and 72 hours post transfection 
(h.p.t) (Figure 5.2B and C). It was clear to see that SGR H-E-H was unable to replicate in either 
Huh7, or Huh7.5, cells as luciferase activity declined from 4 to 72 hours with no detectable signal 
above that of the replication deficient negative control GNN at any time point. A representative 
replication graph for SGR JFH (SGR H-H-H), and a representative RNA gel of input RNA, can be 
seen in Appendices Figure 8.11 A and B respectively). 
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The NS5A low complexity sequence (LCS) 1 of the HCV H77 reference sequence (Accession number 
AF011753.1) was aligned with the corresponding region of the NZPI EqHV a.a. sequence 
(Accession number KP325401) using the online tool Emboss Needle 
(https://www.ebi.ac.uk/Tools/psa/emboss_needle/nucleotide.html) . The conserved serine (S) 
residue at positions 2204, and 2180 are indicated.   
Figure 5.1: HCV S2204 is conserved in EqHV at a.a position 2180 
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A) A schematic representation of SGR H-E-H B) SGR H-E-H, S2180I, and GNN, RNA was transfected 
into Huh7 or C) Huh7.5 cells and assayed for firefly luciferase activity at 4, 24, 48, and 72 h.p.t.  
 
 
 
 
 
  
A 
B C 
Figure 5.2: Transient replication of SGR H-E-H in human hepatoma cells 
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In order to create a complete EqHV SGR it was necessary to introduce the 5′ and 3′ UTRs into 
the H-E-H construct. The first of these to be introduced was the 3′UTR. The EqHV 3′UTR sequence 
(GenBank accession no. JX948116.1) was synthesised in a geneblock (GENEART) along with the 
3′ end of the coding region for NS5B to include an SfiI site (within NS5B) and an XbaI site 
(downstream of the UTR) to facilitate molecular cloning of the 3′UTR into the H-E-H construct.  
The 3′UTR was introduced into the H-E-H, S2180I, and GNN SGRs to create an SGR which 
consisted of the HCV 5′UTR, the EqHV NS3-5B region, and the EqHV 3′UTR (termed H-E-E) (Figure 
5.3A). SGR H-E-E, H-E-E S2180I, and H-E-E GNN were transfected into Huh7 (Figure 5.3B), and 
Huh7.5 (Figure 5.3C), cells and assayed for firefly luciferase activity at 4, 24, 48, and 72 h.p.t. 
Figure 5.3B and 6.3C demonstrate that no transient replication of either H-E-E or H-E-E S2180I 
could be detected up to 72 h.p.e. Firefly luciferase activity consistently decreased from 4 to 72 
hours h.p.e with no detectable signal above that of the replication deficient negative control 
GNN from 24 h.p.e onwards.  
To fully characterise the replicative ability of chimeric HCV/EqHV SGRs the EqHV 5′UTR, and a 
ΔSLI mutant, were introduced into pSGR H-E-H, 2180I, and GNN. The full EqHV 5′UTR, and one 
excluding SLI, had previously been isolated and characterised for their translational ability 
(Stewart et al., 2013), and two XmnI sites, located in the backbone of the plasmid, and in the 
EMCV IRES, were used to introduce these 5’UTRs into pSGR H-E-H , S2180I and GNN, to create 
an SGR consisting of the EqHV 5′UTR, EqHV NS3-5B coding region, and the HCV 3′UTR (termed 
E-E-H) (Figure 5.4A).  
SGR E-E-H was transfected into Huh7 (Figure 5.4B), and Huh7.5 (Figure 5.4C), cells and assayed 
for firefly luciferase activity up to 72 h.p.e. Figure 5.4 clearly demonstrates that SGR E-E-H, ΔSLI, 
and S2180I, were unable to replicate in either cell line. Like H-E-E, firefly luciferase activity 
consistently decreased from 4 to 72 hours h.p.e with no detectable signal above that of the 
replication deficient negative control GNN from 24 h.p.e onwards.  
Put together these data demonstrate that chimeric EqHV/HCV SGRs were not able to replicate 
in the human hepatoma cell lines Huh7 and Huh7.5.  
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A) A schematic representation of SGR H-E-E B) SGR H-E-E, S2180, and GNN, RNA was transfected 
into Huh7 or C) Huh7.5 cells and assayed for firefly luciferase activity at 4, 24, 48, and 72 h.p.t.  
 
 
 
 
 
 
 
 
 
A 
B C 
Figure 5.3: Transient replication of SGR H-E-E in human hepatoma cells 
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A) A schematic representation of SGR E-E-H B) SGR E-E-H, S2180, and GNN, RNA was transfected 
into Huh7 or C) Huh7.5 cells and assayed for firefly luciferase activity at 4, 24, 48, and 72 h.p.t.  
 
 
 
 
  
A 
B C 
Figure 5.4: Transient replication of SGR E-E-H in human hepatoma cells 
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Finally, a full EqHV SGR was created through the molecular cloning of the EqHV 3′UTR from pSGR 
H-E-E, into pSGR E-E-H, using the route describe above for the introduction of the 3′UTR into 
pSGR H-E-H (and the S2180I and GNN variations), to create an SGR which contained the EqHV 5′ 
and 3′ UTRs, and the EqHV NS3-5B coding sequence (termed SGR EqHV) (Figure 5.5A) (See Table 
5.1 for a full list of constructs used in this study). Due to the complex RNA-RNA and RNA-protein 
interactions that take place during HCV replication the lack of replication observed in the 
chimeric constructs could have been due to a lack of these interactions between the different 
RNA sequences and structures, and proteins. Therefore it was hypothesised that a full EqHV SGR 
was more likely to replicate than a chimeric one. 
However, upon transfection into Huh7 (Figure 5.5B), and Huh7.5 (Figure 5.5C) cells, and assay 
up to 72 h.p.t, SGR EqHV did not exhibit any signs of transient replication. As for the chimeric 
SGRs firefly luciferase activity consistently decreased from 4 to 72 h.p.t with no detectable signal 
above that of the replication deficient negative control GNN from 24 h.p.e onwards.  
Transient replication could not be detected from any of the SGRs described here up to 72 h.p.t.  
It can therefore be concluded that the EqHV isolate that was here used to create either chimeric, 
or full, EqHV SGRs is not able to replicate transiently in either Huh7, or Huh7.5 cells. 
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A) A schematic representation of SGR EqHV B) SGR EqHV, S2180, and GNN, RNA was transfected 
into Huh7 or C) Huh7.5 cells and assayed for firefly luciferase activity at 4, 24, 48, and 72 h.p.t.  
 
 
 
 
 
 
 
 
 
 
 
  
B C 
A 
Figure 5.5: Transient replication of SGR EqHV in human hepatoma cells 
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5.2.2 Investigating alternative cell lines for SGR EqHV replication 
 
Given the inability of EqHV to replicate in human hepatoma cells it was hypothesised that an 
antiviral factor may have been inhibiting replication, or a necessary proviral factor may have 
been lacking. The natural host of EqHV is the horse, therefore an equine cell line was sought, as 
well as an alternative human cell line, to assess the ability of EqHV to replicate in equine, and 
non-hepatoma human cells. Only SGR EqHV, and the ΔSLI, S2180I, and GNN variants, were taken 
forward for this investigation.  
EqHV is a liver tropic virus which infects horses, therefore a liver derived equine cell line 
represents the ideal candidate to achieve EqHV replication in cell culture. However, to our 
knowledge, there exists no liver derived equine cell lines. Therefore, a non-liver equine cell line 
was sought as an alternative. Whilst there is a paucity of equine cell lines generally available 
from any organ, Foetal horse kidney (FHK) cells were provided by Dr Hiroshi Sentsui (Nihon 
University, Japan) (Maeda et al., 2007). This cell line has been reported to support the replication 
of a number of equine viruses (Oguma et al., 2013) and therefore, given the lack of equine liver 
cell lines, provided the next best cell line in which to achieve SGR EqHV replication. It was 
hypothesised that an equine derived cell line may expresses an equine specific host factor 
necessary for EqHV replication, or alternatively lack expression of an antiviral host factor which 
inhibits EqHV replication.  
The data described in Chapter 3, and published data, demonstrated a role for miR122 in EqHV 
IRES mediated translation (Scheel et al., 2015), a conserved feature with HCV. miR122 has been 
demonstrated to be essential for HCV replication and its expression can enable HCV replication 
in cell lines that lack endogenous miR122 expression. Therefore the FHK 122 cell line (described 
in Chapter 3) was also included. It was reasoned that the expression of miR122 may cause FHK 
cells to become permissive to EqHV replication, if the parental cell line was not. Furthermore, 
expression of miR122 has been demonstrated to cause 293T cells to become permissive to HCV 
replication and so this cell line (as described in Chapter 3) and the parental 293T cell line were 
also assayed for EqHV replication. However, none of the FHK, FHK 122, 293T, or 293T 122, cell 
lines were able to support transient SGR EqHV replication up to 72 h.p.t (Figure 5.6).  
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SGR EqHV, ,ΔSLI S2180, and GNN, RNA were transfected into A) FHK B) FHK 122 C) 293T and D) 
293T 122 cells and assayed for firefly luciferase activity at 4, 24, 48, and 72 h.p.t. 
 
 
 
 
 
A B 
C D 
Figure 5.6: Transient replication of SGR EqHV in FHK and 293T (+/- 122) cells 
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As transient replication could not be detected in FHK or 293T (+/- miR122) cells, other factors 
which have been demonstrated to enhance, or enable, HCV replication in cell culture were 
investigated. SEC14L2 is a human protein that has been recently demonstrated to enable RNA 
replication of a diverse range of HCV genotypes. Expression of this protein in Huh7.5 cells also 
supports HCV replication following inoculation with patient sera (Saeed et al., 2015). It was 
therefore hypothesised that the dramatic effects of this protein on HCV replication might also 
apply to EqHV, and expression of this protein may enable EqHV SGR replication. Huh7, Huh7.5, 
FHK, and 293T cells were therefore all transduced to stably express SEC14L2, and selected with 
2.5 μg/ml puromycin to maintain expression. 
The parainfluenza virus type 5 (PIV5) V protein has been demonstrated to inhibit STAT1-
mediated immune activation by binding STAT1 to inhibit downstream interferon-α activation 
(Chambers and Takimoto, 2009) and this immune inhibition has been demonstrated to enhance 
HCV replication (Andrus et al., 2011). It was therefore hypothesised that the enhancing effect of 
the V protein on HCV replication may provide the correct cellular environment to enable 
replication of SGR EqHV. 
Huh7, Huh7.5, FHK, and 293T cells expressing SEC14L2, and Huh7.5 cells which stably express 
the PIV5 V protein (provided by S.Griffin, University of Leeds), were transfected with SGR EqHV 
RNA and assayed for transient replication up to 72 h.p.t (Figure 5.7). Transient replication was 
not detectable for SGR EqHV, or 2180I, in any of the cell lines.  
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SGR EqHV, S2180, and GNN, RNA was transfected into A) Huh7 SEC14L2 B) Huh7.5 SEC14L2 C) 
FHK SEC14L2 D) 293T SEC14L2 and E) Huh7.5 V protein cells and assayed for firefly luciferase 
activity at 4, 24, 48, and 72 h.p.t.  
 
A 
C 
E 
B 
D 
Figure 5.7: Transient replication of SGR EqHV in cell lines expressing SEC14L2 or the PIV5 V 
protein. 
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5.2.3 Investigating stable replication of SGR EqHV 
 
Relatively high levels of replication are required to detect transient replication. There was 
therefore a possibility that EqHV was replicating at low levels and was consequently 
undetectable in a transient assay. Therefore, the SGRs described in 5.2.1 were subject to stable 
selection in the cell lines described in 5.2.2. Under selection cells which do not harbour the SGR, 
and thus a resistance reporter gene, die due to the toxic concentration of the compound used 
for selection. Conversely, cells which harbour a replicating SGR express an antibiotic resistance 
gene and therefore the compound is not toxic. The cells therefore survive and are maintained. 
However upon transfection of SGR EqHV, and selection with neomycin, all cells died and 
therefore did not harbour an EqHV SGR.  
The cell lines described in 5.2.2 had different patterns of antibiotic resistance due to the stable 
expression of miR122, SEC14L2, and the V protein. Furthermore FHK cells were transformed 
with the SV40 large T antigen under neomycin selection and so are inherently resistant to 
neomycin, and are therefore not suitable for selecting Feo SGRs (Table 5.2 summarises the 
resistance profile of each cell line). Therefore blasticidin-S deaminase (BsR) and puromycin N-
acetyl transferase (PAC) reporter genes were introduced into SGR EqHV by molecular cloning to 
enable SGR selection in each of the cell lines described in 5.2.2. However, following transfection 
with the SGR, and selection with the appropriate antibiotic for the SGR resistance gene, no cells 
survived indicating that SGR EqHV was not able to establish replication in any of the cell lines 
here described (a summary of the SGR and cell line combinations assayed for stable replication 
can be seen in Table 5.3). 
These data indicate that SGR EqHV is not able to replicate in any of the cell lines tested in this 
study, and it is likely that this isolate of EqHV is not able to replicate in mammalian cell culture. 
(See Table 5.1 for a full list of the constructs used in this study). 
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Table 5.1: pSGR EqHV, and HCV chimeric, constructs used in this study  
This table outlines all of the SGR contracts assayed for replication in this study. Feo is the fused 
FLuc/neomycin phosphotransferase gene that produces firefly luciferase and confers resistance 
to neomycin. GFP-PAC is a dual GFP/puromycin N-acetyl-transferase (PAC) reporter which 
expresses GFP and confers resistance to puromycin. BsR is the blasticidin S resistance gene and 
confers resistance to blasticidin. The species origin of both UTRs is noted, and the ticks and 
crosses represent whether a mutation was present in each given SGR.  
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A list of the cell lines used in this study and the antibiotics to which they are resistant.  
 
 
 
 
Table 5.2: Antibiotic resistance profile of mammalian cells used in this study 
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Table 5.3: Stable selection of EqHV, and chimeric, SGRs in a range of cell lines 
A table of the cell lines and SGRs used in this study indicating whether they were assayed to 
support stable SGR replication. N/A indicates that the cell line/SGR combination was not possible 
due to the antibiotic resistance of the cell line (see Table 5.2) 
 
 
 
 
 
 
 
 
 
 
 
 
153 
 
5.2.4 A second generation, consensus sequence, EqHV SGR 
 
A cell culture replication system for HCV was not developed until the construction of a consensus 
clone Con-1b (Lohmann et al., 1999). Scheel et al constructed a consensus clone of EqHV, NZPI, 
and provided the SGR (pSGR NZPI) for use in this study; they were, however, unable to achieve 
stable replication with this SGR in a range of cell lines (Huh-7.5, E.Derm, E.Derm/miR-122, MDBK, 
MDBK/miR-122, MDCK/miR-122, PK-15, and PK15/miR-122) (Scheel et al., 2015). 
SGR NZPI was constructed to be stably selected using the neomycin phosphotransferase gene 
under control from the EqHV 5′UTR. Therefore, for use in transient replication assays, an 
alternative reporter gene needed to be introduced. Firefly luciferase is widely used as the 
reporter gene for HCV SGRs and recent discoveries have demonstrated a 100 fold increase in 
detection using this reporter when the codon sequence is optimised to be CpG and UpA low 
(Atkinson et al., 2014). This reporter (here termed CpG/UpA low FLuc) was therefore selected 
for this study and introduced into SGR NZPI, and GNN, by molecular cloning, to produce a 
construct from which transient replication could be assayed (pSGR NZCI). Further to this the 
S2180I mutation, and the ΔSLI 5′UTR described in 3.2.1, were also introduced into pSGR NZCI in 
an attempt to achieve detectable transient replication (a schematic representation of SGR 
NZPI/NZCI can be seen in Figure 5.8, and a summary of the SGRs in Table 5.4). 
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A schematic representation of A) SGR NZPI B) SGR NZCI and C) SGR NZCI ΔSLI 
 
 
 
 
 
 
Figure 5.8: A schematic representation of SGR NZPI and SGR NZCI 
A 
B 
C 
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Table 5.4: A summary of pSGR NZPI/NZCI constructs 
A summary of the SGR NZPI, and derivative, constructs used in this study denoting the reporter 
gene and mutation combinations constructed. 
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5.2.5 Replication assays of SGR NZPI and NZCI 
 
To assess the replicative ability of SGR NZCI in a transient assay the cell lines as described in 5.2.2 
were transfected with SGR NZCI, ΔSLI, 2180I, and GNN, and assayed for firefly luciferase activity 
up to 72 h.p.t. As for SGR EqHV, no replication could be detected over the GNN replication 
deficient control up to 72 h.p.e in any of the Huh7, or 7.5, cells or their derivatives (+SEC14L2/V 
protein) (Figure 5.9), FHK cells or their derivatives (+SEC14L2/miR122) (Figure 5.10), or 293T cells 
or their derivatives (+SEC14L2/miR122)  (Figure 5.11). These data conclusively demonstrate that 
SGR NZCI is not able to replicate to a detectable level in a transient assay in Huh7, Huh7.5, FHK, 
or 293T cells, even upon introduction of a predicted culture adaptive mutation into NS5A, or in 
the presence of factors known to support or enhance HCV replication.  
SGR NZPI was also assayed for stable replication in the cell lines described above (excluding the 
already neomycin resistant FHK cell lines, and Huh7.5 V protein cells). In agreement with the 
data presented by Scheel et al no colonies formed following 2-3 weeks under neomycin selection 
following transfection of SGR NZPI (Scheel et al., 2015).  These data conclusively demonstrate 
that SGR NZPI is unable to establish replication in Huh7, Huh7.5, or 293T cells even in the 
presence of factors known to support HCV replication.  
Taken together these data indicate that currently available isolates, and consensus clones, of 
EqHV are not able to establish replication in cell culture. Host factors known to support HCV 
infection do not enable EqHV replication, as is also the case for a viral factor shown to enhance 
HCV replication.  Further work to establish a replicative EqHV SGR is needed, however this may 
well be dependent on the isolation of new sequences, or the development of new, more 
physiologically relevant, cell lines.  
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SGR NZCI, S2180, and GNN, RNA was transfected into A) Huh7 B) Huh7 SEC14L2 C) Huh7.5 D) 
Huh7.5 SEC14L2  and E) Huh7.5 V protein cells and assayed for firefly luciferase activity at 4, 24, 
48, and 72 h.p.t. 
  
A 
C 
E 
B 
D 
Figure 5.9: Transient replication of NZCI in human hepatoma cells 
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SGR NZCI, S2180, and GNN, RNA was transfected into A) FHK B) FHK 122 and C) FHK SEC14L2 
cells and assayed for firefly luciferase activity at 4, 24, 48, and 72 h.p.t.  
  
A 
C 
B 
Figure 5.10: Transient replication of NZCI in equine cells 
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SGR NZCI, S2180, and GNN, RNA was transfected into A) 293T B) 293T 122 and C) 293T SEC14L2 
cells and assayed for firefly luciferase activity at 4, 24, 48, and 72 h.p.t.  
 
 
  
A 
C 
B 
Figure 5.11: Transient replication of NZCI in human kidney cells 
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5.3 Discussion: 
 
5.3.1 Construction of an EqHV SGR from the EF369_11J isolate 
 
The construction of an EqHV SGR involved replacing HCV sequences in an SGR with the 
equivalent EqHV ones. Two well characterised mutations, S2204I and GDDÆGNN were also 
introduced into the EqHV polyprotein.  
HCV replication in cell cultured was not achieved until 10 years following its discovery (Lohmann 
et al., 1999), and even following this remarkable achievement efficient replication was not 
achieved until the discovery of culture adaptive mutations (Blight et al., 2000). It was therefore 
hypothesised that culture adaptive mutations may also be essential to establish efficient in vitro 
replication of EqHV. The HCV culture adaptive mutation 2204I significantly enhances HCV 
replication (Blight et al., 2000) and has been instrumental in the establishment of many HCV cell 
culture systems (Chung et al., 2017). S2204 is conserved between HCV and EqHV at a.a. position 
2180 in EqHV (amino acid numbering according to NZPI consensus sequence polyprotein 
sequence GenBank accession number KP325401) and so an equivalent S2204I mutation was 
introduced into EqHV NS5A (S2180I) in an attempt to enhance replication in cell culture. 
However, this mutation impairs replication of JFH-1, which requires no culture adaptive 
mutations, so both the wild type and S2180I were used for all replication assays in case a similar 
effect was seen for EqHV. Finally, the EqHV NS5B RdRP contains the conserved GDD motif, which 
is well characterised as the active site of many viral RdRPs. The well characterised mutation 
GDDÆGNN mutation was introduced into EqHV NS5B for use as a replication deficient control.  
Two different 5′UTRs were used in this study, the full length 5′UTR, and a deletion mutation ΔSLI, 
both of which have been previously reported to exhibit IRES activity (Stewart et al., 2013). The 
inclusion of the full length 5′UTR was an obvious necessity in the construction of a full EqHV SGR. 
The ΔSLI mutant 5′UTR was included in this study based on the functional (Chapter 3), and 
structural data (Chapter 4), presented here. The functional analysis of the EqHV 5′UTR, in 
agreement with published data (Stewart et al., 2013), demonstrated that the EqHV SLI played 
no role in translation. It was therefore hypothesised that SLI was involved in replication of the 
EqHV genome and consequently may be essential for replication. The structural data obtained 
for ΔSLI (Figure 4.4) showed that the ΔSLI 5′UTR appeared to be structurally similar to the HCV 
5′UTR (Figure 3.1B); with SLIA as the first structural domain of the 5′UTR, mimicking HCV SLI. 
Whilst these SLs did not appear to share any sequence homology, SLIA more closely matches 
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with HCV miR122 seed site 1, there was a possibility that the structure of this region, rather than 
sequence, was conserved between HCV and EqHV, and therefore that EqHV SLIA was a 
determinant of EqHV replication. In this scenario it was hypothesised that the extended, stable, 
structure of SLI may be a regulatory element of EqHV genome replication. If EqHV replication 
were achieved then the ability of the ΔSLI mutant to replicate would have provided further 
information into the role of the 5′UTR structural domains in the EqHV lifecycle. 
Finally, the full 3′UTR from the EqHV EF369_11J isolate was synthesised as a gene block to 
facilitate molecular cloning of this region into the SGR. Only the full length 3′UTR of the sequence 
for this isolate was used.  
The EqHV NS3-5B codon region was initially introduced into an HCV SGR through replacement 
of the HCV NS3-5B coding region, by Cheryl Walter and Hazel Stewart (University of Leeds) to 
create pSGR H-E-H. This construct was used as a master construct into which the NS5A, and 
NS5B, mutations were introduced, and from which the full EqHV SGR would be created. The 5′ 
and 3′ UTRs were sequentially introduced into the pSGR H-E-H backbone by molecular cloning 
to create pSGR EqHV. This process also created intermediate, chimeric, HCV/EqHV SGRs with 
mismatched UTRs termed pSGR E-E-H and pSGR H-E-E (Table 5.1 summarises the pSGR 
constructs created in this study, and the NS3-5B, and 5′UTR mutations each included). 
5.3.2 pSGR NZPI and NZCI 
 
Replication of HCV in cell culture was first achieved through the construction of a consensus 
clone Con-1b (Lohmann et al., 1999). Scheel et al. constructed an EqHV consensus sequence 
(NZPI) and constructed a full length molecular clone, and SGR, based off of this sequence (Scheel 
et al., 2015). pSGR NZPI was provided for use in this study by C. Rice (Rockefeller University). 
pSGR NZPI, and pSGR NZPI GNN, were both provided with the Neo reporter gene and therefore 
were only suitable for use in stable replication assays. Recent studies have demonstrated that a 
100 fold increase in replication of HCV can be achieved through modification of the FLuc gene 
to produce a CpG and UpA low variant (Atkinson et al., 2014). To use SGR NZPI in transient 
replication assays it was necessary to introduce a reporter gene suitable for detection in this 
system into SGR NZPI. Due to the enhancement of detection seen for HCV using the CpG/UpA 
low modified FLuc this was chosen for use in this study as it is readily detectable in transient 
replication assays, and represented the best option to maximise the possibility of achieving and 
detecting replication of EqHV in cell culture. CpG/UpA low FLuc was therefore introduced into 
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pSGR NZPI to create a new construct termed pSGR NZCI. Furthermore, the NZPI consensus 
sequence contained the conserved serine at position 2180 and so the S2180I mutation 
(described in 5.3.1) was introduced into pSGR NZCI.  
This SGR represented two major improvements over SGR EqHV (described in 5.3.1): SGR EqHV 
was created from a single EqHV isolate and therefore may not be representative of the viral 
population in nature, and could potentially harbour detrimental mutations that are only 
represented in this isolate which prevent EqHV replication in cell culture. Secondly, SGR NZPI 
includes the full length EqHV 3′UTR. The isolate used for construction of SGR EqHV had an 
unusually short 3′UTR. At the time of creation of SGR EqHV it was not known whether this truly 
represented the EqHV 3′UTR or whether it was an incomplete sequence. The work conducted 
by Scheel et al. showed that it was in fact an incomplete 3′UTR and their work demonstrated 
that the EqHV 3′UTR was the longest hepacivirus 3′UTR discovered to date (Appendices Figure 
8.12-8.14). The full EqHV 3′UTR is 328 nucleotides long with a conserved 3′X region and an 
extremely long poly U tract spanning 96 nucleotides (Scheel et al., 2015). The original EqHV 
3′UTR isolate used in the construction of the “first generation” SGRs matches well with the 3′ 
portion of the HCV 3′UTR immediately downstream of the polyU region. However the EqHV 
polyA region did not align well with any region of the HCV 3′UTR and the 3′ X region appears to 
be completely absent in this EqHV isolate. On the other hand, whilst the NZPI 3′UTR does 
exhibited an extended polyU tract, it also appears to align quite well throughout the 3′ portion 
of the HCV 3′UTR, covering the polyU region and 3′ X tail. The variable region of NZPI has limited 
conservation with HCV and is extended, however conservation in this region is low even 
between different HCV genotypes. There are also stark differences between the “original” EqHV 
isolate and the NZPI 3′UTRs. Whilst some regions align well the original sequence is missing the 
polyU tract and there are large regions where there are apparent gaps in the original sequence 
in comparison to NZPI.  
The NZPI 3′UTR demonstrates much higher levels of conservation with the HCV 3′UTR indicating 
that this 3′UTR sequence is indeed the full 3′UTR. The original EqHV 3′UTR isolate demonstrates 
incompletely alignment with the HCV 3′UTR and upon alignment with the NZPI sequence it is 
clear that some potions of this 3′UTR sequence are missing and it can be said that this 3′UTR 
isolate is incomplete. Whilst the NZPI derived SGRs, even with the complete 3′UTR, sequence 
were also not able to replicate. The absence of a complete 3′UTR sequence for the first 
generation EqHV SGRs may have played a crucial role in their inability to replicate. 
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5.3.3 Cell lines for the assay of EqHV SGR replication 
 
EqHV is an equine virus which exhibits liver tropism (Ramsay et al., 2015; Pfaender et al., 2017; 
Scheel et al., 2015), therefore the ideal cell line in which to assay replication of this virus would 
be a liver derived equine cell line. Furthermore, if EqHV were to be established as a model 
system with which to study HCV, the cell line in which it is assayed would ideally be widely 
available, easy to culture and maintain, and support HCV replication for use in comparative 
analysis. It was also hypothesised that cell lines capable of supporting HCV replication, and 
equine derived cell lines, may be more likely to support EqHV replication than others. 
Unfortunately, to our knowledge, there are currently no equine liver cell lines available. Human 
foetal liver cultures (HFLCs) have been demonstrated to support replication of HCV (Andrus et 
al., 2011) and Scheel et al. established a similar equine foetal liver culture (EFLCs), however they 
were unable to establish EqHV replication using this system (Scheel et al., 2015). Given this data, 
EFLCs were not used in this study.  
Due to the lack of equine liver cell lines alternative cell culture systems needed to be used in the 
attempt to establish EqHV replication.  Huh7, and Huh7.5, cells have long been established as 
the cell line of choice for HCV research, with Huh7 cells the first in which replication was 
establish (Lohmann et al., 1999). Huh7.5 cells are a derivate of the Huh7 cell line which were 
cured of an HCV SGR using IFNα and have been shown to facilitate higher levels of replication 
(Blight et al., 2002). EqHV is a liver tropic virus and as such, in the absence of an equine derived 
cell line it was believed the human hepatoma Huh7, and Huh7.5, cell lines provided a viable 
alternative to potentially establish EqHV replication. 
Whilst Huh7 cells are a liver derived line and therefore provide the liver specific factors required 
for HCV replication, and potentially for EqHV replication, being a human derived cell line they 
may lack horse specific factors that enable EqHV replication. Therefore a horse cell line was 
sourced. Foetal horse kidney (FHK) cells were originally established to study the replication of 
equine herpesviruses, but have also been demonstrated to support the replication of a range of 
equine viruses, and remain viable for over 100 passages (Andoh et al., 2009). These 
characteristics identified FHK cells as the next best alternative to an equine liver cell line and 
were provided for use in this study Dr Hiroshi Sentsui (Nihon University, Japan) (Maeda et al., 
2007). The final cell line selected for use was the human kidney cell line 293T. This cell line has 
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previously been demonstrated to support replication of HCV, upon the expression of miR122, is 
widely used, and easy to culture and maintain. 
The cell lines described above all shared the ideal characteristic of being easy to culture and 
maintain, and are widely available. Huh7, Huh7.5, and 293T cells have all been demonstrated to 
support HCV replication, and whilst FHK cells have not been demonstrated to support HCV 
replication they are equine derived. Therefore all of the cells selected for this study had two of 
the three characteristics believed to constitute an ideal cell line to study EqHV replication. 
5.3.4 Alternative factors to enable EqHV replication in cell culture 
 
As no “perfect” cell culture system was available to study EqHV it was hypothesised that the 
expression of protein, or RNA, shown to enable or enhance HCV replication may be required to 
establish EqHV replication in cell culture.  
miR122 is a liver specific microRNA which has been demonstrated to function in HCV translation 
and replication, and the stability of the genome. The data presented in Chapter 3, in agreement 
with published data (Scheel et al., 2015), showed that the presence of miR122 enhances 
translation from the EqHV IRES and further demonstrated that this effect was dependent on a 
miR122 seed site within the 5′UTR. Due to the large scale conservation between an array of 
structural, and functional, aspects of EqHV and HCV translation described here, and the array of 
other conserved features between these two closely related viruses (Tanaka et al., 2014; Parera 
et al., 2012; Stewart et al., 2016; Pfaender et al., 2017) it was considered likely that miR122 
would play a role in the EqHV lifecycle beyond translation, and may  be a key determinant of 
replication. 293T and FHK cells, unlike the human hepatoma cell lines, do not naturally express 
miR122, therefore retroviral transduction was used to establish stable expression of miR122 in 
both 293T and FHK cells. It was hypothesised that this may enable replication of EqHV in these 
cells, as has previously been demonstrated for HCV in cell lines which do not endogenously 
express miR122. 
SEC14L2 is a human protein that has recently been described to enable pan genotypic replication 
of HCV in cell culture, even supporting infection and replication from infected patient sera 
(Saeed et al., 2015). SEC14L2 is ubiquitous in human tissues and is a member of the family of 
cytosolic lipid-binding proteins however it cannot be readily detected in human derived cell 
lines, including Huh7 and Huh7.5 cells (Saeed et al., 2015). The SEC14L2 expression levels of 
165 
 
293T and FHK cells were not tested by Saeed et al. or in this study, however given the lack of 
expression of this protein in a range of human cells lines it was probable that SEC14L2 levels 
were low, or non-existent, in these lines. Therefore Huh7, Huh7.5, FHK, and 293T cells were all 
engineered, using a lentiviral vector, to stably express SEC14L2. EqHV displays a divergence from 
HCV at ~50% at the nucleotide level, with up to 65% conservation in the a.a sequence of NS3 
and NS5B. HCV genotypes and subtypes are 30%–35% divergent. Although EqHV diverges from 
HCV to a greater extent than HCV genotypes diverge from one and other, as SEC14L2 enables 
pan genotypic HCV replication in Huh7.5 cells it was hypothesised that a similar effect may been 
seen on EqHV replication. Expression of this protein may enable cells to support replication of 
the EqHV SGRs.  
The PIV5 V protein is a multifunctional protein which binds STAT1, blocking downstream IFN 
signalling, and interacts with MDA-5, a mediator of the virally induced IFN response (Yang et al., 
2015).  Upon transfection of HCV RNA into HFLCs stably expressing the V protein HCV replication 
was enhanced. It was hypothesised that expression of this viral protein may also be able to 
enhance replication of EqHV, or alternatively induce a cellular environment which is permissive 
to EqHV replication. Huh7.5 cells which stably expressed the PIV5 V protein were provided by S. 
Griffin (University of Leeds) for use in this study.  
The addition of these cellular and viral factors which have been demonstrated to enable or 
enhance HCV replication, in addition to the parental cell lines discussed in 5.3.4, provided a 
comprehensive panel of cell lines in which to assess the replicative ability of EqHV. 
5.3.5 Alternative resistance genes to study stable replication in antibiotic resistant cell lines 
 
The construction of the panel of cell lines discussed in 5.3.4 required the stable expression of 
viral and host factors, and therefore required these cells to be under selection with either 
puromycin (miR122 and SEC14L2) or neomycin (V protein). FHK cells are also neomycin resistant 
due to the way in which they were created (Maeda et al., 2007) (Table 5.2 summarises the 
antibiotic resistance profile of the cells lines). Therefore the Feo and Neo reporter genes, which 
confer resistance to neomycin, would not be sufficient to assay each cell line for stable 
replication.  
Two different reporter genes were selected, PAC encoding puromycin N-acetyl transferase, and 
BsR encoding blasticidin-S deaminase, conferring resistance to puromycin and balsticidin. PAC 
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and BsR have both previously been utilised in the selection of cells harbouring stable replication 
of HCV SGRs, and provided resistance to antibiotics which were not included in any, or a subset, 
of the cell lines used in this study (Table 5.2). Therefore these genes were introduced into SGR 
EqHV in order to assay it for stable replication in each cell line (Table 5.3 summarises the cell 
line/SGR combinations assayed for stable replication). 
5.3.6 Currently available EqHV SGRs are unable to replicate in cell culture 
 
It has here been conclusively demonstrated that SGRs generated from either the EF369_11J 
isolate (GenBank accession no. JX948116.1) or NZPI consensus clone (GenBank accession no. 
KP325401) are not able to achieve detectable replication in any of the cell lines described here.  
A rational design of SGR EqHV was undertaken, with the well-known HCV culture adaptive 
mutation S2204I (S2180I in EqHV), and a ΔSLI 5′UTR included in an attempt to facilitate SGR 
EqHV replication (discussed in 5.3.1). Chimeric SGRs were created as intermediates in the 
creation of SGR EqHV; however these were also unable to replicate. In order to assess the ability 
of SGR EqHV to establish stable replication alternative resistance genes (BsR and PAC), in 
addition to Feo/Neo, were introduced into SGR EqHV to allow selection in all cell lines. Each cell 
line was transfected with the relevant SGR EqHV (Table 5.3) and selected with the appropriate 
antibiotic, however no colonies were formed following selection and it can therefore be said 
that SGR EqHV was not replicating, or replicating at such a low level as to not confer resistance. 
The lack of replication exhibited by SGR EqHV was most likely due to the incompleteness of the 
3′UTR, an essential feature of the genome for HCV replication (Yi and Lemon, 2003). However 
Scheel et al. were successful in sequencing the entire EqHV 3′UTR, and included this in the 
construction of an SGR termed NZPI (Scheel et al., 2015). The SGR NZPI construct was provided 
for use in this study by C. Rice (Rockefeller University). A reporter gene amenable to transient 
replication assays (CpG low FLuc) was introduced into this construct, as was the S2180I culture 
adaptive mutation and the ΔSLI 5’UTR. However, even with the full length 3′UTR, and consensus 
sequence, this construct was not able to achieve transient replication to a detectable level in 
any of the cell lines tested in this study. Finally, SGR NZPI was assayed for stable replication, 
however this construct was only assayed with the Neo reporter gene and so the FHK cell lines, 
and Huh7.5 V protein cells, could not be assayed for replication. As for SGR EqHV, no colonies 
could be detected following selection. 
167 
 
This chapter therefore describes a rational and comprehensive approach to the establishment 
of an EqHV SGR capable of replication in mammalian cell culture. The data provided here, 
coupled with published data, indicate that the currently available EqHV SGRs are not able to 
achieve replication in current cell culture systems, even with the addition of viral and host 
factors predicted to enable or increase replication. Factors that may be preventing the 
establishment of in vitro replication of EqHV are discussed in 5.3.8. 
5.3.7 Roadblocks to establishing a cell culture system to study EqHV replication  
 
Taken together with published data the data here clearly demonstrate that there is more work 
to be done if an EqHV SGR system capable of replicating in mammalian cell culture is to be 
established. Some major obstacles face the scientific community in achieving this goal.  
There are two potentially key factors which are currently inhibiting EqHV replication in vitro. 
Firstly is the lack of a physiologically relevant cell line in which to assay EqHV replication. It is no 
coincidence that HCV replication was first achieved in human hepatoma cells, and that these 
cells are still widely used to this day.  EqHV, like HCV, appears to have an extremely narrow 
tropism (Pfaender et al., 2017; Scheel et al., 2015; Ramsay et al., 2015) and it is predicted that if 
EqHV replication is to be achieved it will be done so in equine liver derived cell lines. However, 
such a cell line is not available for use. Therefore the main priority must be the establishment of 
an equine derived liver cell that is easy to maintain and culture in the laboratory, if EqHV 
replication is to be studied. 
Secondly is the potential sequence variation within the EqHV genome. Although EqHV isolate 
numbers are growing, a search for “equine hepacivirus” in pubmed returns 369 sequences, 
whilst “hepatitis C virus” returns 1,020,438. HCV genotypes are known to have differential 
abilities to replicate in cell culture, and patient isolates do not readily replicate. The increasing 
pool of EqHV sequences has already revealed the putative existence of viral subtypes (Pronost 
et al., 2016). Increasing this pool may result in the identification and classification of further 
EqHV subtypes; and potentially different genotypes. If they mimic the biology of HCV they may 
prove to be more amenable to replication in vitro. Furthermore a consensus clone was required 
to establish the first HCV SGR, and whilst this has been attempted for EqHV current sequences 
have exhibited minimal divergence, with ~99% identity in some studies (Kapoor et al., 2011). 
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Increasing the number of EqHV sequences with which to establish a consensus will surely make 
this approach more powerful.  
EqHV does not readily replicate in mammalian cell culture, and the appropriate reagents with 
which to study it do not currently exist. There appears to be a great deal of work that needs to 
be carried out before this goal will be achieved.  
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Chapter 6 Conclusions and 
future perspectives 
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HCV is a major global health concern, however no model system exists to study this important 
pathogen. Recent advances in sequencing technology have led to the discovery of a variety of 
animal hepaciviruses in bovines, bats, dogs, equines, rodents, an old world primate, and even 
the graceful catshark (Kapoor et al., 2011; Baechlein et al., 2015; Corman et al., 2015; Drexler et 
al., 2013; Kapoor et al., 2013; Shi et al., 2015; Quan et al., 2012; Burbelo et al., 2012). The first 
of these to be identified, and the closest phylogenetic relation to HCV, is equine hepacivirus 
(EqHV), previously known as canine hepacivirus (CHV) or non-primate hepacivirus (NPHV). This 
study set out to investigate the molecular biology of EqHV; focussing on 5′UTR IRES function, 
how RNA secondary structure is linked to this function, how the 5′UTR interacts with the host 
cell translational machinery, and finally to establish an EqHV SGR capable of replicating in 
mammalian cell culture.  
Following determination of the EqHV 5′UTR secondary structure, deletions of 5′UTR structural 
regions (ΔSLI, ΔSLI+II, ΔSLIIII, ΔSLIIIb, and ΔSLIIId) were made to investigate how the structure of 
the 5′UTR was linked to IRES function. These deletion mutations were assayed in the context of 
an RLuc/FLuc bicistronic reporter construct, and an SGR, to assess IRES activity. This investigation 
revealed that SLI plays no role in IRES activity and that SLII plays a non-essential role. SLIII, SLIIIb 
and SLIIId were found to be essential. The observations made on the role of these structural 
regions in EqHV were similar to those that have been previously published for HCV, and began 
to provide evidence for the existence of a conserved mechanism of translation initiation from 
these two closely related viruses.  
This study has provided, to our knowledge, the first experimental description of the secondary 
structure of the EqHV 5′UTR. The EqHV 5′UTR contains three major structural domains: SLI, SLII, 
and SLIII(a ,b ,c ,d, e , and f). Evidence for the existence of a pseudoknot was also observed, but 
this structure was not experimentally confirmed. The secondary structure of the EqHV 5′UTR 
exhibited three major differences from HCV: a large and extended SLI, an intermediate SLIA, and 
does not contain SLIV. However, SLII, and SLIII are extremely well structurally conserved and 
exhibit localised sequence conservation across the apical loops of SLIIIa, SLIIIc, and SLIIId, and 
the predicted pseudoknot. Secondary structure analysis also confirmed that the effects of 
structural deletions in the 5′UTR were specific to the deleted region, and thus confirmed the 
hypothesis that arose from the functional analysis regarding the roles of these structures. The 
conservation of structure, coupled with the functional observations, provided further evidence 
for a conserved mechanism of translation initiation.  
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Following the observations made regarding how the structure of the EqHV 5′UTR links to its 
function, a more detailed investigation of the roles of the apical loops of SLIIIb and SLIIId were 
carried out. This investigation revealed that the sequence of the SLIIIb apical loop plays a role in 
IRES activity, but that the structure of SLIIIb appears to be more important. To investigate the 
mechanisms influencing the diminished ability of sequence mutants to initiate translation SHAPE 
footprinting analysis was carried out. This demonstrated that eIF3 specifically interacts with 
SLIIIb, and that mutation of the apical loop abolishes this interaction. However the ability of the 
SLIIIb apical loop mutant to initiate translation in the absence of an interaction with eIF3 raises 
some interesting questions regarding the role of eIF3 in EqHV IRES mediated translation. There 
may be structural features that also mediate an IRES-eIF3 interaction. The differences observed 
between the sequence, and structural, mutations of SLIIIb indicate that the structure of SLIIIb, 
and potentially the conservation of the SLIIIa,b,c junction, are more important than the apical 
loop in translation.  
A double mutation in the apical loop of SLIIId abolished translation. SHAPE footprinting revealed 
that the apical loop interacts with the 40S ribosomal subunit, and that a double mutation in the 
GGG motif disrupts this. The GGG motif in the apical loop of EqHV SLIIId plays an essential role 
in translation through its interaction with the 40S ribosomal subunit, presumably acting to 
recruit 40s and correctly position it on the AUG start codon. The observations made regarding 
the roles of the apical loops of SLIIIb and SLIIId provided further evidence toward the hypothesis 
that there exists a conserved mechanism of translation initiation between EqHV and HCV. 
Further evidence was provided using the EqHV 5′UTR as bait in a pull-down assay, and identifying 
the interacting partners by TMT MS. This analysis revealed that the EqHV 5′UTR interacts with 
all of the eIFs required for HCV translation initiation, as well as the 40S and 60S ribosomal 
subunits required for the assembly of the 80S ribosome. Taken together these data provide 
evidence for a conserved mechanism of translation between EqHV and HCV, and potentially 
indicates a conserved mechanism of hepaciviral translation.  
Finally, it was set out to establish an EqHV SGR capable of replicating in mammalian cell culture. 
SGR EqHV was constructed using sequences derived from the first EqHV isolate. SGR NZPI was 
provided for use by C. Rice (Rockefeller University), and a CpG/UpA low FLuc introduced into 
this construct to create SGR NZCI. A range of cell lines expressing cellular and viral factors known 
to enable, or enhance, HCV replication were assayed. Furthermore the well-known S2204I 
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(S2180I in EqHV) culture adaptive mutation was introduced into EqHV NS5A in an attempt to 
achieve in vitro replication. Different transient reporter, and antibiotic resistance genes, were 
also utilised to maximise the possibility of achieving EqHV replication. Neither transient nor 
stable replication was observed in this study. The currently available EqHV sequences, and cell 
lines in which to assay them, may therefore lack some fundamental factors or characteristics 
that are required for in vitro EqHV replication.  
The natural progression of this study would be to further investigate EqHV translation initiation. 
The exact role of SLIIIb, and how its interaction with eIF3 affects translation, was not determined 
in this study. Further mutational analysis on the stem of SLIIIb, and the SLIIIa,b,c junction, in 
combination with SHAPE footprinting, may well provide the evidence needed to determine this. 
A more detailed mutational analysis of EqHV SLII would also be required to understand the role 
that this domain plays in EqHV translation initiation, and whether this is determined by 
sequence or structure. In vitro translation experiments using purified initiation factors to 
investigate the individual steps that occur towards initiation from the EqHV IRES would also be 
needed to confirm the exact method of translation initiation. Sequential addition, or depletion, 
of initiation factors, and sucrose density centrifugation, could be utilised to investigate the order 
of assembly of eIFs and determine the minimal requirement of eIFs for EqHV IRES mediated 
translation.  
There is also a large body of work that needs to be carried out if replication of EqHV is to be 
achieved in vitro. The establishment of an equine derived liver cell line which is easy to culture 
and maintain is an essential next step towards in vitro EqHV replication. In the absence of full 
EqHV SGR replication, however, parts of the viral lifecycle may still be amenable to study by 
constructing chimeric HCV/EqHV SGRs or viruses. Furthermore SGRs constructed from newly 
isolated EqHV sequences from different genotypes, if they are discovered, and updated 
consensus sequences, will need to be constructed. However this work will depend upon the 
continued isolation of EqHV sequences by the scientific community. Furthermore the 
construction of SGRs from the other hepaciviral species which have been, and are still being, 
discovered may provide a replicative model system to study HCV, as well as providing a means 
by which to establish whether there is indeed a conserved mechanism of hepaciviral translation.  
A recent report has described a mouse model for acute, and chronic, infection with NrHV 
(hepacivirus G) (Billerbeck et al., 2017) and provides a shining example of the potential 
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usefulness of the newly discovered animal hepaciviruses. However, given the genetic 
heterogeneity within the genus, and the observed differences that have been reported with 
regards to the molecular biology and pathogenicity of these viruses, further investigation is still 
required.  Establishing a complete picture with regards to the molecular biology, lifecycle, and 
pathogenicity of this model virus is absolutely crucial. If the animal hepaciviruses demonstrate 
fundamental differences from HCV these will need to be known, and taken into account, when 
using them as models.   
Furthermore, the 5′UTR of NrHV has not yet been described, and the sequence has not yet been 
determined. Isolation of this sequence, and the characterisation of structural features and their 
functions as described here, provides an interesting avenue of investigation to begin to 
understand the molecular biology of this model virus. In addition to this, rational design of an 
NrHV SGR could potentially provide an in vitro model to study the viral lifecycle. A number of 
mouse derived liver cell lines are available and listed on the American Type Culture Collection 
(ATCC) website for purchase, potentially providing the ideal cell line in which to assay NrHV 
replication. Construction of a replicative SGR would provide an additional method with which to 
study this virus; current HCV DAAs could be assayed for effect against NrHV in cell culture, 
reducing the need for animal test subjects. Conversely, if currently available DAAs could be 
demonstrated to have an effect against NrHV, an SGR could provide an excellent model with 
which to test putative new HCV DAAs without the need for animals. Therefore rational 
construction of an NrHV SGR, as has been described here for EqHV, could prove an exciting and 
valuable tool for the future of HCV research.  
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Figure 8.1: Mfold predicted structure of the EqHV 5’UTR 
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Figure 8.2: Mfold predicted structure of the EqHV ΔSLI 5′UTR 
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Figure 8.3: Mfold predicted structure of the EqHV ΔSLI+II 5′UTR  
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Figure 8.4: Mfold predicted structure of the EqHV ΔSLIII 5′UTR  
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Figure 8.5: Mfold predicted structure of the EqHV ΔSLIIIb 5′UTR  
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Figure 8.6: Mfold predicted structure of the EqHV ΔSLIIId 5′UTR  
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Figure 8.7: Mfold predicted structure of the EqHV GUC 5′UTR  
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Figure 8.8: Mfold predicted structure of the EqHV AGU 5′UTR  
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Figure 8.9: SHAPE primer sequences 
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Figure 8.10: Comparison of SHAPE reactivity data between SGR NZCI and pGL3 NPHV 
SHAPE reactivity data for pGL3 WT was subtracted from that of SGR NZCI to create a 
representative reactivity profile which displays the differences in reactivity between the NPHV 
5′UTR in the context of the replicon, or bicistronic construct. Red represents those nucleotides 
where the SGR exhibited higher reactivity and blue where reactivity was higher in the bicistronic 
construct. 
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Figure 8.11 A representative SGR JFH Replication assay and RNA gel 
A) SGR JFH (2 μg) was electroporated into Huh7s and assayed for luciferase activity up to 72 
h.p.e. B) A representative MOPS gel showing 0.5 μg of IVT SGR JFH and SGR NZCI 
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Figure 8.12: Alignment of the EqHV 3′UTR (accession number JX948116.1 [denoted SMKL]) 
and the HCV 3′UTR (accession number AF011753.1) 
 
 
Figure 8.13: Alignment of the EqHV NZPI 3′UTR (accession number KP325401) and the HCV 
3′UTR (accession number AF011753.1) 
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Figure 8.14: Alignment of the “original” EqHV 3′UTR (accession number JX948116.1 [denoted 
SMKL]) and the consensus EqHV NZPI 3′UTR (accession number KP325401) 
 
 
 
 
 
 
 
 
 
 
